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Preface
In order to effectively contain and combat a virus, one has to understand the natural 
history of the virus and its microbiology, pathology, immunology, pathogenicity, 
clinical features, treatment and prevention options, and control measures. Never 
has this been clearer than now when the world is experiencing the COVID-19 
pandemic. Of course, there are other viruses that must be dealt with as well.
This book is about the highly infective Human papillomavirus (HPV). There 
are more than 200 strains of HPV, though only a few, like HPV 16 and HPV 18, are 
oncogenic. HPV infections can lead to cancers of the cervix, vulva, vagina, anus, 
penis, and oral cavity.
Written by authors from across the globe, this book is a comprehensive look at 
HPV. Chapters cover such topics as the epidemiology of HPV, treatment of the 
manifestations of HPV, which can include warts on the skin and genitals, diagnosis 
and management of oral mucosal cancers due to HPV, HPV and pregnancy, and 
HPV vaccines.
This book serves as a useful reference for researchers and scientists, guiding them 
in the objective of eliminating HPV infections and related cancers, especially in 
developing countries with limited resources.
I am grateful to Dr. Rijula Raj, MPT, SRMIST, Chennai, Er. Rixon Raj, ME, MIT, 
Chennai, and Er. Pavith Raj for their valuable technical inputs. I thank my family 
Celin Rani and the lovely angel Helena Raj for their concern and care during 
the preparation of this book. My special thanks to Ms. Romina Rovan of IntechOpen 
publishing for her highly efficient management and skillful guidance during my 
editorship of this book.
Dr. Rajamanickam Rajkumar MD, PhD
Professor,
Community Medicine,
Meenakshi Medical College Hospital and Research Institute,
Meenakshi Academy of Higher Education and Research - MAHER,
Kanchipuram, Tamil Nadu, India
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Chapter 1
The Importance of the Problem 
of HPV-Associated Diseases 
in KhMAO-Ugra: Vaccination 
of Adolescents against 
HPV - Problems and Prospects
Larisa Dmitrievna Belotserkovtseva and Yulia Igorevna Mayer
Abstract
In a survey of adolescents aged 14–17 years, we found that 25% already have 
experience of sexual contact and they do not know the methods of contraception 
and neglect condoms. About 77.6% of sexually active adolescent girls had genital 
infection, including HPV 52.7%, highly oncogenic types 37.9%, and mixed infec-
tions 51.4%. Adolescents are extremely vulnerable to HPV-related diseases. Cervical 
cancer takes the 2nd place in the structure of cancer in women in KHMAO-Ugra and 
the 1st place at the age of 30 years. Since 2009, girls have been vaccinated against 
HPV in Ugra. Over 10 years, there was a 39% decrease in the incidence of anogenital 
warts. We meet with parents, provide information about the risks of HPV infection, 
expose myths, and discuss the safety and effectiveness of HPV vaccines. Our goal 
is to win the trust of parents in vaccines, resist anti-vaccine propaganda, increase 
motivation, and reduce the number of refusal.
Keywords: papillomavirus, vaccination, cervical cancer, anogenital warts, adolescent 
reproductive behavior
1.  The problem of HPV in Russia and in the Khanty-Mansiysk 
autonomous region-Ugra
Human papillomavirus (HPV) is the most frequent sexually transmitted infec-
tion. The prevalence of HPV in the world is about 10%.
HPV is the cause of a wide range of serious diseases in both men and women, 
including cancer and precancerous lesions of the cervix, vulva and vagina, anogeni-
tal area and anal canal, penis, and oropharynx, and also plays a crucial  etiological 
role in the development of anogenital warts in both sexes [1–4]. Anogenital 
(venereal) warts are the most common clinical manifestation of HPV infection. 
More than 90% of all cases of anogenital warts are caused by 6 and 11 types of 
HPV. These types of HPV are also responsible for the development of recurrent 
respiratory papillomatosis [1–3, 5].
The problem of HPV infections during pregnancy can lead to complications 
such as intrauterine and intrapartum infections of the fetus, increased frequency of 
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cesarean sections, and the risk of developing laryngeal papillomatosis of the larynx 
of the newborn, increasing the risk of infant mortality and the number of surgi-
cal interventions on the cervix for severe dysplasia in young women with risk of 
complications for subsequent pregnancies—spontaneous abortions and premature 
births.
2.  Epidemiology of HPV-associated pathology in Russia and 
KhMAO-Ugra
Every year, more than 600,000 new cases of HPV-associated cancer are regis-
tered in the world, approximately 90% of which is cervical cancer. According to the 
statistics of the Russian Center for Information Technology and Epidemiological 
Research in Oncology of the Herzen Institute (branch of the Federal State Institute 
“National Medical Research Center of Radiology” of the Ministry of Health of the 
Russian Federation), in the structure of the incidence of malignant neoplasms of 
the population of the Russian Federation in 2015, cancers associated with HPV 
infection accounted for about 10% of the total incidence of cancer, and their total 
number was about 32,000 cases [6].
In the structure of female cancer incidence, cancers of the anogenital region 
are presented in different ways. Thus, cervical cancer in the Russian Federation 
occupies the 5th place (5.2%); cancer of the rectum, rectosigmoid junction, and 
anus, 6th place (4.6%); vulvar cancer, 20th place (0.6%); pharyngeal cancer 
(0.2%) and vaginal cancer (0.2%), 25–26th place; and laryngeal cancer—28th 
place (0.1%) [6].
However, if we consider the structure of oncological diseases of the female 
reproductive system, cervical cancer takes the second place in prevalence among 
malignant neoplasms of women under 45 years and the first in the number of lost 
years of life (the life expectancy of sick women is reduced by 26 years on average). 
The incidence of cervical cancer is steadily increasing and has increased by 28% on 
average over the past 10 years [7].
Only in 10 years, the incidence of cervical cancer in Russia has increased by an 
order of magnitude: from 7.9 per 100,000 of the female population in 2002 to 17.2—
in 2012 [7]. In 2018, 17,000 new cases of cervical cancer and 6.6 thousand deaths 
were registered in the Russian Federation. In 2018, the incidence rate fell slightly 
to 15.76. Important markers characterizing the neglect of cervical cancer and the 
quality of treatment are the proportion of patients with advanced tumor process 
(3–4 stages), as well as the mortality of patients within a year from the moment of 
diagnosis, which in the Russian Federation in 2018 remained at a fairly high level: 
34.6 and 13.8%, respectively. In the structure of disability, 83% of cases in onco-
gynecology are cervical cancer [8]. The frequent incidence of cervical cancer, the 
tendency to rejuvenate this pathology, a high percentage of neglected cases, and, as 
a consequence, the growth of disability among women of working age are a world 
problem, involving the most active, socially significant part of the female popula-
tion. The occurrence of cervical cancer in young women is a serious social problem, 
causing deterioration in health, disability, and reduced fertility.
As for cancers of other localizations, annually in the Russian Federation, 
about 4000 cases of laryngeal cancer and 3000 deaths, for this reason, are 
registered. Morbidity and mortality from cancer of the vulva, vagina, anus, and 
penis in the Russian Federation are not registered, which is obviously due to low 
diagnosis and underreporting of cases. There are about 100,000 new cases of 
cancer of these locations in the world every year, and two-thirds of the incidence 
falls on women [8].
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Anogenital (venereal) warts are the most common clinical manifestation of 
HPV infection, more than 90% of which are caused by HPV types 6 and 11. In 
Russia, this pathology is among the five leaders among sexually transmitted infec-
tions. It should be emphasized that the level of official registration is significantly 
different from the true prevalence and the possible true figure of the prevalence of 
anogenital warts, according to ongoing studies to assess the prevalence, can be more 
than 1,000,000 cases, which will bring this nosology to the first place in frequency 
among all recorded genital infections. The lack of specific antiviral therapy, as well 
as frequent relapses after the use of destructive methods, complicates the treatment 
of the disease, significantly reducing the quality of life of these patients [9].
The average annual population of Khanty-Mansiysk Autonomous Region-Ugra is 
1,659,436 people, of which 851,588 are women and 805,848 are men.
Cervical cancer in our region occupies the second place in the structure of 
tumors of the reproductive system of women and the first place in the age category 
up to 30 years. Precancerous lesions of the cervix are detected more than 6000 cases 
per year [10].
The clinical burden of cancer (cervical cancer, vulvar and vaginal cancer, 
anal cancer) among the female population in our region is up to 300 cases per 
year, which is relevant within the workload of cancer beds and rationalization 
of health-care costs. In KhMAO-Ugra, according to the state registration, the 
incidence of cervical cancer does not tend to decrease: in 2018, it was 14.7 per 
100 thousand population and in Russia 15.76. The number of registered women 
diagnosed with cervical cancer is steadily increasing. Annually in Ugra, about 
160–170 cases of cervical cancer are registered for the first time. Among the newly 
identified cases, every second patient (50.8%) is under the reproductive age of 
45 years and every third woman (33.2%) had an advanced stage 3–4 of the disease. 
About 12–15% of patients with cervical cancer die in the first year of diagnosis. 
Mortality from this disease in Ugra in 2018 was 6.0 per 100,000 population; in 
2018 54 women died [10].
The standard screening procedure in KhMAO-Ugra, as well as in the world, 
is the PAP test, the effectiveness of which does not exceed 30–40%. Despite the 
introduction of modern methods and some progress in diagnosis and treatment, 
cancer prevention is still crucial.
3.  Study of the expression of oncoprotein E7 in the diagnosis of cervical 
diseases associated with human papillomavirus
Infection caused by human papillomavirus occurs in 50–80% of the population 
and in 99.7% of cases of confirmed cervical cancer and therefore is an important 
problem of modern health care. First of all, this applies to the pathology of the 
cervix, which is the most important organ of the reproductive system of a woman. 
Thus, recent data indicate a fourfold increase in cases of cervical cancer among 
women under 35 years. The incidence of papillomavirus infection in general has 
also increased, which occurs in 44% of women who have seen a gynecologist. 
Against the background of persistent HPV of the urogenital tract, most cervical 
intraepithelial neoplasms develop, which in 15–20% of cases can end in oncological 
pathology (carcinoma in situ and invasive cancer) [3, 6, 9].
Given the high prevalence of papillomavirus infection, the uncertainty of its 
outcome, it is important to determine the phase of interaction of HPV with the cell. 
During the reproduction of HPV in the body, there is a persistence of its genome in 
the episomal form with the production of viral particles. In this phase of reproduc-
tion, there is a high probability of spontaneous remission [2, 9].
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The integrative phase is characterized by the embedding of HPV DNA sequences 
of the 16th and 18th serotypes into the chromosome of the infected cell, which is 
accompanied by the synthesis of oncoprotein E7. Viral particles are not produced. 
Expression of oncoprotein E7 is a factor that significantly increases the risk of 
oncogenic transformation of the cervical epithelium. Increased synthesis of oncop-
rotein E7, a product of the viral genome, indicates an integrative phase of HPV-cell 
interaction in which the probability of spontaneous remission is low. However, this 
pattern is not absolute, as some cases in malignant tumors identified episomal form 
of HPV DNA or a combination of episomal and integrated forms [11, 12].
The insufficient number of clinical studies on the content of oncoprotein E7 in 
HPV does not yet allow for widespread use of this indicator in practical health care.
The aim of the study was to study the level of expression of cancer protein E7 in 
patients with cervical pathology with positive and negative HPV tests [11, 12].
Materials and methods: We conducted a continuous randomized prospective 
study. According to the results of HPV testing by polymerase chain reaction (PCR), 
all patients with cervical pathology (95 women) were divided into two groups: the 1 
group ( control group) (HPV-negative, n = 57) and the 2 group ( main group)(HPV-
positive, n = 38). Group 1 (control group), consisting of 57 women with cervical 
pathology (HPV-negative test) was divided into two subgroups by analysis for the 
presence of oncoprotein E7 expression. In first subgroup, 13 women had a positive 
result which is 1 E7-positive subgroup, and 44 women had a negative result which 
is 1 E7-negative subgroup. Group 2 (main group) consisting of 38 women with 
cervical pathology, were infected with human papillomavirus of high carcinogenic 
risk. Group 2 (main group) was divided into two subgroups: subgroup of 11 women 
is 2 E7-positive subgroup, who tested positive for oncoprotein E7, and of 27 women, 
whose E7 was not detected—a negative result is 2 E7-negative subgroup.
Clinical observation and bacteriological, bacterioscopic, cytological, endo-
scopic (colposcopy), and histomorphological methods were used during the 
examination. All women were tested for papillomavirus infection. Verification 
of the diagnosis of papillomavirus infection was carried out by polymerase chain 
reaction. Quantitative determination of oncoprotein E7 in cervical samples 
was carried out using the enzyme immunoassay system NPF “Mirax-Pharma” 
(Moscow). Purified recombinant type 16 protein E7 was titrated as standard. The 
optical density, which is critical for each formulation, was determined. The test 
result of the sample was considered positive if the optical density was greater than 
or equal to the critical. The result of the sample study was considered negative if 
the optical density was less than the critical one. A survey card was filled in for 
each patient.
The comparison was carried out on the basis of sample averages (M), medians 
(Me), and standard deviation (Q25–Q75). Statistical analysis was performed using 
the nonparametric Mann–Whitney criterion (U) for independent groups. The reli-
ability of the differences between the percentages of the two samples was estimated 
by the value of the Fisher angular distribution criterion (φ). The values at p < 0.05 
were considered reliable.
4. Results and discussion
The average age of the patients, the onset of menstrual function, the duration 
of their residence in the North, and the onset of sexual life were comparable in all 
groups and had no statistical significance (p > 0.05). The number of sexual partners 
had statistical significance in 1 E7-negative subgroup of the control group compared 
with the main group—2.00 (2.00–3.00), 2.00 (1.00–3.00), 3.00 (2.00–7.00), and 
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3.00 (2.00–5.00), respectively (2–3,4*p < 0.05). In the study of obstetric history, the 
number of births and abortions in all groups had no statistical significance (p > 0.05).
In the study of somatic history in 2 E7-positive subgroup, kidney disease 
accounted for 27.3% and endocrine disease 27.3% and had statistical significance in 
comparison with 1 E7-negative subgroup (*p < 0.05), respectively.
In the study of hereditary oncological history, oncological diseases were found 
in relatives, 15.38, 40.91, 45.45, and 22.22% in subgroups, respectively (21–2, 
3*p < 0.05; 2–4*p < 0.05), where in the 2 E7-positive subgroup, a burdened family 
oncological history was revealed in 45.45% of cases.
In the study of gynecological history, we paid attention to diseases that could 
serve as additional factors in the development of neoplasia and cervical cancer. 
Among gynecological pathology, inflammatory diseases of the female genital 
organs in the 2 E7-positive subgroup were significantly more common, such as 
endometritis (27.27%) (3–2*p < 0.05), vulvovaginitis (90.90%) (*p < 0.05), and 
salpingo-oophoritis (36.36%) (3–4*p < 0.05); inflammatory diseases can reduce 
immunity and stimulate the tumor process. Infection of the genitourinary organs 
by pathogens of sexually transmissible infections according to the anamnesis also 
prevailed in the 2 E7-positive subgroup, such as Ureaplasma (27.27%), Mycoplasma 
(18.18%), and Chlamydia infection (18.18%) (4–2*p < 0.05), which required an 
in-depth study of the anamnesis and examination of the sexual partner.
Attention is drawn to a large number of cervical pathology in history. Cervical 
diseases in the history of patients in subgroups had, respectively, 84.62, 88.64, 
100.00, and 81.42%.
When cytological examination of patients for atypical cells is performed, signs 
of cervical intraepithelial neoplasia (CIN) were found in 45,5, 61,54, 77,3, 81,81, 
and 66.66% (1–3* * p < 0.01; 1–4. 5*p < 0.05) in subgroups, respectively (Table 1).
A HPV effect was observed in patients only in 1 E7-negative (in 4.5% of cases) 
and 2 E7-positive (in 18.2% of cases); the reliability was confirmed in comparison 
with the control group (3,4–1,2**p < 0.01).
In recent years, the impact of sexually transmitted infections on the likelihood 
of developing dysplasia and cervical cancer has been considered. The structure of 
chronic inflammatory diseases of the cervical canal and cervix is currently domi-
nated by cervicitis caused by Chlamydia trachomatis in combination with human 
papillomavirus. In these conditions, CIN and possibly cervical cancer often develop. 
Many researchers note that Chlamydia infection is a cofactor in the occurrence of 
cervical intraepithelial neoplasia in the presence of HPV.
Chlamydia infection was found only in 2 E7-positive subgroup (9.1%); Ureaplasma 
infection also prevailed in this subgroup (27.3%) (3–2*p < 0.05). Mycoplasma infec-
tion prevailed in the 2 E7-positive subgroup (14.8%) (4–1**p < 0.01) (Table 2).












NILM 38,46% (5) 25,00% (11) 18,18% (2) 33,33% (9)
LSIL 61,54% (8) 77,27% (34) 81,81% (9) 66,66% (18)
HSIL 7,69% (1) 4,54% (2) 18,18% (2) 14,81% (4)
HPV effect 0,00% (0)*3 2,27% (1)*3 18,18% (2)**4 0,00% (0)
φ **p < 0,01; φ *p < 0,05.
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The results of the PAP test.
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chronic inflammatory diseases of the cervical canal and cervix is currently domi-
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Many researchers note that Chlamydia infection is a cofactor in the occurrence of 
cervical intraepithelial neoplasia in the presence of HPV.
Chlamydia infection was found only in 2 E7-positive subgroup (9.1%); Ureaplasma 
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Table 1. 
The results of the PAP test.
Human Papillomavirus
6
Infection with human papillomavirus in women with cervical pathology was 
confirmed in 40% of patients. In the main group, a positive test for HPV type 
16 was detected in 68.4% (26 women) and HPV type 18 in 42.1% (16 women). 
The combination of HPV 16 and 18 genotypes was found in 10.5% (4 women). 
HPV type 16 infection in the main group was found in subgroups 54.54 and 
74.07%, respectively, and HPV type 18 was found in subgroups 54.54 and 37.04%, 
respectively.
Thus, HPV infection alone is not enough to induce tumor growth and confirms 
the role of mixed infection as a cofactor in HPV-dependent carcinogenesis.
During colposcopy (Table 3), the condition of the cervix and vagina was 
assessed, the localization and boundaries of the lesion were determined, benign 
changes were differentiated from suspected malignancies, and cytological smears 
and biopsies were taken from suspicious areas of the cervix. Among the results 
of a colposcopic view, 2 E7-positive and 2 E7-negative subgroups prevailed of 
CIN (45.45%) (3-2* p < 0.05). Atypical vessels were determined in 63.63% (3–2** 
p < 0.01; 3–1*p < 0.05) and 59.26% (4–2**p < 0.01; 4–1*p < 0.05), respectively; the 
mosaic in the subgroups was 54.54% (3–2** p < 0.01; 3–1*p < 0.05) and 44.44% 
(4–2**p < 0.01; 4–1*p < 0.05), respectively.
In the group of HPV-positive women, abnormal colposcopic views (iodine-
negative epithelium, punctuation, mosaic, aceto-white epithelium, atypical vessels) 
were much more common, which confirms the damaging effect of the human 












Normal 0,00% (0) 0,00% (0) 0,00% (0) 0,00% (0)
Aceto-white epithelium 23,08% (3)*4 13,64% (6)*3**4 45,45% (5) 55,55% (15)
CIS 0,00% (0) 0,00% (0)*3 9,09% (1) 3,70% (1)
Atypical vessels 23,08% (3)*3,4 18,18% (8)**3,4 63,63% (7) 59,26% (16)
Mosaic 15,38% (2)*3,4 11,36% (5)**3,4 54,54% (6) 44,44% (12)
Punctuation 0,00% (0) 4,54% (2) 9,09% (1) 7,40% (2)
φ **p < 0,01; *p < 0,05; φ *p < 0,05.
Table 3. 
Extended colposcopy results.












Chlamydia trachomatis 0,00% (0) 0,00% (0)*3 9,09% (1)*4 0,00% (0)
Ureaplasma spp. 15,38% (2) 6,82% (3)*3 27,27% (3) 11,11% (3)
Mycoplasma spp. 0,00% (0)*2**4 9,09% (4) 9,09% (1) 14,81% (4)
HPV 16 0,00% (0)**3,4 0,00% (0)**3,4 54,54% (6) 74,07% (20)
HPV 18 0,00% (0)**3,4 0,00% (0)**3,4 54,54% (6) 37,04% (10)
φ **p < 0,01; *p < 0,05; φ *р < 0,05.
Table 2. 
Results of examination for sexually transmitted infections.
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papillomavirus on the state of the cervical epithelium and complicates the course of 
pathological processes toward carcinogenesis. All abnormal colposcopic views were 
indications for biopsy. Tissue for biopsy was taken by radio-wave loop.
Histological examination revealed the following results (Table 4). Signs of 
chronic inflammatory process prevailed in the control group and amounted to 
61.54% and 56.82%, respectively (2–1, 3–1* * p < 0.01). Signs of stationary endo-
cervicosis were found in the control group (30.77 and 38.63%, respectively) and in 
the main group (18.18 and 33.33%, respectively). This had no statistical significance 
(p > 0.05). Epidermizing endocervicosis prevailed in 2 E7-positive, and its detec-
tion rate was 45.45% (4–1* * p < 0.01; 4–5*p < 0.05).
CIN I, II, and III prevailed in women with HPV (+) in the main group, and 
according to the results of histological conclusion, CIN I was found in subgroup 2 
E7-positive in 36.36% of cases (4–1* * p < 0.01; 4–2*p < 0.05) and in subgroup 2 
E7-negative in 40.74% of cases (5–1,2**p < 0.01).
CIN II was diagnosed in the main group in 27.27% (4-1**p < 0.01) and in 
29.63% of cases (5-1**p < 0.01; 5-3*p < 0.05), respectively, subgroups. CIN III was 
observed in women with HPV (+) of the main group in 27.27% (4–1,3**p < 0.01) 
and in 22.22% of cases (4–1,3**p < 0.01), respectively. Cancer in situ was diagnosed 
in the main group in 9.09% (4-3*p < 0.05) and 7.40% of cases (5-1,3*p < 0.05), 
respectively, subgroups, indicating the role of HPV in the carcinogenesis of cervical 
cancer.
Signs of koilocytosis were determined in subgroups 0, 7,69, 2,27, 54,54, and 
51.85%, respectively. In women with HPV (+) of the main group, these indicators 
were maximum and had statistical significance (4,5–1,2,3**p < 0.01). It should be 
noted that the maximum of abnormal colposcopic species were women in sub-
groups with increased expression of oncoprotein E7.
Thus, in the group of HPV-positive women, according to the results of histologi-
cal examination, cervical intraepithelial neoplasia of medium and severe degree 
and cervical cancer were more common. Moreover, koilocytic transformation of 
the epithelium, CIN III, and cervical cancer was diagnosed more often in subgroup 












No evidence 0,00% (0) 0,00% (0) 0,00% (0) 0,00% (0)
Chronic cervicitis 61,54% (8) 56,82% (25) 45,45% (5) 55,55% (15)
Stationary endocervicosis 30,77% (4) 38,63% (17) 18,18% (2) 33,33% (9)
Epidermizing endocervicosis 38,46% (5) 38,63% (17)*4 45,45% (5)*4 18,52% (5)
Leukoplakia 23,08% (3) 9,09% (4) 18,18% (2) 18,52% (5)
CIN I 7,69% (1)*3**4 22,72% (10) 36,36%(4) 40,74%(11)
CIN II 15,38% (2) 9,09% (4)*4 27,27% (3) 29,63% (8)
CIN III 7,69% (1)*2 0,00% (0)**3,4 27,27% (3) 22,22% (6)
Cervical cancer 0,00% (0) 0,00% (0)*4 9,09% (1) 7,40% (2)
Koilocytes 7,69% (1)**3,4 2,27% (1)**3,4 54,54% (6) 51,85% (14)
**p < 0,01; *p < 0,05.
Table 4. 
Results of histological examination.
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2 E7-positive than in subgroup 2 E7-negative, according to the conclusion of 
morphologists.
The results of the study of the level of expression of cancer protein E7 are 
presented in Table 5. Indicators were distributed according to subgroups: 0,087 
(0,07–0,12); 0,190 (0,18–0,39); 0,074 (0,06–0,10); 0,200 (0,17–0,31); and 0.081 
(0.07–0.10) (**p < 0.01). We found a significant increase in the indicator in the 
main group (2 E7-positive), compared with the control group 1 E7-negative and 2 
E7-negative (**p < 0.01). In the main group (subgroup 1 E7-positive), this indicator 
also had statistical significance in comparison with subgroups 1 E7-negative and 2 
E7-negative (**p < 0.01).
The increased expression of oncoprotein E7 in the main group (2 E7-positive) 
was maximal in comparison with subgroups 1 E7-negative and 2 E7-negative 
(**p < 0.01), which is an indicator of the aggressiveness of the incipient tumor 
process and a criterion for an unfavorable prognosis. In subgroup 1 E7-positive, 
increased expression of oncoprotein E7 was also detected in comparison with the 
control 1 E7-negative subgroup and the main 2 E7-negative subgroup (**p < 0.01).
As a result of studying the level of expression of oncoprotein E7 in HPV-positive 
and HPV-negative women, we made the following conclusions:
1. In the group of women with cervical pathology associated with human papil-
lomavirus infection, an increased frequency of abnormal colposcopic views, 
mosaic (3.5 times higher, p <0.01), acetone-white epithelium (2.4 times higher, 
p < 0.05), atypical vessels (3.5 times higher, p <0.01), punctuation (2.3 times 
more often, p <0.05), as well as cytological examination, LSIL signs (2.4 times 
higher), HSIL was found only in the HPV group (p <0.01), and histological 
examination of CIN I found is 4.7 times higher (p < 0.05), CIN II is 3.2 times 
more likely (p < 0.05), CIN III is 22.3 times more often (p < 0.01), and cervical 
cancer is 7.89%. This confirms the damaging effect of the human papilloma-
virus on the cervical epithelium and complicates the course of pathological 
processes toward carcinogenesis.
2. The results of the study showed that in cervical pathology caused by HPV of 
high carcinogenic risk, the increased content of cancer protein E7 is detected 
2.5 times (p < 0.01) more often than in women that are HPV (−). The level of 
E7 indicates an aggressive process of carcinogenesis and can be considered as 


















































Kruskall-Wallis: χ2; р (**p < 0,01; *p < 0,05); Mann–Whitney (U) U **p < 0.
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3. Laboratory test evaluation of oncogenic transformation of the cervical epithe-
lium requires further study, as it allows in conjunction with other diagnostic 
methods to determine the group of increased oncogenic risk among patients 
with gynecological diseases. The proven relationship between elevated levels 
of expression of oncoprotein E7 and the presence of CIN allows us to recom-
mend the definition of oncoprotein E7 for inclusion in the diagnostic program 
for HPV-positive women with changes in the cervix and pathological cervical 
smears.
5.  Teenagers are a risk group: reproductive behavior and adolescent 
reproductive health
Biological susceptibility to HPV and structural immaturity of the cervix in 
adolescence, high frequency of ectopia of the cylindrical epithelium, and activation 
of squamous metaplasia processes create optimal conditions for the introduction 
and replication of human papillomavirus, which makes the adolescent population 
extremely vulnerable to the development of CIN.
Features of reproductive behavior of adolescents determine the risks that 
contribute to the development of diseases of the reproductive system. These are 
the early beginning of sexual life, frequent change of sexual partners due to the 
absence of persistent lasting relations in paired unlike adults, who create families 
and in most adhere to monogamous relations. As a result of adolescents’ neglect of 
barrier contraception, they have a high incidence of sexually transmitted infec-
tions. Early sexual life and especially sexual behavior of adolescents contribute to 
the spread of sexual infections among them, which often remain undiagnosed and 
not treated in time [13].
Physiological features of the anatomy of the cervix in adolescent girls’ anatomy 
create prerequisites for the persistence of HPV in the epithelial cells of the cervix of 
the girl; long-term persistence of the virus can lead to the development of precan-
cerous lesions and cervical cancer. Chlamydia and Mycoplasma infections associated 
with HPV are cofactors that exacerbate the situation. Age-related physiological 
ectopia of the cylindrical epithelium, characteristic of adolescence, and defective 
hormonal homeostasis lead to a violation of the physiological barriers of the genitals. 
The cylindrical epithelium is an ideal environment for papillomavirus invasion due 
to the availability of reserve cells and the large area of the transformation zone [14].
Promiscuity and unsettled partnerships are of primary importance in early HPV 
infection and increased risk of CIN against the background of high infection rates 
among adolescents with sexually transmitted infections.
In sexually active girls, genital inflammation is detected three times more 
often (45.2%) than in their peers who do not live a sexual life—in 15.1% of girls. 
Pathology of the cervix at the age of 18 is detected in 33.4% of girls. According 
to the results of the survey of sexually active adolescents for genital infections, 
sexually transmissible infections were detected in 77.8%, including Mycoplasma 
genitalium, 18.4%; Chlamydia trachomatis, 6.2%; and HPV, 52.7% (including highly 
oncogenic types—34.7%), and mixed infections in 51.4%. In KhMAO-Ugra, the 
HPV infection rate of girls aged 14–16 is 40%, and among girls aged 17–18, the 
infection rate increases to 60% [13].
We conducted an anonymous survey of schoolchildren in Surgut, which was 
attended by 389 high school students, including 201 girls and 188 boys aged from 14 
to 18. The median age was 16.9 years. Among them, 24% have experience of sexual 
contact. About 50% of sexually active adolescents indicated that they had a sexual 
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of squamous metaplasia processes create optimal conditions for the introduction 
and replication of human papillomavirus, which makes the adolescent population 
extremely vulnerable to the development of CIN.
Features of reproductive behavior of adolescents determine the risks that 
contribute to the development of diseases of the reproductive system. These are 
the early beginning of sexual life, frequent change of sexual partners due to the 
absence of persistent lasting relations in paired unlike adults, who create families 
and in most adhere to monogamous relations. As a result of adolescents’ neglect of 
barrier contraception, they have a high incidence of sexually transmitted infec-
tions. Early sexual life and especially sexual behavior of adolescents contribute to 
the spread of sexual infections among them, which often remain undiagnosed and 
not treated in time [13].
Physiological features of the anatomy of the cervix in adolescent girls’ anatomy 
create prerequisites for the persistence of HPV in the epithelial cells of the cervix of 
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with HPV are cofactors that exacerbate the situation. Age-related physiological 
ectopia of the cylindrical epithelium, characteristic of adolescence, and defective 
hormonal homeostasis lead to a violation of the physiological barriers of the genitals. 
The cylindrical epithelium is an ideal environment for papillomavirus invasion due 
to the availability of reserve cells and the large area of the transformation zone [14].
Promiscuity and unsettled partnerships are of primary importance in early HPV 
infection and increased risk of CIN against the background of high infection rates 
among adolescents with sexually transmitted infections.
In sexually active girls, genital inflammation is detected three times more 
often (45.2%) than in their peers who do not live a sexual life—in 15.1% of girls. 
Pathology of the cervix at the age of 18 is detected in 33.4% of girls. According 
to the results of the survey of sexually active adolescents for genital infections, 
sexually transmissible infections were detected in 77.8%, including Mycoplasma 
genitalium, 18.4%; Chlamydia trachomatis, 6.2%; and HPV, 52.7% (including highly 
oncogenic types—34.7%), and mixed infections in 51.4%. In KhMAO-Ugra, the 
HPV infection rate of girls aged 14–16 is 40%, and among girls aged 17–18, the 
infection rate increases to 60% [13].
We conducted an anonymous survey of schoolchildren in Surgut, which was 
attended by 389 high school students, including 201 girls and 188 boys aged from 14 
to 18. The median age was 16.9 years. Among them, 24% have experience of sexual 
contact. About 50% of sexually active adolescents indicated that they had a sexual 
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debut at the age of 16 and younger. About 14.6% of them had the first sexual contact 
at the age of 15, 10.4% from 13 to 14 years old, 31.2% from 17 years old, and 16.7% 
from 18 years old. About 66.7% of them had 1 sexual partner; every third (33.3%) 
sexually active teenager under the age of 18 had 2 or more sexual partners. For 
contraception, 57% of respondents use a condom, 29%—combined oral contracep-
tives. Only 23.5% of adolescents are regularly protected from sexual infections, 27% 
never use barrier contraception.
6.  Introduction of vaccination of adolescents against HPV infection in 
KhMAO-Ugra: problems and solutions
The strategic direction of the development of modern health care in the Russian 
Federation is prevention and early detection of diseases, which contributes to more 
effective treatment and improvement of demographic indicators of public health. 
One of the most important preventive measures is vaccination, and today more than 
30 diseases that cause serious damage to human health can be prevented with its 
help. Immunization prevents 2.5 million deaths per year across all age groups.
These facts indicate that the issues of prevention and treatment of HPV-
associated diseases require a multidisciplinary approach, as they affect such special-
ists as gynecologists, oncologists, epidemiologists, pediatricians, immunologists, 
dermatologists, etc.
The World Health Organization has been recommending the inclusion of HPV 
vaccination in vaccination calendars around the world since 2009 [15]. The WHO 
and the United Nations Children’s Fund (UNICEF) consider HPV vaccination 
a priority for national immunization programs. More than 60 countries have 
already introduced universal mass vaccination of girls; in a number of countries 
(the USA, Australia, Canada, Austria, New Zealand, etc.), boys are vaccinated 
along with girls.
To date, the Russian Federation has two documents regulating measures for the 
prevention of HPV-associated diseases.
1. “Federal clinical guidelines for the management of patients with anogenital 
(venereal) warts,” Russian society of dermatovenerologists and cosmetolo-
gists, (Moscow, 2015). For the prevention of diseases associated with HPV, two 
vaccines are registered in the Russian Federation: bivalent and quadrivalent. 
The bivalent HPV vaccine is used to prevent cancer and precancerous diseases 
of the cervix, vulva, and vagina in women aged 9 to 45 years. Quadrivalent 
HPV vaccine is used for the prevention of cancer and precancerous changes of 
the cervix; vulva cancer, vagina cancer, and anal cancer; and anogenital warts 
in women from 9 to 45 years, as well as anal cancer and anogenital warts in 
men from 9 to 26 years [16].
2. “Federal clinical guidelines for HPV vaccine prevention,” Union of Pediatri-
cians of Russia (Moscow, 2016). These clinical guidelines regulate two vac-
cination regimens. Standard scheme: girls/women from 14 to 45 years old and 
boys/men from 14 to 26 years old—three doses (0–2–6 months). Alternative 
scheme: girls and boys from 9 to 13 years old—it is possible to carry out two-
dose immunization (0–6 months) [17].
Despite government HPV vaccination programs, female vaccination rates 
remain below targets in many countries [18, 19]. Models tend to demonstrate that 
vaccination of boys is most cost-effective if vaccination coverage of the female 
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population is at a suboptimal level (less than 50%) [20, 21]. The benefits of vacci-
nating adolescent boys are not only the prevention of HPV infection for the partner 
but also the prevention of cancer of the penis and anal canal and anogenital warts.
Vaccination is the most effective investment in health care. The cost of treat-
ment of one case of cervical cancer in the Russian Federation on average is $3000 
and the cost of vaccination with preventive vaccination Gardasil—$235. With mass 
immunization of adolescents aged 12 years old, the pharmacoeconomic efficacy of 
vaccine introduction was calculated on a national scale, which showed the amount 
of prevented costs to be $235,000,000, and in the first 5 years, only $16,000,000 
will be prevented by reducing genital warts [22].
There are numerous publications confirming the pharmacoeconomic effective-
ness of HPV vaccination not only in computational models but also in real life 
[22–28].
In 2013, the Research Institute of Childhood Infections of the FMBA con-
ducted a pharmacoeconomical evaluation of the cost-effectiveness of vaccination 
of 12-year-old girls with a quadrivalent HPV vaccine in Russia. For the period of 
survival, taking into account both direct medical and indirect costs, the vaccine 
is characterized by a cost-effectiveness ratio equal to $5800/QALY. When the 
gross domestic product of the Russian Federation was $6000, vaccination of 
girls with a quadrivalent HPV vaccine in the Russian Federation is characterized 
by high cost efficiency and can be recommended for routine use in the Russian 
population.
According to the instructions, the vaccine is approved for use in women aged 9 
to 45 years old and in men aged 9 to 26 years old and can protect against diseases 
such as cervical cancer, vulvar cancer, vaginal cancer, anal cancer, and anogenital 
warts. Due to the fact that the human papillomavirus causes serious diseases in 
men, and screening methods for HPV-associated lesions of the anal canal and penis 
do not exist today, universal vaccination of adolescents of both sexes with quadri-
valent HPV vaccine, the only one approved for use in boys, will achieve significant 
results in reducing the level of HPV-associated diseases and the rapid spread of 
HPV infection in the world [29].
The primary target cohort for HPV vaccination is children and adolescents 
aged 9 to 13 years before sexual debut, as recommended by the World Health 
Organization. The WHO since 2009 recommends that vaccination against human 
papillomavirus be included in vaccination calendars of all countries of the world. 
The WHO and the United Nations Children’s Fund consider HPV vaccination as a 
priority for national immunization programs. Sixty countries have already intro-
duced universal mass vaccination of girls, and three countries (the USA, Australia, 
Canada) also vaccinate boys against HPV.
At the moment, two HPV vaccines are registered in the Russian Federation: 
bivalent vaccine (Cervarix, contains antigens to 16 and 18 types of HPV) and 
quadrivalent vaccine (Gardasil, contains antigens 6, 11, 16, and 18 types of HPV). 
Bivalent HPV vaccine is used to prevent cancer and precancerous lesions of the 
cervix, vulva, and vagina. Quadrivalent HPV vaccine can protect not only from 
cervical, vulvar, and vaginal cancer but also from cancer of the anal canal and 
anogenital warts in women and men. The primary target cohort for HPV vaccina-
tion is adolescents aged 9–13 years old prior to sexual debut, as recommended by 
the World Health Organization [1].
The monitoring of epidemiological effectiveness is an integral part of HPV vac-
cination programs. In the long term, HPV vaccination can reduce the incidence and 
mortality from a number of cancers (cervical cancer, anal cancer, etc.), the preven-
tion of which is a public health priority. Evaluation of the effectiveness of vaccina-
tion programs in the medium term is possible to reduce precancerous dysplasia 
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and in the short term (2–4 years from the beginning of the program)—to reduce 
the prevalence of anogenital warts. Experience with national HPV vaccination 
programs has shown that maximum coverage can be achieved with school-based 
vaccination, as recommended by the WHO.
Since 2007, 27 regional programs of primary prevention of HPV-associated 
diseases have been implemented in Russia, which indicates the importance of 
protection against HPV infection.
A decrease in the incidence of anogenital warts in the general population 
has been recorded in the USA, Australia, New Zealand, Belgium, Sweden, and 
Germany. For example, in Australia, 4 years after the introduction of vaccination, 
there were the almost complete disappearance of anogenital warts in the population 
of young women and almost 40% reduction in precancerous lesions of the cervix in 
young women. The rate of decline was clearly correlated with vaccination coverage. 
The greatest effect was observed in countries with high coverage (70–85%) [26, 27, 
30–33].
The experience of such regions as KhMAO, where the vaccination calendar is 
constantly being improved and the result is evaluated, can be an example for other 
regions and become one of the arguments for expanding the national calendar of 
preventive vaccinations.
The regional HPV vaccination program for adolescent girls in KHMAO was 
launched in 2009. In the process of introducing the vaccination program, we faced 
a number of difficulties and objections, which were mainly related to the lack of 
awareness of pediatricians and parents, and a lot of myths and negative reviews on 
the Internet and in the media.
We studied the opinions of parents and doctors on the vaccine prevention 
of HPV-associated diseases. Our goal was to raise awareness among parents and 
health-care providers and to assess the impact of anti-vaccine advocacy on the 
population in order to develop a program of further interventions to improve vac-
cination adherence.
The results of the opinion study of 358 people demonstrated that parents are 
extremely poorly aware of the problem of HPV infection, the associated risks, 
and the possibility of preventing diseases caused by HPV with vaccines. Only 
21% of respondents know about the HPV problem and 31% have heard about 
vaccination. Only 49% of parents believe that it is necessary to vaccinate, but 
only 9% of respondents are ready to vaccinate their children. About 69% of 
parents doubt the need for vaccination, 22% categorically refused. Also, parents 
do not have exact knowledge at what age and who needs to be vaccinated, 63% 
believe that only girls need to be vaccinated, and 35% believe that adolescents 
of both sexes need to be vaccinated. For explanations about vaccination, 31% 
will turn to a pediatrician and 15% to a gynecologist; 39% prefer to study 
reviews on the Internet, and only 12% will receive information on official 
websites about vaccination.
The results of the opinion study of 254 doctors showed better awareness, and 
83% gave a positive answer about the risks of HPV infection and the possibilities of 
vaccination; the most informed were obstetricians and gynecologists. The majority 
of doctors (98%) support vaccination, but only 50% are ready to vaccinate their 
child, 36% of them doubt the effectiveness, and 14% are not sure about the safety of 
vaccines, which also indicates a lack of knowledge. Obstetricians and gynecologists 
showed the highest adherence to HPV vaccination (86%). The majority of doc-
tors are ready to receive additional information on vaccination of HPV-associated 
diseases from official sources: when contacting a polyclinic 59%; a skin and venereal 
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dispensary, 21%; a pediatrician, 11%; an obstetrician-gynecologist, 28%, a derma-
tologist, 9%; and on official websites about vaccination—47%.
To raise awareness of the population and the medical community in our region, 
we have developed lectures and presentations for medical professionals and 
parents; created a video about vaccination, which was demonstrated in children’s 
polyclinics; and developed and published booklets, posters, and leaflets for the 
population. Meetings were held with parents and teachers and medical workers in 
schools of the city, which were organized with the assistance of the Department of 
Education of KhMAO-Ugra. The text of the voluntary informed consent for parents 
has been developed, which includes all necessary information about the risk of 
HPV-associated diseases, the vaccination program and the effectiveness of immuni-
zation, and contraindications and possible postvaccination reactions. The introduc-
tion of such voluntary informed consent has increased the commitment of health 
professionals and parents to vaccination and reduced the frequency of refusals.
A “School of Health” is organized, where meetings with parents and schoolchil-
dren are held on a regular basis. The objectives of this school are the following:
• Advocate to motivate vaccination and provide information on the risks of HPV 
infection and associated diseases
• Expose myths in order to gain the trust of parents and counter anti-vaccine 
agitation
• Persuade doubters on the example of highlighting the effectiveness of the 
regions where vaccination is carried out and familiarization with their own 
experience of vaccination in previous years in the KhMAO
• Live stream on Instagram account “School of Health”
Monitoring the effectiveness and safety of vaccines is an integral part of any vac-
cination program, which should be carried out both at the vaccination implementa-
tion stage and in the future.
Evaluation of the effectiveness of vaccination in the short term is traditionally 
carried out according to the incidence of genital warts, as the earliest marker of 
HPV infection.
HPV vaccination in the long term aims to reduce the incidence and mortality 
from cervical cancer, anal cancer, and other HPV-associated cancers. However, the 
introduction of a monitoring system, or register of vaccinated, will allow assessing 
not only the indicators of early effectiveness but also monitoring adverse events 
associated or not associated with vaccination.
Indicators such as a decrease in cases of genital warts or genital intraepithelial neo-
plasia in the vaccinated population will be recorded earlier than results in a decrease 
in HPV-associated cancers and may indicate the effectiveness of HPV vaccination.
For monitoring it is necessary to have a register of vaccinated. The creation of 
the register of vaccinated will allow assessing the following parameters: indicators 
of early effectiveness and monitoring adverse events associated and not associated 
with vaccination. The introduction of the HPV register should be carried out at all 
levels, from doctors involved in vaccination to health administrators involved in 
evaluating strategies to improve the health of citizens.
The information contained in the register will assess the following criteria for 
the implementation of the HPV vaccination program:
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and in the short term (2–4 years from the beginning of the program)—to reduce 
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vaccination, as recommended by the WHO.
Since 2007, 27 regional programs of primary prevention of HPV-associated 
diseases have been implemented in Russia, which indicates the importance of 
protection against HPV infection.
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believe that only girls need to be vaccinated, and 35% believe that adolescents 
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will turn to a pediatrician and 15% to a gynecologist; 39% prefer to study 
reviews on the Internet, and only 12% will receive information on official 
websites about vaccination.
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of doctors (98%) support vaccination, but only 50% are ready to vaccinate their 
child, 36% of them doubt the effectiveness, and 14% are not sure about the safety of 
vaccines, which also indicates a lack of knowledge. Obstetricians and gynecologists 
showed the highest adherence to HPV vaccination (86%). The majority of doc-
tors are ready to receive additional information on vaccination of HPV-associated 
diseases from official sources: when contacting a polyclinic 59%; a skin and venereal 
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• Advocate to motivate vaccination and provide information on the risks of HPV 
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• Expose myths in order to gain the trust of parents and counter anti-vaccine 
agitation
• Persuade doubters on the example of highlighting the effectiveness of the 
regions where vaccination is carried out and familiarization with their own 
experience of vaccination in previous years in the KhMAO
• Live stream on Instagram account “School of Health”
Monitoring the effectiveness and safety of vaccines is an integral part of any vac-
cination program, which should be carried out both at the vaccination implementa-
tion stage and in the future.
Evaluation of the effectiveness of vaccination in the short term is traditionally 
carried out according to the incidence of genital warts, as the earliest marker of 
HPV infection.
HPV vaccination in the long term aims to reduce the incidence and mortality 
from cervical cancer, anal cancer, and other HPV-associated cancers. However, the 
introduction of a monitoring system, or register of vaccinated, will allow assessing 
not only the indicators of early effectiveness but also monitoring adverse events 
associated or not associated with vaccination.
Indicators such as a decrease in cases of genital warts or genital intraepithelial neo-
plasia in the vaccinated population will be recorded earlier than results in a decrease 
in HPV-associated cancers and may indicate the effectiveness of HPV vaccination.
For monitoring it is necessary to have a register of vaccinated. The creation of 
the register of vaccinated will allow assessing the following parameters: indicators 
of early effectiveness and monitoring adverse events associated and not associated 
with vaccination. The introduction of the HPV register should be carried out at all 
levels, from doctors involved in vaccination to health administrators involved in 
evaluating strategies to improve the health of citizens.
The information contained in the register will assess the following criteria for 
the implementation of the HPV vaccination program:
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1. Accounting of vaccine coverage, age, and sex of the vaccinated. The ability to 
call adolescents for missed doses of the vaccine
2. Efficacy in reducing precancerous, cancerous, and other HPV-associated 
diseases: HPV infection; cervical and other HPV-associated genital neoplasia 
(CIN, AIN, VIN, VaIN); cervical cancer, adenocarcinoma in situ (AIS), anal 
cancer, vulvar cancer, and vaginal cancer; and anogenital warts
3. Monitoring adverse events related to vaccination time and distant in time
4. Modeling or correcting existing cervical cancer prevention screening programs
7. First results and expected effect of vaccination
The average age of development of cervical cancer and other HPV-associated 
cancers is 45 years, but it should be understood that cancer of the cervix, vulva, 
vagina, and anal canal is preceded by precancerous lesions, namely, cervical 
intraepithelial neoplasia 1/2/3 degree (CIN), adenocarcinoma in situ, vulvar and 
vaginal intraepithelial neoplasia (VIN, VaIN), and anal intraepithelial neoplasia 
(AIN), which occur at a younger age. The time required to develop cervical, vul-
var, vaginal, and anal cancer from CIN, VIN, VaIN, AIN can take 9–15 years [1, 2].
International experts, including experts from the World Health Organization, 
agree that the ethical and time frame necessitates the use of precancerous lesions 
rather than cancer as the endpoint of HPV vaccination effectiveness. The ability of 
vaccination to effectively reduce precancerous lesions of the anogenital region in 
men and women suggests the absence of anogenital cancers in the future. Thus, the 
reduction of precancerous lesions of the anogenital region and the development of 
genital warts in women and men is recognized as the main marker for assessing the 
short- and medium-term effectiveness of HPV vaccination.
The economic damage of HPV in the Khanty-Mansiysk Autonomous Region-
Ugra is about $5,730,000 per year.
Predicted effect of HPV-associated disease vaccination in KhMAO-Ugra:
• will be prevented by infection with human papillomavirus 6, 11, 16, and 18 
types, which is not less than 99% of vaccinated teenagers due to develop-
ment of postvaccinal immunity; this will prevent about 70% of all cervical 
cancer cases, 80% of cases of anal cancer, 60% of oropharyngeal cancer 
cases, 55% of cases of vaginal cancer, 48% of vulvar cancer cases, and 48% 
of cases of penile cancer.
• The incidence of genital warts will be reduced by at least 90% in the cohort 
(compared with unvaccinated groups) in the future 3–5 years.
• HPV vaccination will prevent costs by reducing the incidence of HPV in the 
amount of $3,900,000.
• Positive economic effect will be provided for the period of 5 years in the 
amount of $2,300,000, provided 70% vaccination coverage for girls 12 years in 
the Khanty-Mansiysk Autonomous Region-Ugra
• HPV vaccination will save 11,015 bed occupancy per year and prevent 101 
deaths from malignant neoplasms per year.
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When analyzing the incidence of HPV-associated diseases in KhMAO-Ugra, it 
was found that since 2011, the incidence of anogenital warts in adolescent girls has 
decreased both by the results of preventive examinations and by the incidence in 
the offices of a gynecologist. The incidence of HPV-associated diseases was moni-
tored in a group of young women 8 and 10 years after vaccination. We examined 
871 girls aged 20–22 who received vaccination at the age of 12 years old, and we did 
not register clinical manifestations of HPV infection (anogenital warts, CIN).
In addition, we noted the general population effect. The rate of primary inci-
dence of anogenital warts in the adult population in KhMAO-Ugra for the period 
2009–2008 decreased by 39%.
8. Conclusion
The lack of national HPV vaccination programs is not due to the lack of rel-
evance of HPV-associated disease prevention but to the lack of sufficient financial 
resources to implement it. We hope that in the coming years, HPV vaccination will 
also be included in the Russian national vaccination calendar.
Factors that prevent the formation of recognition of vaccination are ignorance 
about HPV and cancer, lack of awareness of the risks of cancer, fears of undesirable 
consequences, and uncertainty about long-term vaccine protection. The effective-
ness of HPV vaccination programs depends on the level of vaccination coverage, 
which in turn depends on the recognition of the importance of HPV vaccination by 
the government, health authorities, doctors, vaccinees, and their parents.
During vaccination, we should:
• Consider the possibility of protection against the largest range of HPV-
associated cancer and other diseases, that is, use at least quadrivalent HPV 
vaccine with inclusion in the vaccination program for boys aged 12–14.
• Achieve vaccination coverage for at least 70% of girls aged 12–13.
• Implement a system to monitor the effectiveness of the vaccination program, 
including short-, medium-, and long-term indicators.
It is necessary to work on the improvement of professional training of health 
workers in preventing communicable diseases—organization of thematic confer-
ences and round tables and development of thematic improvement of doctors and 
nurses.
We see the need to continue to work to provide the public with reliable and 
objective information on vaccination.
In order to promote vaccination and improve its effectiveness, further activities 
should be undertaken with the involvement of the pediatric care service under the 
immunization program:
• Conduct field meetings with parents, representatives of schools, and children’s 
clinics.
• Continue explanatory work in mass media in connection with high activity of 
anti-vaccine agitation on the Internet.
• Prepare booklets with questions on reproductive health, develop volunteer 
movement among students, and conduct surveys of young people.
Human Papillomavirus
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1. Accounting of vaccine coverage, age, and sex of the vaccinated. The ability to 
call adolescents for missed doses of the vaccine
2. Efficacy in reducing precancerous, cancerous, and other HPV-associated 
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(AIN), which occur at a younger age. The time required to develop cervical, vul-
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rather than cancer as the endpoint of HPV vaccination effectiveness. The ability of 
vaccination to effectively reduce precancerous lesions of the anogenital region in 
men and women suggests the absence of anogenital cancers in the future. Thus, the 
reduction of precancerous lesions of the anogenital region and the development of 
genital warts in women and men is recognized as the main marker for assessing the 
short- and medium-term effectiveness of HPV vaccination.
The economic damage of HPV in the Khanty-Mansiysk Autonomous Region-
Ugra is about $5,730,000 per year.
Predicted effect of HPV-associated disease vaccination in KhMAO-Ugra:
• will be prevented by infection with human papillomavirus 6, 11, 16, and 18 
types, which is not less than 99% of vaccinated teenagers due to develop-
ment of postvaccinal immunity; this will prevent about 70% of all cervical 
cancer cases, 80% of cases of anal cancer, 60% of oropharyngeal cancer 
cases, 55% of cases of vaginal cancer, 48% of vulvar cancer cases, and 48% 
of cases of penile cancer.
• The incidence of genital warts will be reduced by at least 90% in the cohort 
(compared with unvaccinated groups) in the future 3–5 years.
• HPV vaccination will prevent costs by reducing the incidence of HPV in the 
amount of $3,900,000.
• Positive economic effect will be provided for the period of 5 years in the 
amount of $2,300,000, provided 70% vaccination coverage for girls 12 years in 
the Khanty-Mansiysk Autonomous Region-Ugra
• HPV vaccination will save 11,015 bed occupancy per year and prevent 101 
deaths from malignant neoplasms per year.
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When analyzing the incidence of HPV-associated diseases in KhMAO-Ugra, it 
was found that since 2011, the incidence of anogenital warts in adolescent girls has 
decreased both by the results of preventive examinations and by the incidence in 
the offices of a gynecologist. The incidence of HPV-associated diseases was moni-
tored in a group of young women 8 and 10 years after vaccination. We examined 
871 girls aged 20–22 who received vaccination at the age of 12 years old, and we did 
not register clinical manifestations of HPV infection (anogenital warts, CIN).
In addition, we noted the general population effect. The rate of primary inci-
dence of anogenital warts in the adult population in KhMAO-Ugra for the period 
2009–2008 decreased by 39%.
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The lack of national HPV vaccination programs is not due to the lack of rel-
evance of HPV-associated disease prevention but to the lack of sufficient financial 
resources to implement it. We hope that in the coming years, HPV vaccination will 
also be included in the Russian national vaccination calendar.
Factors that prevent the formation of recognition of vaccination are ignorance 
about HPV and cancer, lack of awareness of the risks of cancer, fears of undesirable 
consequences, and uncertainty about long-term vaccine protection. The effective-
ness of HPV vaccination programs depends on the level of vaccination coverage, 
which in turn depends on the recognition of the importance of HPV vaccination by 
the government, health authorities, doctors, vaccinees, and their parents.
During vaccination, we should:
• Consider the possibility of protection against the largest range of HPV-
associated cancer and other diseases, that is, use at least quadrivalent HPV 
vaccine with inclusion in the vaccination program for boys aged 12–14.
• Achieve vaccination coverage for at least 70% of girls aged 12–13.
• Implement a system to monitor the effectiveness of the vaccination program, 
including short-, medium-, and long-term indicators.
It is necessary to work on the improvement of professional training of health 
workers in preventing communicable diseases—organization of thematic confer-
ences and round tables and development of thematic improvement of doctors and 
nurses.
We see the need to continue to work to provide the public with reliable and 
objective information on vaccination.
In order to promote vaccination and improve its effectiveness, further activities 
should be undertaken with the involvement of the pediatric care service under the 
immunization program:
• Conduct field meetings with parents, representatives of schools, and children’s 
clinics.
• Continue explanatory work in mass media in connection with high activity of 
anti-vaccine agitation on the Internet.
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Abstract
Head and neck malignancies represent the sixth most frequent type of cancer 
currently in worldwide statistics. Of these, oral and pharyngeal cancers have 
steadily increased, being linked with the increase in HPV infection pandemic. This 
rise is not due to one cause, but rather multiple factors such as lifestyle and sexual 
behavior pattern changes and globalization. Because of the anatomy of the oral 
cavity and oropharynx, the proper diagnosis is easily delayed, and patients present 
with advanced stage disease, which requires aggressive and extensive surgery along 
with neck dissection and chemoradiotherapy. Patients with advanced stage disease 
have a high recurrence risk with a low 5-year survival rate. Preventing the HPV 
infection is of course desirable, but right now, for adults which already are infected 
and have a higher risk of developing HPV-related neoplasias, as well as for our head 
and neck cancer patients, alternative treatment algorithms are necessary.
Keywords: head and neck cancer, HPV, OPSCC, oral cancer, neck dissection
1. Introduction
Head and neck squamous cell carcinoma (HNSCC) is the sixth most common 
malignancy in the world [1]. The tonsils are the most common location in oropha-
ryngeal malignancy. Despite being easily accessible to examination, its symptoms 
are usually ignored especially in early stages, leading to high morbidity and mor-
tality. Traditionally oral and oropharyngeal cancers were attributed to smoking 
and alcohol abuse, but in more recent years there has been an increase in numbers 
due to high prevalence of Human papillomavirus (HPV) infection. The presence of 
HPV can alter the prognosis of the disease, and recently there was a change in the 
WHO classifications and TNM staging to reflect this [2]. Depending on the stage 
of the disease, treatment for oral and oropharyngeal cancers consists of surgery 
and/or chemoradiotherapy.
2. Etiology
Traditionally smoking is considered the major factor in developing tonsil cancer. 
More than three quarters of oropharyngeal cancers are associated with tobacco use 
in all its forms (cigarettes, cigars, pipes, chewed tobacco). Secondhand smokers also 
have an increased risk of developing head and neck cancers. Alcohol is the second 
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major risk factor in the etiology of tonsil cancer. Although studies have not shown a 
direct link between the use of alcohol alone in carcinogenesis, the combined effect 
of tobacco and alcohol has a synergic effect on the development of cancer cells [3].
In the last 10 years, HPV infection has been widely recognized as an important 
etiological factor in the development of head and neck squamous cell carcinomas. 
The development of PCR analysis or in situ hybridization has demonstrated the 
impact of HPV in oropharyngeal malignancy [1]. Gillison [4] was the first to show 
that HPV-positive oropharyngeal cancers have different molecular, clinical, and 
pathological traits than HPV-negative cancers. Although HPV is considered to play 
a vital role in most head and neck cancers, studies have only proven its impact in 
oropharyngeal cancers [5].
HPV is a double-stranded DNA oncovirus and is epitheliotropic, infecting 
the basal cells of the epithelium and can be found in up to 60% of squamous cell 
carcinomas of the oropharynx [6]. There are more than 150 isolated strains of HPV, 
but only two types 16 and 18 are most commonly linked to oropharyngeal cancers. 
The oncogenic effect of HPV is due to two proteins E6 and E7 that target the p53 
and pRB (retinoblastoma) tumor suppressor genes of the infected cells making 
them vulnerable to mutations [7]. The loss of the pRB tumor suppressor deter-
mines the intranuclear accumulation of p16. p16 has a tumor suppressor role which 
normally would inhibit cell cycle but is overexpressed in HPV-positive tumors due 
to the action of E7. It is considered a useful marker in oropharyngeal cancers [8]. 
Due to the large body of evidence that suggest that HPV-positive and HPV-negative 
oropharyngeal cancers represent distinct subgroups of OPSCC, the National 
Comprehensive Cancer Network (NCCN) guidelines as of 2017 require HPV testing 
for all oropharyngeal tumors and that the HPV status must be included as a stratifi-
cation factor [2]. The latest staging for oropharyngeal cancers takes into account the 
distinct groups of OPSCC, and because HPV-positive cancers tend to have a better 
prognosis, separate TNM staging systems are used [9, 10].
Dietary habits also play a role in carcinogenesis although harder to properly 
quantify. For example, iron deficiency may lead to an increased vulnerability of 
the oropharyngeal mucosa and decreased immune system. A diet low in fruits and 
vegetables can lead to a vitamin A and vitamin E deficiency that is associated with 
an increased risk of developing oropharyngeal malignancies. Poor oral hygiene can 
also be a risk factor especially for tobacco and alcohol users [11].
3. Symptoms and diagnosis
Oropharyngeal cancer is usually located in the tonsillar fossa, but extension to 
adjacent structures is common (Figure 1). Frequently tonsillar carcinoma extends 
downward to the tongue base along the glosso-tonsillar sulcus (Figure 2) and to the 
soft palate laterally. Laterally the tonsillar fossa is bounded by the superior constric-
tor muscle of the pharynx which offers some resistance to the spread of carcinoma. 
Extension past the superior constrictor muscle represents involvement of the para-
pharyngeal space with consecutive involvement of the pterygoid musculature or 
mandible locally advanced disease. Extension to the skull base is rare but possible.
Due to its rich lymphatic drainage, lymph node involvement is present in about 70% 
of patients. The most common lymph node levels affected are level II and level III [12].
Distant metastasis from tonsillar cancer occurs in about 15–30% of cases; the 
most common sites are the lung, liver, and bones [13].
Tonsillar cancer may present with a variety of signs and symptoms. In the early 
stages, the patient is usually asymptomatic, or it can mimic some mild diseases like 
sore throat or acute tonsillitis. Patients usually complain of sore throat, unilateral 
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otalgia, or a feeling of a mass in the throat. In advanced stages it can present with 
dysphagia. In latter stages the patient may present with trismus or bleeding from 
the mouth. If the tumor has ulcerations and necrosis, patients will usually complain 
of bad breath. The rich lymphatic drainage could mean that the first sign of disease 
is enlarged lymph nodes especially in the jugulodigastric region (group II). Such 
patients must be asked about weight loss, hoarseness, and odynophagia. A thorough 
patient history about tobacco and alcohol use and other known etiological factors 
(including known HPV infection) may raise suspicion of a malignant tumor. HPV-
positive tumors will typically appear in younger nonsmoking patients.
Patients diagnosed with a tumor involving the oral and oropharyngeal regions 
must undergo a full ENT examination, with neck palpation, flexible endoscopy, and 
biopsy. After histological confirmation of the malignancy, imaging studies must be 
obtained to stage the tumor. Contrast CT scans represent the standard method for 
Figure 1. 
Oral examination of a male patient with a left oropharyngeal tumor which infiltrates and deforms the 
tonsillar fossa as well as part of the soft palate, with ulceration and suprainfection.
Figure 2. 
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staging and should include the skull base, cervical region, thorax, and abdomen to 
possibly identify secondary tumors. Contrast-enhanced MRI is superior to CT in 
detecting soft tissue extension and involvement but may be influenced by dental 
foreign materials.
Staging of the disease is done by using the AJCC cancer staging system (Table 1) 
that uses three variables—primary tumor characteristics (T), lymph node involve-
ment (N), and the existence of metastases (M).
Starting from 1 January 2017, all patients with oropharyngeal cancer should 
be tested for the presence of HPV, thus classifying them in one of two possible 
categories—HPV positive (p16INK4A+) and HPV negative. There is no current gold 
standard test, because all available testing methods were developed for cervical 
cancer, and not perfectly adapted for tonsillar cancer. However, p16 protein IHC is 
currently used for detecting HPV presence [15].
Tumor Characteristics
T0 No primary tumor identified
T1 Tumor less than 2 cm in any dimension
T2 Tumor between 2 and 4 cm
T3 Tumor greater than 4 cm in any dimension or extension to lingual surface of the 
epiglottis
T4 = moderately advanced local disease—tumor invades the larynx, extrinsic muscles of 
the tongue, medial pterygoid muscles, hard palate, mandible or beyond
Table 2. 
AJCC tumor characteristics regarding HPV-positive (p16+) oropharyngeal carcinoma [14].
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Table 1. 
AJCC staging of HPV-positive (p16+) oropharyngeal cancer [14].
Lymph 
node (N)
Clinical N (cN) Pathological N (pN)
Nx Regional lymph nodes cannot be assessed Regional lymph nodes cannot be 
assessed
N0 No regional lymph node metastasis No regional lymph node metastasis
N1 One or more ipsilateral lymph nodes, none 
>6 cm
Metastasis in 4 or fewer lymph nodes
N2 Contralateral or bilateral lymph nodes, none 
>6 cm
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Tumor and lymph node characteristics are described in Tables 2 and 3, whereas 
the presence of distant metastases automatically stages the disease into the last and 
most severe stage—stage IV (Table 1).
4. Treatment and outcome
Treatment of oropharyngeal malignancy depends on the disease stage, but the 
principle that guides it is the same as in all cancer surgery: local disease control. 
Thus, with modern surgical and irradiation techniques, 5-year survival rates of 
almost 100% are attainable [16].
For the purpose of management protocol, oropharyngeal cancer is divided 
into early-stage (T1 and T2) and advanced diseases (T3 and T4). The latter are 
divided into resectable and non-resectable tumors. According to this, treatment for 
early-stage disease should be either surgery or radiation therapy with concurrent 
chemotherapy. Surgical treatment consists of excision of the primary tumor, either 
by a trans-oral approach or by external approach (lateral pharyngotomy or trans-
mandibular approach by mandibular swing technique (Figures 3–5)).
Most oropharyngeal tumors are accessible by trans-oral approach. This is the 
least aggressive type of surgical approach, with the least morbidity. Auto-static 
mouth gags (McIver, Dingmann, etc.) permit good exposure of the surgical site, 
and excision by electrocautery, radiofrequency, and CO2 laser, and optical augmen-
tation either using surgical loupes or operating microscopes permit tackling most of 
the T1 to T3 tumors [17].
Tumors extending downward to the epiglottis and hypopharynx (pyriform 
sinus) require an external approach, by lateral pharyngotomy. This approach 
provides access to the oro- and hypopharynx, as well as control of the cervical large 
blood vessels and lymph nodes [18–20].
Advanced tumors (T4), tumors which involve adjacent structures (extrinsic 
muscles of the tongue, larynx, mandible, pterygoid muscles, or hard palate), often 
require an even more aggressive external approach—by lateral mandibulotomy—
the so-called mandibular swing technique. This approach permits access to the 
Figure 3. 
External approach to a right side advanced (T4) oropharyngeal cancer which shows the neck dissection, with 
internal jugular vein and bifurcation of the common carotid artery visible inferior to the posterior belly of the 
omohyoid muscle, as well as the mandibulotomy—The creation of the mandibular “swing.”
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oral cavity, oropharynx, as well as hypopharynx and lateral cervical lymph nodes, 
parapharyngeal space, and masticator space and allows instrumentation of the 
entire oral cavity, making hard palate resections possible [21, 22].
Whichever surgical approach to the primary tumor the surgeon opts for, just 
as important as the complete excision of the tumor (the T) is the neck dissection. 
Tumors that do not pass the midline usually require ipsilateral lymph node dissec-
tion. However, bilateral neck dissection is sometimes required because of the vast 
network of lymphatics that drain the lateral pharyngeal area—most patients present 
with at least clinically N1 on diagnosis [23, 24].
The alternative to surgical excision of the tumor is external intensity-modulated 
radiation therapy (IMRT) with or without adjuvant chemotherapy. This procedure 
has similar outcomes compared to surgery in cases of early-stage tumors but is 
slightly inferior compared to surgery when addressing advanced tumors. The dose 
delivered to the surrounding tissues is responsible for the toxicity and late adverse 
Figure 4. 
External approach to a left side advanced oropharyngeal tumor, via mandibular “swing” demonstrating 
closure of the mandibulotomy using two titanium miniplates anchored with screws.
Figure 5. 
Extensive external approach to a left side advanced (T4) tumor of the oropharynx and hypopharynx 
extending to the bony cortex of the mandible—with modified radical neck dissection and lateral 
mandibulotomy, with the two resulting mandibular pieces being pulled apart at different angles so as to permit 
wider access.
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effects of radiation therapy, such as osteoradionecrosis of the mandible, radiomuco-
sitis, xerostomia, dental cavities, and teeth avulsion [25]. These have a high impact 
on the patients’ quality of life; thus modern management of HPV-positive oropha-
ryngeal cancer consists in trans-oral excision (with a rising trend towards robotic 
surgery) of the primary tumor with selective neck dissection followed by low-dose 
radiation therapy [25].
5. Conclusions
As HPV infection is a growing concern worldwide, cases of HPV-positive oral 
and oropharyngeal carcinoma become more frequently encountered. Treatment 
options for this type of malignancy follow the same principles as for non-HPV-
positive squamous cell carcinoma of the oral cavity and pharynx, consisting in 
surgery for locoregional control of the primary tumor and regional lymph nodes 
and radiation therapy—either as a stand-alone option or as an adjuvant therapy 
following surgical excision.
However, particularities of HPV-positive oropharyngeal cancer have led to a 
separation of this pathologic entity from the rest of squamous cell carcinomas 
involving the oropharynx. These tumors have a better outcome following treatment 
and thus treatment options were de-escalated to offer the same outcome and 5-year 
survival as well as less morbidity and a better quality of life.
New perspectives in treating the chronic HPV infection as well as preventing this 
infection by introducing efficient vaccination programs that target girls and boys 
also offer a positive future perspective on reducing malignancies associated with 
this viral infection, including those affecting the oral cavity and pharynx.
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oral cavity, oropharynx, as well as hypopharynx and lateral cervical lymph nodes, 
parapharyngeal space, and masticator space and allows instrumentation of the 
entire oral cavity, making hard palate resections possible [21, 22].
Whichever surgical approach to the primary tumor the surgeon opts for, just 
as important as the complete excision of the tumor (the T) is the neck dissection. 
Tumors that do not pass the midline usually require ipsilateral lymph node dissec-
tion. However, bilateral neck dissection is sometimes required because of the vast 
network of lymphatics that drain the lateral pharyngeal area—most patients present 
with at least clinically N1 on diagnosis [23, 24].
The alternative to surgical excision of the tumor is external intensity-modulated 
radiation therapy (IMRT) with or without adjuvant chemotherapy. This procedure 
has similar outcomes compared to surgery in cases of early-stage tumors but is 
slightly inferior compared to surgery when addressing advanced tumors. The dose 
delivered to the surrounding tissues is responsible for the toxicity and late adverse 
Figure 4. 
External approach to a left side advanced oropharyngeal tumor, via mandibular “swing” demonstrating 
closure of the mandibulotomy using two titanium miniplates anchored with screws.
Figure 5. 
Extensive external approach to a left side advanced (T4) tumor of the oropharynx and hypopharynx 
extending to the bony cortex of the mandible—with modified radical neck dissection and lateral 
mandibulotomy, with the two resulting mandibular pieces being pulled apart at different angles so as to permit 
wider access.
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effects of radiation therapy, such as osteoradionecrosis of the mandible, radiomuco-
sitis, xerostomia, dental cavities, and teeth avulsion [25]. These have a high impact 
on the patients’ quality of life; thus modern management of HPV-positive oropha-
ryngeal cancer consists in trans-oral excision (with a rising trend towards robotic 
surgery) of the primary tumor with selective neck dissection followed by low-dose 
radiation therapy [25].
5. Conclusions
As HPV infection is a growing concern worldwide, cases of HPV-positive oral 
and oropharyngeal carcinoma become more frequently encountered. Treatment 
options for this type of malignancy follow the same principles as for non-HPV-
positive squamous cell carcinoma of the oral cavity and pharynx, consisting in 
surgery for locoregional control of the primary tumor and regional lymph nodes 
and radiation therapy—either as a stand-alone option or as an adjuvant therapy 
following surgical excision.
However, particularities of HPV-positive oropharyngeal cancer have led to a 
separation of this pathologic entity from the rest of squamous cell carcinomas 
involving the oropharynx. These tumors have a better outcome following treatment 
and thus treatment options were de-escalated to offer the same outcome and 5-year 
survival as well as less morbidity and a better quality of life.
New perspectives in treating the chronic HPV infection as well as preventing this 
infection by introducing efficient vaccination programs that target girls and boys 
also offer a positive future perspective on reducing malignancies associated with 
this viral infection, including those affecting the oral cavity and pharynx.
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Human papillomavirus infections are very common and recurrent. Their presen-
tation varies according to their site of affection. Spontaneous recovery is common in 
a good number of patients. An ideal wart therapy resolves all or maximum number 
of warts, is painless, needs only one or a part of a wart treated, needs only minimum 
number of treatments, leaves no scar, offers lifetime HPV immunity and is easily 
available for all patients. Various modalities of treatment are available—from some 
folk and alternative therapies to destructive, antimitotic, virucidal, immunotherapy 
and combination of therapies. In every modality, the result is significant. Younger 
individuals with short duration of illness usually have the highest clearance rates for 
various treatments. Recurrence rate is also high in almost every treatment modality. 
Immunotherapy has a promising role.
Keywords: human papillomavirus infection, chemical cautery, electrocautery, 
cryotherapy, laser therapy, immunotherapy
1. Introduction
Human papillomaviruses (HPVs) are a large and diverse group of viruses with 174 
completely characterised types, with new HPV types being continuously found [1]. 
There are five major HPV genera: Alphapapillomavirus, Betapapillomavirus, Gamma 
papillomavirus, Mu papillomavirus and Nu papillomavirus. HPVs infect epithelial 
cells in genital mucosa (Alphapapillomaviruses only), oral mucosa or skin (repre-
sentatives of all five genera). The most common clinical manifestation is verruca, 
with different morphological forms. The histology shows acanthosis, elongation of 
dermal papillae, presence of vacuolated cells and koilocytes. Subclinical manifesta-
tions are invisible to the human eye. These subclinical lesions are flat and multiple. 
Their clinical insignificance facilitates their spread, and in women their persistence 
is possibly related to genital cancer.
2. Diagnosis
2.1 Clinical diagnosis
The clinical picture of cutaneous warts differs by specific location on the 
body [2]. Most extragenital warts are benign, and usually clinical diagnosis is 
adequate, but sometimes additional methods are required especially in atypical, 
subclinical or dysplastic lesions. Genital lesions are more prone to transform to 
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malignancy, so determining the extent of disease is essential. Examining the wart 
and scraping off the top layer of the wart to check for signs of dark, pinpoint dots—
clotted blood vessels—are common with warts.
2.2 Dermatoscopy
Warts can be visualised exceptionally well by dermoscopy, especially the 
black dots. Dermoscopy is also very useful in terms of differential diagnosis and 
follow-up [2].
2.3 Acetowhitening
Genital/mucosal lesions remain undetected for a long time; not only that, all 
lesions may not be clinically evident at a time. Topical application of 3–5% of acetic 
acid for 3–5 min and followed by examination with 10X hand lens or colposcope 
is a reasonable accurate diagnostic tool. Lesions will be represented as tiny white 
papules. The routine use of this procedure to detect mucosal changes attributed to 




Acanthosis, epidermal hyperplasia, papillomatosis, compact orthokeratosis, 
hypergranulosis, tortuous dermal papillary capillaries, and vertical tiers of para-
keratotic cells are the typical histological findings of warts. In the granular layer, 
cells have coarse keratohyalin granules and vacuoles surrounding wrinkled-
appearing nuclei. Koilocytes are pathognomonic.
3.2  Immunohistochemistry or immunocytochemistry using type-common  
and type-specific antibodies
3.2.1 DNA in situ hybridization
In situ hybridization is a direct signal detection assay. It preserves the morpho-
logical context with HPV DNA signals. It has low sensitivity; however, in recent 
years, using improved signal-detecting method, sensitivity increased. It is becom-
ing a valuable screening tool for women of age more than 30 years.
3.3  Polymer-based enzyme-linked immunosorbent assay (ELISA) for 
immunoglobulin G (IgG) antibody (Ab) against HPV 16 capsid
3.3.1 PCR for HPV DNA
Patients who are diagnosed with condylomata need a Papanicolaou (Pap) 
test of the cervix in accordance with the guidelines of the American College of 
Obstetricians and Gynaecologists
Computed tomography (CT) or magnetic resonance imaging (MRI) can be used 
to determine the extent of spread of cervical carcinoma and extensive anogenital 
papillomatosis that has spread into the pelvis.
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4. Treatment
Warts are usually self-limiting. Large studies have shown complete spontane-
ous remission in 42% of patients after 2 months; in 53%, after 6 months; and in 
65%, after 2 years [2]. The intact immune system plays the most important role for 
preventing HPV infection. This can be seen in patients with primary immunodefi-
ciency or in immunosuppressed patients.
HPV-induced warts are the most common skin disorder in organ transplant 
recipients [3]. Children with recalcitrant extragenital wart may suffer from primary 
immunodeficiency. It has been shown that immunosuppressed patients experience 
resolution of treatment-refractory warts once their immune status has improved [4]. 
The known spontaneous remission of HPV-induced warts, which is attributed to cell-
bound mechanisms, underscores the role of the immune system, including an increase 
in Th1 cytokines and infiltration of T cells (CD4+, CD8+) around the diseased tissue [5].
Guidelines for the management of cutaneous warts have been prepared for 
dermatologists on behalf of the British Association of Dermatologists [6]. The 
guideline highlighted the ideal aims of treatment of warts as follows: (i) Removal of 
wart without recurrence. (ii) Treatment should result with no scars. (iii) Immunity 
that induced by treatment should be lifelong [5]. The general principles observed 
in the treatment of warts are the following: (1) There is no need to treat all warts. 
(2) Treatment indications are pain, interference with function, cosmetic embar-
rassment and risk of malignancy. (3) All the treatments have success rate not very 
high (average 60 ± 70% clearance in 3 months). (4) An immune response is usually 
essential for clearance. Immunocompromised individuals may never show wart 
clearance. (5) Younger individuals with short duration of illness usually have the 
highest clearance rates for various treatments [5].
There is a high rate of spontaneous remission, especially in children, so ‘wait-and-
see’ approach is feasible in many cases. Regular filing or paring down the hyperkera-
totic layer makes the lesion thin and comfortable. Simple measure to limit the spread 
of lesion should be encouraged. The treatment of warts can be broadly classified into 
destructive, antimitotic, virucidal, immunotherapy, and some folk and alternative 
therapies which have recently become popular again.
The goals of wart treatment are to resolve all or a maximum number of warts, 
make it painless, need only one or a part of a wart treated, only need minimum 
number of treatments, leave no scar, offer lifetime HPV immunity and be easily 
available for all patients [7]. The criteria for wart treatment, developed by the 
American Academy of Dermatology in 1995, [7] include (1) the patient’s desire 
for therapy; (2) symptoms of pain, bleeding, itching or burning; (3) disabling or 
disfiguring lesions; (4) large numbers or large sizes of lesions; (5) the patient’s 
desire to prevent the spread of warts to unblemished skin of self or others; and (6) 
an immunocompromised condition [6].
4.1 Destructive therapy
The lesions are damaged or removed by different procedures followed by clinical 
cure. The destructive therapies include surgical removal by curettage and cautery, 
chemical cautery, cantharidin, cryotherapy, electrocautery, radiocautery ablation, 
infrared coagulation, photodynamic therapy, and lasers.
4.1.1 Surgery
Curettage followed by cautery was an early and still widely practiced method of 
surgical removal of warts. A success rate of 65–85% has been reported in surgical 
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preventing HPV infection. This can be seen in patients with primary immunodefi-
ciency or in immunosuppressed patients.
HPV-induced warts are the most common skin disorder in organ transplant 
recipients [3]. Children with recalcitrant extragenital wart may suffer from primary 
immunodeficiency. It has been shown that immunosuppressed patients experience 
resolution of treatment-refractory warts once their immune status has improved [4]. 
The known spontaneous remission of HPV-induced warts, which is attributed to cell-
bound mechanisms, underscores the role of the immune system, including an increase 
in Th1 cytokines and infiltration of T cells (CD4+, CD8+) around the diseased tissue [5].
Guidelines for the management of cutaneous warts have been prepared for 
dermatologists on behalf of the British Association of Dermatologists [6]. The 
guideline highlighted the ideal aims of treatment of warts as follows: (i) Removal of 
wart without recurrence. (ii) Treatment should result with no scars. (iii) Immunity 
that induced by treatment should be lifelong [5]. The general principles observed 
in the treatment of warts are the following: (1) There is no need to treat all warts. 
(2) Treatment indications are pain, interference with function, cosmetic embar-
rassment and risk of malignancy. (3) All the treatments have success rate not very 
high (average 60 ± 70% clearance in 3 months). (4) An immune response is usually 
essential for clearance. Immunocompromised individuals may never show wart 
clearance. (5) Younger individuals with short duration of illness usually have the 
highest clearance rates for various treatments [5].
There is a high rate of spontaneous remission, especially in children, so ‘wait-and-
see’ approach is feasible in many cases. Regular filing or paring down the hyperkera-
totic layer makes the lesion thin and comfortable. Simple measure to limit the spread 
of lesion should be encouraged. The treatment of warts can be broadly classified into 
destructive, antimitotic, virucidal, immunotherapy, and some folk and alternative 
therapies which have recently become popular again.
The goals of wart treatment are to resolve all or a maximum number of warts, 
make it painless, need only one or a part of a wart treated, only need minimum 
number of treatments, leave no scar, offer lifetime HPV immunity and be easily 
available for all patients [7]. The criteria for wart treatment, developed by the 
American Academy of Dermatology in 1995, [7] include (1) the patient’s desire 
for therapy; (2) symptoms of pain, bleeding, itching or burning; (3) disabling or 
disfiguring lesions; (4) large numbers or large sizes of lesions; (5) the patient’s 
desire to prevent the spread of warts to unblemished skin of self or others; and (6) 
an immunocompromised condition [6].
4.1 Destructive therapy
The lesions are damaged or removed by different procedures followed by clinical 
cure. The destructive therapies include surgical removal by curettage and cautery, 
chemical cautery, cantharidin, cryotherapy, electrocautery, radiocautery ablation, 
infrared coagulation, photodynamic therapy, and lasers.
4.1.1 Surgery
Curettage followed by cautery was an early and still widely practiced method of 
surgical removal of warts. A success rate of 65–85% has been reported in surgical 
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therapy, but scarring and recurrence rate are high (30%), and the sole of the foot is 
the site where scarring is particularly problematic. Curettage followed by cautery is 
most commonly used for filiform warts on the limbs and face [8]. Excision is usually 
to be avoided as scarring is inevitable, and there is frequent chance of recurrence in 
the scar.
4.2 Salicylic acid
It is keratolytic, reduces the thickness of warts and may also stimulate an inflam-
matory response. Over-the-counter preparations are available as 17% salicylic acid 
combined in a base of flexible collodion or as a 40% salicylic acid plaster patch [9]. 
It is minimally expensive, convenient and reasonably effective, with negligible pain, 
but results require weeks to months of treatment. Occasionally, contact dermatitis 
due to colophony may develop, and to avoid systemic toxicity, it should be applied 
only in limited area. Treatment result with salicylic acid therapy extremely depends 
on patient compliance. Before pairing or debridement of the dead, hyperkeratotic 
tissue, wart(s) should be soaked in warm water for 5 min. The salicylic acid prepa-
ration should then be applied to the debrided wart [10].
4.3 Chemical cautery
Strong chemicals can destroy tissue. Trichloroacetic acid (TCA) and bichloro-
acetic acid (BCA) are not readily absorbed by tissue; it kills warts by denaturing 
and destroying the proteins in the cells. Treatment via chemical cautery with a 
solution of 60–90% trichloroacetic acid (TCA) is most effective when treating 
few small, moist lesions. There is a complete clearance of warts in 70% of patients 
who received up to 6 treatments of trichloroacetic acid. Thirty percent of patients 
who were treated with trichloroacetic acid developed ulcerations at the site of its 
application [11]. Recurrence rate is not clear. Silver nitrate is probably most widely 
recognised in its historical use to prevent conjunctivitis in newborns [12]. This 
treatment for warts is currently more widely used in the United Kingdom where 
non-prescription 95% silver nitrate caustic applicator pencils are available [13]. 
Chances of excessive burn and pigmentation are there.
4.4 Cantharidin
A terpenoid secreted by blister beetles, which is absorbed by lipids in kerati-
nocytes, activates serine proteases and leads to acantholysis [14, 15]. Depending 
on the amount, concentration, duration of exposure and occlusion, an intraepi-
dermal blister will form and resolve, within a week [16]. The superficial nature 
of the injury reduces the risk of scarring. One randomised control trial shows 
that cantharidin is effective, is safe, yields better cosmesis and requires fewer 
applications than TCA for the treatment of warts when used sufficiently far 
from mucosal and intertriginous areas. It was also shown to be well tolerated and 
that patients being treated with Cantharone were significantly more satisfied 
than those treated with TCA. This may be attributed to less pain during applica-
tion and during the entire treatment, better cosmetic results and perhaps fewer 
visits [17].
4.5 Phenol (carbolic acid)
It is a strong caustic agent that can penetrate deep into tissue, produces chemical 
burn with escher and is not used routinely for treatment of common wart.  
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Strong (80%) phenol solution for the treatment of common warts showed that 
phenol was an effective form of treatment for warts. It must be used by a physician 
and should not be used in extensive areas [18].
4.6 Retinoic acid
Topical tretinoin, although currently recommended for the treatment of acne, 
has also been reported to be of benefit in plane warts. A study of 25 children 
with plane warts treated with 0.05% topical tretinoin cream (applied once daily 
for 6 weeks) was compared with a control group of 25 untreated children. After 
12 weeks, clearance of warts was observed in 84.6% of the treated group as com-
pared with 32% of the control group. It was well tolerated with some redness and 
peeling in 42.3% of the treated group [19].
4.7 Photodynamic therapy
Photodynamic therapy (PDT) with topical 5-aminolevulinic acid has a good 
curative effect, especially in recalcitrant facial flat warts [20–22]. It is unclear, but 
selective photothermolysis of oxyhaemoglobin within the dilated microvasculature 
of the warts leads to destruction of capillaries followed by improvement of warts, 
may be the mechanism of action of this curative effect [23]. Many factors affect the 
efficacy of PDT, including photosensitizer concentration; solvent type; incubation 
time; type, dose, and time of irradiation of the light; and the area of exposed parts. 
ALA gel (10%) was applied topically to lesions and incubated for 3 h. The lesions 
were irradiated by an LED light of 630 ± 10 nm at dose levels of 60–100 mW/cm. At 
the 24-week follow-up, the average effective rate was 88.8%, with no recurrences. 
No significant side effects were reported [24].
4.8 Cryotherapy
Cryotherapy induces cold thermal injury in the lesion. Cryotherapy may have 
an effect on wart clearance either by simple necrotic destruction of HPV-infected 
keratinocytes or possibly by inducing local inflammation conducive to the develop-
ment of an effective cell-mediated response [25]. Dimethyl ether spray, carbon 
dioxide snow and liquid nitrogen all produce cold thermal damage to the skin. 
Different types of devices and techniques are used to induce targeted cold injury to 
warts. Carbon dioxide slush (−79°C) is now less commonly used.
4.8.1 Mixture of dimethyl ether and propane (DMEP)
It is in aerosol form, easy to handle and stored in normal room temperature, and 
its preservation time is very high (nearly 3 years), available in market and easy to 
buy. As the evaporation temperature reaches −57°, therefore, it is likely to be less 
effective, and efficacy in inducing tissue temperatures adequate for cell necrosis 
appears low [26]. But one multicentre RCT on comparing effects of DMEP and LN2 
shows that no clinically relevant differences between the efficacy, tolerance and 
safety of the two cryogenic agents used in primary care were found. The low freez-
ing of DMEP was sufficient for the cryotherapy of benign lesions [27].
4.8.2 Liquid nitrogen therapy
Having a temperature of −196°C, the coldest freeze, is the most commonly 
used method in medical practice. It is very effective in elimination of a large 
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variety of very common benign and premalignant skin lesions (verrucas, 
Molluscum contagiosum, seborrheic and actinic keratoses) [25]. Wart clearance 
may be through necrotic destruction of HPV-infected keratinocytes or by induc-
ing local inflammation that triggers an effective cell-mediated response [25]. 
Liquid nitrogen can easily be stored and used by simple equipment in clinic-based 
practice. Available techniques are dipstick, roller, spray gun and Probe. Dipstick 
is the simplest technique where a cotton swab is dipped in liquid nitrogen and 
applied on a lesion. It is suitable only for superficial, benign lesions. Cryoroller, 
whose tip is cylindrical, is dipped in liquid nitrogen and then rolled over the 
lesional area. It acts better in severe acne and hypertrophic scar. The most popular 
method is spray technique using cryoprobes [10]. There are variations in freeze 
times, mode of application and intervals between treatments. Freeze time is the 
time elapsed from start to end of freeze cycle, i.e., from formation of uniform 
ice field until lesion is thawed, varying from 5 to 20 s. In short freeze for warts, 
cryotherapy continued till a 2-mm white halo develops around the lesion; this is 
enough for plane wart or filiform warts. But long freeze time (maintaining white 
halo for 5–20 s) is required for plantar warts. The cycle is repeated every 3 weeks 
on 8–10 occasions. It is better to pare hyperkeratotic lesions before cryosurgery as 
it acts as insulator. A cure rate of 60–80% can be anticipated [28]. Longer freeze 
is more effective than traditional (shorter) freeze, and blistering is significantly 
greater [29]. Plantar warts need comparatively more aggressive therapy. There 
is no difference between single freeze-thaw cycle and double freeze-thaw cycle 
in palmer warts but in plantar warts, and double freeze-thaw is more effective 
[30]. The number of session is important, not the interval between sessions for 
percentage cure [31]. Two-week intervals between sessions may be an optimal 
treatment [31].
4.9 Ablation radiofrequency
Localised heating with radiofrequency heat generators and surgical excision 
with radiofrequency electrosurgical knives have been used with moderate success 
[32, 33].
Radiofrequency ablation is a common mode of treatment, and it involves the 
principle of tissue destruction with various waveforms of alternating electric 
current whose frequencies fall within the range of radiofrequency (500–4000 khz) 
[34]. The overall cure rate for warts with radiosurgery ranges between 33 and 80% 
depending on the number of sittings and the type of warts [35, 36].
Electrocautery is a form of electrosurgery that utilises galvanic or direct current 
for generating heat. Although rarely used nowadays in the developed nations, it is 
still widely used in the developing countries and is considered more effective for 
treating thicker lesions with an overall success rate of 56–80% [7].
4.10 Infrared coagulation
It is an instrument that produces noncoherent infrared light with a spectrum 
of 400–2700 nm. It has been reported as a cheaper, safer and more easily handled 
alternative to CO2 laser treatment. Direct application of infrared contact coagula-
tors causes thermal injury to a depth dependent on the duration of exposure [37]. 
A bulla arises after IRC that may protect the lesion against infection. Cure rate was 
66.7% for warts treated with IRC. The instrument allows adjustable tissue necrosis 
without tissue adhesion and has yielded remissions with a 10.8% recurrence rate 
[38]. In comparison to electrocoagulation, infrared coagulation produces similar 
outcomes [37], but it is safer than EC in side effect profile.
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4.11 Laser therapy
4.11.1 Carbon dioxide (CO2) laser
The CO2 laser was the initial laser modality used to treat warts and has been used 
since 1980s [39–41]. The CO2 laser emits infrared light of wavelength 10,600 nm. It 
is absorbed by tissue water and results nonselective thermal tissue destruction. The 
CO2 laser treats warts via two mechanisms. A focused CO2 laser beam used as a scal-
pel to excise the wart down to the subcutaneous tissue, followed by the base of the 
wart, which is vaporised by a defocused beam until a clean surgical field is obtained 
[42–45]. Cohort studies report that simple and recalcitrant common, palmar, plan-
tar, periungual and subungual warts have been successfully treated with CO2 laser, 
with response rates ranging from 50 to 100% [40, 43, 46–53]. Usually, excision by 
focused mode followed by vaporisation and haemostasis with defocused mode is 
the common practice. Deeper warts need more passes. Using two to four passes per 
wart is adequate [46–49]. CO2 laser treatment may be used for recalcitrant warts but 
also as a first-line of therapy for warts—mainly in the sole, hands and other parts 
also [46]. Single verruca lesions usually result better (66.7%) than multiple verruca 
(62.5%) [46]. It can be used for first-line therapy for periungual and subungual 
warts. It has been seen that patients with subungual and periungual warts, who 
have failed previous conventional therapy, respond less than in patients when CO2 
laser therapy was given as first line (47.9% compared to 80.0%) [47]. Subungual 
warts respond better than periungual warts [47]. Usually one or two sessions 
are adequate [48]. Patients with one session heal earlier than patients with more 
than one session [48]. Adverse effects include permanent nail matrix damage and 
scarring, and nail changes such as distal onycholysis and thickening may occur [47, 
48, 51]. CO2 laser may also be used as excision tool, with a remission rate of 95.5%, 
but requires specialised unit [49]. Scarring is a possibility [49]. ‘En bloc’ excision of 
wart is very much effective [100%] in paediatric age group also with no recurrence, 
and usually single session is adequate [50]. Many treatment modalities are not fea-
sible in immunosuppressive patients. CO2 laser can be a safe and comparably effec-
tive modality of treatment, even in one intervention [51]. Complete excision of the 
lesional skin with a portion of deeper tissue and 1-mm non-lesional margin leads to 
the complete clearance of HPV DNA, which leads to very lower recurrence, though 
chance of scar formation is there. Dressing with artificial dermis leads to less scar 
formation [52]. Application of Imiquad after CO2 laser in recalcitrant wart reduces 
or stops recurrences [53]. Vapour produced by CO2 laser with any power density 
and fluence contains intact papillomavirus DNA. This infected vapour may cause 
pulmonary infection [54]. Plume produced from laser procedure collected and used 
as inoculum may produce identical lesions [55]. So, safety precautions during laser 
surgery may be strictly maintained [55]. It is important to wear surgical masks as 
it is capable of removing all laser- or electrocoagulation-derived viruses [56], even 
gas scavenging system to be in use [57]. But a study among CO2 laser surgeons in 
all the members of American Society of Laser Medicine shows that the plume does 
not possess enough infectious material to produce significantly more amount of 
warts in laser surgeons in comparison to population-based common subjects [58]. 
But, sitewise, CO2 laser surgeons have a greater risk of acquiring nasopharyngeal 
lesions, especially when they treat genital warts with HPV types 6 and 11 [58]. 
Scar formation is a known side effect of CO2 lasers, and there are more chances of 
hypertrophic scar formation if the patient is on cyclosporine for other reasons [59]. 
In superpulsed CO2 LASERs, the high irradiances and brief duration make pos-
sible very precise removal of target lesion volumes and controlled excision. Here, 
thermal damage is very less leading to less inflammation and less scarring [60].
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4.11.2 Erbium:yttrium/aluminium/garnet (Er:YAG) laser
Non-ablative lasers are largely replacing ablative CO2 lasers as side effects are 
less, both for patients and clinicians [61]. Er:YAG laser emits 2940 nm wavelength. 
It is absorbed 12–18 times more efficiently by water containing superficial cutane-
ous tissue than CO2 laser. At 250 microsecond pulse duration and 5 J/cm2 fluence 
short pulse, Er:YAG laser ablates 5–20 micrometre of tissue per laser pass, and 
minimal residual thermal damage that results faster tissue re-epithelialization and 
less side effects. The disadvantage is intraoperative bleeding [62]. Its mechanism 
of action in treating warts is through direct ablation of the lesion in the epidermis, 
layer by layer until normal tissue is visualised. This laser type also has bactericidal 
effects [61]. Er:YAG laser was tried in all types of common warts—periungual, 
subungual and plantar warts; complete clearance rate was 68% for plantar warts, 
78% for periungual warts and 76% for subungual warts. In patients with extensive 
involvement, more than one session were needed. Relapse was only in plantar wart 
patients (17.8%) [62]. Chance of scarring is less in Er:YAG laser [62, 63]. For hard-to-
treat palmoplantar warts, a combination of ablative Er:YAG laser and topical 0.5% 
podophyllotoxin solution yields higher success with complete clearance of 88.6% 
without any pigmentary changes, wound infection and scarring. Relapse rate is also 
less [64]. Er:YAG laser procedure can be done without anaesthesia or with topical 
cream anaesthesia as there is minimal pain, except only in large, very thick plaque 
in the plantar or palm. The plume contains no viral DNA [65]. Side effects are less 
with Er:YAG laser, no hyper- or hypopigmentation and no post-operative infection. 
Healing is very fast, within 7–10 days. Redness persists up to 3 months [66]. In a 
study of 69 patients with difficult-to-treat warts (periungual or plantar), 72.5% of 
patients with wart observed complete response (CR) irrespective of the duration 
of infection with HPV or the age of the patients. Plantar warts were more resistant 
(13.5% non-responders) than periungual warts (5.9% non-responders), and larger 
mosaic plantar warts were less sensitive than single warts; 24.0% of patients showed 
relapse [67]. Wound healing may be assisted/accelerated with LED phototherapy 
(633 nm). Immediately after Er:YAG ablation, with precise removal of wart tissue, a 
red LED therapy system is applied (633 nm, 20 min, 96 J/cm2) to the wound and sur-
rounding area, LED system with same parameters were repeated on the second, sixth 
and tenth post-operative day. On the sixth post-operative day, the wound has shrunk 
noticeably and is filled with healthy, granulation tissue, and on day 15, the wound 
healed completely with minimal scarring; recurrence rate was also less (<6%) [68].
4.11.3 Neodymium:YAG (Nd:YAG) laser
Principal emission of Nd:YAG is at 1064 nm, in the infrared range [Nd:YAG 
produces heat]. Heat therapy depends on the principle that diseased tissue which 
is being treated is more sensitive to the effects of the elevated temperature than 
normal tissue and this is less able to recover after heat exposure [69]. Side effects 
such as coagulation, blister or crusts are less after hyperthermia. Response is 
excellent (77%), though in 23% of the method failed, and there is no recurrence 
in 9 months follow-up. Nd:YAG can be used in all types and site warts including 
periungual, hand and plantar warts [70]. HPV DNA becomes completely absent 
in hyperthermia-treated wart lesions, in comparison to cryotherapy where 96% 
wart lesions are positive for HPV DNA by in situ hybridization [71]. The light of 
the solid state Nd:YAG laser can easily be guided by fibres to tissue and perform 
good coagulation and homeostatic function, in laryngeal, as well as genital, easily 
and more precisely. Its continuous suction endures a minimal load of potential 
infectious laser plume [72]. For therapeutic treatment, Nd:YAG laser can be utilised 
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for genital tract lesion and cervical conization for early neoplasms like dysplasia, 
carcinoma in situ and microinvasive carcinoma [73, 74]; these are caused by HPV 
infections. Invasive lasers like CO2 are normally considerably more painful and 
require longer recovery time, and also side effects like scarring are high. A long 
pulsed Nd:YAG laser emits 1064 nm wavelength light, in infrared spectrum, in 
longer wavelength with lower haemoglobin, and melanin absorption coefficients 
allows deeper delivery of higher energy in hyperkeratotic and thicker epidermis that 
are assisted with warts [75]. Several studies have evaluated the use of the Nd:YAG 
laser in the treatment of simple and recalcitrant common, palmoplantar, periungual 
and subungual warts, with efficacies ranging from 46 to 100% [61, 76–78]. Laser 
protocol varied among different studies: spot size between 3 and 7 mm, pulse 
duration of 1–20 ms, fluence of 100–200 J/cm2, cooling methods, number of pulses 
between 1 and 8, treatment interval from 2 weeks to 12 months and mean number 
of treatments between 1.49 and 4.65. In a study of Han et al. [76], 348 patients of 
all types of simple and recalcitrant common, palmoplantar and periungual warts 
are treated with Nd:YAG laser (spot size, 5 mm; pulse duration, 20 ms; 200 J/cm2; 
no cooling; 1–2 pulses). After a mean of 1.49 treatments, wart clearance rate was 
96% though there were differences in clearance rates after initial treatment depend-
ing on location (72.6% for common warts vs. 44.1% for palmoplantar warts) [76]. 
For determination of effectiveness and safety of a novel 100 microsecond pulsed 
1064 nm Nd:YAG laser in treatment of Verruca vulgaris, low energy (200 mjouls) 
Nd:YAG, in monthly intervals for 3 months was given to 25 patients with lesion on 
hands-nineteen patients had complete clearance; with minimal discomfort [61]. 
At least partial response (50% reduction) in verruca size was noticed in all lesions 
[61]. Aggressive treatment of hand warts may cause tissue damage. To avoid the 
tissue damage, a novel modification was tried [77]. Fifty one recalcitrant verrucas 
were treated with ND:YAG laser; all warts were administered in at least three pulses. 
The circle of pulses given in that way that the three circles overlapped each other 
only on the site of verruca- so that highest level of energy reached only to the wart. 
The adjacent tissue can avoid unintended tissue damage [77]. All lesions subsided, 
88.35% lesions in one laser session, remaining patients were required two laser 
sessions- those lesions were periungual and palmar. There was no recurrence in 12 
months follow-up, no major side effects, no nail dystrophy or severe post-treatment 
scarring. Hyperpigmentation was present in 5.48% patients [77].
4.11.4 Pulsed dye laser
Among non-ablative modalities, pulsed dye laser (PDL) can be used for a 
selective, non-bloody destruction of extragenital and genital warts [79]. It emits 
a wavelength of 585, which is absorbed by haemoglobin and oxyhaemoglobin 
[79, 80]. Mechanism of action is unclear, but may be a result of intense heating of 
dermal vessels that leads to damage of viral DNA-containing keratinocytes. The 
theory is based on the presence of dilated and congested vessels at the base of most 
verruca and the mechanism of selective photothermolysis that results in the target-
ting of haemoglobin by the PDL [80]. The heat and immunological process and the 
removal of the blood supply to the wart may be the reason for the effectiveness of 
PDL in verruca therapy, but it is not above controversy [81]. This selective damage 
to blood vessels, sparing unnecessary damage to healthy adjacent cellular structure, 
avoids the scarring [82]. The local dermal vascular destruction of the warts stimu-
lates cell-mediated immune response that is important for eradication of viral warts 
[83]. So, PDL for wart therapy, even in facial wart, is attractive [84] for its efficient 
and cosmetic resolution [84, 85]. The PDL is usually painless or minimally pain-
ful like snapped by a rubber band [86], though some patients complain of severe 
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for genital tract lesion and cervical conization for early neoplasms like dysplasia, 
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intraoperative pain [87, 88], so local anaesthesia may be required. Purpura may 
develop due to sudden burst of wart vasculature—that develops within minutes in 
the treated areas—which takes 10–14 days to subside spontaneously [88]. Even peri-
anal warts in child patients are also treatable with PDL without any complications 
and with 100% clearance [89]. Verruca plana lesions on face in Asian (type IV-V 
skin) clear completely with PDL without producing significant pigmentary and 
textural complications [90]. Safety is one of the major advantages of this technique 
[91]. But the absence of any proven superiority over the standard treatments in 
terms of efficacy, coupled with high costs, means that PDL should only be used as 
second-line therapy in patients with cosmetic needs [91].
Laser protocols are different in all studies, and variation of results may be for that 
reason. Different protocols include spot size of 5–10 mm, fluence of 5 j/m2–15 j/m2, 
pulse duration of 38 ns–1.5 ms, consecutive 2–3 pulses with overlap of 1–2 mm, 1–12 
sessions, interval of 2–4 weeks and cooling methods [90–98]. In immunocompetent 
children, the overall response rate is 75%, and the remaining 25% had partial clear-
ance, with an average number of treatment for complete clearance to be 3.1—face 
and perineum are areas most likely to be cleared in one treatment (50 and 20%, 
respectively) [99, 100]. It is also a more effective therapy especially against those 
that have not been eradicated by other treatments [101]. Though less, adverse effects 
are also not very much uncommon, about 8.2% of patients had adverse effects like 
wound formation (3.8%), residual scarring (2.9%), infection (1.0%) and collapse 
(0.5%); 63% of patients had excessive pain [97]. But opinion about pain and patient 
compliance are different in other study [102]. Here only 6.34% of patients classi-
fied the method as too painful and withdrew after the first one or two treatments 
They have concluded that FPDL is safe and effective for the removal or reduction 
of verrucae vulgares, and requires less patient compliance compared with other 
treatment options. PDL followed by intralesional Bleomycin gives very good result 
with complete clearance, even in immunosuppressive patients, though the overall 
treatment session was high (1.8 vs. 3) [98], but should be aware of common side 
effects seen such as painful haemorrhagic blistering and superficial ulceration [103].
4.11.5 Potassium titanyl phosphate (KTP) laser
The KTP laser has been utilised in the treatment of recalcitrant cutaneous warts, 
and when treated to complete clearance, no recurrence occurred [104].
5. Virucidal therapy
5.1 Glutaraldehyde
Glutaraldehyde is a tissue fixative that polymerises keratin. Its effectiveness lies 
in desiccation of surface virions and resultant reduction of antigenic load [105]. 
However the mechanism of action of glutaraldehyde against warts has not been 
clarified precisely. Glutaraldehyde therapy (GA) for warts was first introduced in 
1971 [106]. Therapeutic responses with glutaraldehyde in periungual, palmar and 
plantar warts were 80, 60 and 68.5%, respectively [107]. When GA is buffered by 
suitable alkalinating agents to a pH of 7.5–8.5, the solution becomes antimicrobially 
active [108]. The concentration of glutaraldehyde is another consideration for use. 
Though 2 w/v% is the minimum for antimicrobial activity [108], undiluted high 
concentration of 25% solution appeared to work faster on warts of all kinds [107]. 
The benefits of using glutaraldehyde as first-line treatment for warts, especially 
resistant ones, are the same as those of cryotherapy [107].
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5.2 Formaldehyde
Formalin (formaldehyde) is a virucidal agent and has strong disinfectant 
properties and exerts its effects by causing damage to the upper layers of epidermal 
cells that contain the virus, thus destroying viruses [28, 109]. Formalin application 
was effective in 83.3% of patients, but complete disappearance of warts was seen in 
11.1% [110]. The most common side effects of formalin include redness, irritation 
and dryness of skin [111].
5.3 Acyclovir, valacyclovir and other antiretroviral drugs
Oral antivirals are not a regular treatment modality, but isolated case report 
about improvement in wart lesion after oral treatment with acyclovir [112], vala-
cyclovir are there. Plantar wart is cleared completely with 1 gm valacyclovir for 
60 days [113]. Improvements of wart with intravenous cidofovir in one HIV sero-
positive patient with complete clearance are available [114]. Nearly total clearance 
of multiple viral wart with didanosine, stavudine and efavirenz triple antiretroviral 
therapy in a 34-year-old male homosexual patient was seen, accompanied by a 
significant improvement in immune status [115]. The observations are not powerful 
enough to assume causality (instead of a simple casual or placebo effect).
6. Antimitotic therapy
6.1 Bleomycin
Bleomycin is a chemotherapeutic agent which has an antitumor, antibacterial and 
antiviral activity which may be related to its ability to bind with deoxyribonucleic acid 
(DNA), causing bleomycin strand scission and elimination of pyrimidine and purine 
bases [116]. It selectively affects squamous cell and reticuloendothelial tissue [117]. 
Bleomycin is not thought to bind directly to HPV [10]. Bleomycin causes acute tissue 
necrosis that may stimulate an immune response, as evidenced by the fact that it is less 
effective as a wart treatment in immunosuppressed renal transplant patients [118–121].
Adverse effects include injection pain and burning, erythema, swelling and pain 
within 24–72 h after injection before a black thrombotic eschar forms. Local compli-
cations after periungual injections are nail loss [122] or dystrophy [123]. Reynaud’s 
phenomenon in treated fingers, local pigmentation [124] or urticaria [122], even 
flagellate hyperpigmentation [125] are reported after.
In a systemic review [126], comparing intralesional bleomycin with placebo, 
the studies have given conflicting results. Intralesional bleomycin was compared 
with saline or sesame oil; duration was 6 weeks to 3 months. The RCTs in the review 
favour I/L Bleomycin, and only one study opined placebo to be more effective. The 
result of wart clearance was between 18 and 94%, but the study showed clear-
ance rate to be 94%, which was not significantly different from the result (73%) 
achieved by placebo injections of saline. Concentration of 0.5% bleomycin is more 
effective than concentration of 0.25% or 1% bleomycin. Pain was experienced by 
most patients, irrespective of doses. In a study of comparison between intralesional 
Bleomycin and cryotherapy, 0.1% concentration of bleomycin was used [127]. 
Greater efficacy in clearing warts was shown with intralesional bleomycin than in 
cryotherapy. The clearance rates of warts for intralesional bleomycin therapy found 
were 97%, and in 94.9% of patients, all warts treated with bleomycin were cleared. 
There was significantly less number of treatment sessions, with a mean of 1.38 in 
case of bleomycin treatment than the cryotherapy where the mean is 3.08.
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Podophyllotoxin is a topical antimitotic that is purified from the plant fami-
lies Coniferae and Berberidaceae (e.g. species of Juniperus and Podophyllum) 
or can be synthesised chemically. It is the active agent of podophyllin resin 
and is available as a 0.5% solution. Podophyllotoxin binds to microtubules and 
causes mitotic arrest in the metaphase of cell division [128]. Treatment should 
be limited to no more than 10 cm2 of wart tissue, and no more than 0.5 mL/day 
of solution should be given. This is a patient-applied therapy. Podophyllin is a 
non-standardised unstable plant extract, derived from may apple (Podophyllum 
peltatum Linné), and contains the active agent podophyllotoxin. American 
Podophyllum contains one fourth the amount of podophyllotoxin than Indian 
Podophyllum does. The potency of podophyllin varies considerably between 
batches. The exact mechanism of action is unknown. Since it tends to work better 
on mucosal surfaces, it is used primarily to treat genital warts. Little informa-
tion is available regarding treatment of non-genital warts with this medication. 
A single topical application of podophyllin cures less than one third of patients 
with genital warts [129, 130].
It results in necrosis when applied to anogenital warts. Only a trained medical 
professional can apply it, and it cannot be dispensed to a patient. CDC guidelines 
for anogenital warts, recommended regimens for External Anogenital Warts (i.e. 
penis, groin, scrotum, vulva, perineum, external anus and perianus), includes 
patient-applied therapy with podofilox (podophyllotoxin) 0.5% solution or 
gel—using a cotton swab or finger. This podofilox solution (using a cotton swab) 
or gel (using a finger) should be applied to anogenital warts twice daily for 3 
consecutive days, followed by 4 days of drug interval. If necessary, it can be 
repeated, for up to four cycles. The total treated area should not exceed 10 cm2,  
and up to 0.5 ml podofilox should be used per day [131]. If possible initial 
application should be demonstrated by one healthcare provider for demonstra-
tion of proper application and technique and to identify the appropriate warts 
for treatment. Mild to moderate pain or local irritation might develop after 
 treatment [131].
Podophyllotoxin, the active ingredients of podophyllin, is contraindicated 
in pregnancy. Though human data not available during application in lactating 
mother, it is considered as potential toxic. Podophylline, a raw form, is also con-
traindicated in pregnancy and breastfeeding mother, due to the potential severe 
myelotoxicity and neurotoxicity in the mother, though no human data available. 
The American college of Obstetricians and Gynecologists and other sources con-
traindicated the use of podophyllum agents include the use of podophyllotoxin 
(podofilox) during pregnancy and in the vagina or cervix at any time [132]. In a 
randomised comparative study, 60 women with genital warts were treated with 
either weekly application of 20% podophyllin solution or self-treatment with 0.5% 
podophyllotoxin cream twice daily for 3 days in weekly intervals. Patients were 
treated for a maximum of four treatment cycles, and final assessment was carried 
out after 3 months. Podophyllotoxin cream had a significantly better clearance 
than podophyllin solution, a primary clearance of was 82% vs 59%. These final 
clearance decreased to 71% and 48% at the 3-month follow-up, respectively. Total 
wart clearance was 94% with podophyllotoxin and 74% with podophyllin solution. 
Podophyllin cream came to as easy to apply and effects significantly better than 
podophyllin solution. Local side effects were mild to moderate with erythema, and 
erosion appeared to be higher in the podophyllotoxin group but not so serious to 
discontinue treatment [133].
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7. Immunotherapy
This treatment uses the patient’s own immune system to fight the warts. Some 
types of immunotherapy only target certain cells of the immune system. Others 
affect the immune system in general. Because of the cumbersome nature of the 
conventional procedures and a high risk of recurrence, immunotherapy is becoming 
more and more popular, especially in the treatment of refractory cutaneous and 
genital warts. These include various topical, intralesional and systemic agents. There 
are no well-defined criteria or consensus on when immunotherapy should be tried in 




4. Difficult-to-treat areas—periungual and palmoplantar sites
7.1 Imiquimod
Imiquimod is a non-nucleoside heterocyclic amine which acts as an immune 
response modifier that may stimulate cytokines, including interferon-α, inter-
leukin-1, interleukin-6, tumour necrosis factor-α, granulocyte-macrophage 
colony-stimulating factor and granulocyte colony-stimulating factor [135]. In a 
quantitative systemic review of published randomised control trials, six RCTs were 
evaluated, and all six studies were conducted in the sitting of home administration 
Courtesy of Prof Devinder M Thappa and Minu J Chiramel [134].
Table 1. 
Various agents used in immunotherapy of warts.
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after initial professional examination and advice wart locations are genital, both in 
males and females. Five of the studies are on immunocompetent patients and one 
study on HIV-positive patients; 90% of the study population are male. Imiquimod 
was used as 5% cream in 4 trials and 2% cream in one trial, with complete clearance 
achieved in 51% in imiquimod group but only 6% patients in placebo group. The 
number needed to treat (NNT) was 2.2 (95% confidence interval 2.0–2.6). At least 
50% reduction in wart area occurred in 72% of patients treated with Imiquimod 
5% cream and 20% in placebo treated group. The number needed to treat was 1.9 
(1.7–2.2). Warts were completely cured and did not recur in 37% (31% to 43%) 
of patients treated with imiquimod 5%, and 4% (2% to 6%) of patients treated 
with placebo. The NNT was 3.0 (2.5 to 3.8). Fewer patients were cured with 1% 
imiquimod in two trials, and for this concentration the NNT was 9.5 (5.9 to 25). 
Imiquimod 5% cream was significantly more effective than imiquimod 1% cream 
for complete wart clearance [136]. Common adverse events were localised itching, 
erythema, burning and erosion or excoriation, there was rarely any withdrawal 
from study due to these adverse effects. In HIV infected patients with warts, at least 
50% reduction of wart area was seen in 38%, and in placebo it was 14%. Adverse 
events were similar to non-HIV group [137]. It is found to be effective and safe in 
children and there are reports of safe use in pregnancy [138, 139]. Disadvantages of 
using imiquimod 5% cream were the high cost and the length of average treatment 
(9.5 weeks).
7.2 Mycobacterium w
Mycobacterium indicus pranii or Mycobacterium w is rapid growing nontuber-
cular mycobacteria, which has been found to induce a strong pro-inflammatory 
response while injected intralesionally. There is a prominent delayed hypersensitiv-
ity response, leading to clearance of warts both at the site of injection and distally 
[140]. The response varied by 54–93% in cutaneous warts and 89% in genital warts 
[140–143]. It is administered in two ways—either with an intradermal sensitising 
dose or without it. In the first method, a sensitising dose of 0.1 ml is administered 
intradermally in the deltoid region followed by 2–4 weekly intralesional injections 
in few warts (maximum 0.1 ml in each sitting) for up to 10 sittings. In the latter, 
the sensitization dose is missed, and direct intralesional injections are started [140, 
141]. Mycobacterium w vaccine came as equally efficacious in treatment of refrac-
tory extragenital warts in comparison with cryotherapy and Imiquimod, 5%,. Mw 
vaccine has an added advantage of clearance of distant warts and reduction of viral 
load [144, 145]. The reported side effects include pain, nodularity, ulceration, scar-
ring at the site of injection, flu-like symptoms, fever and lymphadenopathy [143]. 
Paraesthesia on the limb distal to the site of injection has also been reported [146].
7.3 Bacillus Calmette-Guérin vaccine
The delayed hypersensitivity response against the antigen is the key to clinical 
response against warts, same as that of the Mw vaccine. It increases the serum levels 
of IL-12 and decreases the level of IL-4 [147]. One to three doses are administered 
1 month apart. In cutaneous warts (common, plantar, and plane warts), there was 
a resolution rate of 39.7% [148]. Topically applied BCG paste (weekly for 6 weeks) 
has also been found to be effective in children with common warts and plane warts 
with 65% resolution [149], and usually there are no side effects. However, another 
report in India showed a high incidence of flu-like symptoms precluding further 
doses in 57% of patients, making one question its safety in tuberculosis endemic 
countries like India [150].
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7.4 MMR vaccine, Candida, Trichophyton and tuberculin antigens
Various types of vaccines and antigens were tried for wart management. 
Measles, mumps and rubella (MMR) viral vaccine accelerates the clearance of 
virus and viral infected cells by stimulation of cell-mediated and humoral immu-
nity [151]. In this double-blind RCT, MMR vaccine was tried for three injections 
in 2-week interval with normal saline as control; 75% of patients had complete 
clearance, and another 16.6% had more than 50% clearance. There were no side 
effects, and in 6-month follow-up, there was no relapse [151]. In another study 
of MMR vaccine, 81.4% of patients had complete clearance; another 10% had 
partial clearance, in comparison to 27.5% and 15% with saline control [152]. A 
preliminary, open-label (PPD: purified protein derivative) study to investigate 
the effectiveness of the tuberculin antigen in the treatment of recalcitrant warts, 
taking advantage of the vaccination schedule in their country was designed. Three 
consecutive intralesional tuberculin (5TU PPD RT23-tween 80 solution) injections 
with 3-week intervals into each target wart, depending on the tuberculin reactivity, 
were performed. Injections of 0.3, 0.2 and 0.1 mL of antigen were administered 
to patients with indurations of 5–9, 10–15 and > 15 mm, respectively. Five patients 
(29.4%) demonstrated complete clearance, five (29.4%) had partial and five 
(29.4%) minimal response. Some patients showed complete clearance of untreated 
facial warts also. Patients with initial PPD test site in duration less than 10 mm had 
no or minimal response [153]. Mumps and Candida antigen injection in paediatric 
age group with recalcitrant warts had 47% complete resolution, and 13% had 
partial resolution. Injections were given in three weekly intervals, and an average 
of 3.87 injections was given. Patients with initial high response to skin antigen 
test shows excellent result [154]. Injection with mumps, Candida or Trichophyton 
antigen, alone or in combination, is given in 3-week interval, up to 10 injections. In 
patients who have completed the study, 50% had complete clearance, and the other 
50% had 75–90% clearance. Local erythema and oedema were the only side effects, 
in 30% of patients. Patients who had complete clearance had clearance also in their 
distant verruca lesions [155]. Candida albicans intralesional immunotherapy in 
single also came as safe, well tolerated and suitable for multiple warts of hand and 
fingers, plantar warts and recalcitrant warts, even in non-injected warts [156]. In a 
randomised, single blinded, placebo-controlled large study of mumps, Candida and 
Trichophyton antigen, with or without interferon α 2b, 41% of patients with antigen 
alone, 57% antigen and interferon and 9% in only interferon had complete clear-
ance in comparison to 19% only in the normal saline group [157]. The combination 
of mumps, Candida and Trichophyton also came to be effective as 74% of patients 
responded to test antigen had complete clearance with significant number also 
showing resolution of untreated distant warts [158]. Response of other studies with 
Candida antigen varied as 72% [159], 74% [160], 85% [161], 56% [162] and 87% 
[163], indicating antigen therapy in wart is a good hope for target and distant wart 
lesions with minimum side effects.
7.5 Interferons
Interferon has been shown to be active against HPV both in vitro and in vivo, to 
protect murine cells against infection with bovine papillomaviruses and to elimi-
nate extrachromosomal viral DNA from infected cells [164, 165]. In a systematic 
meta-analysis, the rate of complete response in locally used interferon was 44.4% 
in comparison to placebo, 16.1%. The complete response rate of systemically used 
interferon as compared to placebo for treating genital warts had no perceivable 
discrepancy, for systemically used interferon 27.4% and placebo 26.4%. Both groups 
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7.4 MMR vaccine, Candida, Trichophyton and tuberculin antigens
Various types of vaccines and antigens were tried for wart management. 
Measles, mumps and rubella (MMR) viral vaccine accelerates the clearance of 
virus and viral infected cells by stimulation of cell-mediated and humoral immu-
nity [151]. In this double-blind RCT, MMR vaccine was tried for three injections 
in 2-week interval with normal saline as control; 75% of patients had complete 
clearance, and another 16.6% had more than 50% clearance. There were no side 
effects, and in 6-month follow-up, there was no relapse [151]. In another study 
of MMR vaccine, 81.4% of patients had complete clearance; another 10% had 
partial clearance, in comparison to 27.5% and 15% with saline control [152]. A 
preliminary, open-label (PPD: purified protein derivative) study to investigate 
the effectiveness of the tuberculin antigen in the treatment of recalcitrant warts, 
taking advantage of the vaccination schedule in their country was designed. Three 
consecutive intralesional tuberculin (5TU PPD RT23-tween 80 solution) injections 
with 3-week intervals into each target wart, depending on the tuberculin reactivity, 
were performed. Injections of 0.3, 0.2 and 0.1 mL of antigen were administered 
to patients with indurations of 5–9, 10–15 and > 15 mm, respectively. Five patients 
(29.4%) demonstrated complete clearance, five (29.4%) had partial and five 
(29.4%) minimal response. Some patients showed complete clearance of untreated 
facial warts also. Patients with initial PPD test site in duration less than 10 mm had 
no or minimal response [153]. Mumps and Candida antigen injection in paediatric 
age group with recalcitrant warts had 47% complete resolution, and 13% had 
partial resolution. Injections were given in three weekly intervals, and an average 
of 3.87 injections was given. Patients with initial high response to skin antigen 
test shows excellent result [154]. Injection with mumps, Candida or Trichophyton 
antigen, alone or in combination, is given in 3-week interval, up to 10 injections. In 
patients who have completed the study, 50% had complete clearance, and the other 
50% had 75–90% clearance. Local erythema and oedema were the only side effects, 
in 30% of patients. Patients who had complete clearance had clearance also in their 
distant verruca lesions [155]. Candida albicans intralesional immunotherapy in 
single also came as safe, well tolerated and suitable for multiple warts of hand and 
fingers, plantar warts and recalcitrant warts, even in non-injected warts [156]. In a 
randomised, single blinded, placebo-controlled large study of mumps, Candida and 
Trichophyton antigen, with or without interferon α 2b, 41% of patients with antigen 
alone, 57% antigen and interferon and 9% in only interferon had complete clear-
ance in comparison to 19% only in the normal saline group [157]. The combination 
of mumps, Candida and Trichophyton also came to be effective as 74% of patients 
responded to test antigen had complete clearance with significant number also 
showing resolution of untreated distant warts [158]. Response of other studies with 
Candida antigen varied as 72% [159], 74% [160], 85% [161], 56% [162] and 87% 
[163], indicating antigen therapy in wart is a good hope for target and distant wart 
lesions with minimum side effects.
7.5 Interferons
Interferon has been shown to be active against HPV both in vitro and in vivo, to 
protect murine cells against infection with bovine papillomaviruses and to elimi-
nate extrachromosomal viral DNA from infected cells [164, 165]. In a systematic 
meta-analysis, the rate of complete response in locally used interferon was 44.4% 
in comparison to placebo, 16.1%. The complete response rate of systemically used 
interferon as compared to placebo for treating genital warts had no perceivable 
discrepancy, for systemically used interferon 27.4% and placebo 26.4%. Both groups 
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had near same recurrence rate (interferon 21.1% vs. placebo 34.2%, p > 0.05). In 
subgroup analysis, it was noticed that relapse was less in intralesional interferon in 
comparison to placebo group, but relapse rate were the same in between systemic 
and placebo groups. Adverse events were mostly mild and transient and could be 
tolerated [166].
7.6 Zinc
Dietary zinc has profound effects on the human immune system and deficiency 
leads to reduced immune capacity [167, 168]. It can be given as topical preparation, 
oral medication or intralesional. Topical preparation as 10% zinc sulphate lotion 
yields complete clearance in 80% in plane wart [169]; plane warts were seen in 
85.7% [170]. Complete clearance noticed in 61% patients after 1 month therapy and 
87% after 2 months of therapy with oral zinc sulphate 10 mg/kg/day in a placebo-
controlled trial [171]. But it was not the same in other studies, 50% complete 
clearance with the same dose after 2 months in another open level clinical study 
[172]. Intralesional 2% zinc sulphate too has been found to induce clearance of 
warts [173].
7.7 H2 receptor blockers
H2 blockers, such as cimetidine and ranitidine, have been tried in treatment of 
warts. They block the type 2 histamine receptors on suppressor T cells and aug-
ment cell-mediated immunity [174]. It increases the levels of IFNγ and IL-2 and 
decreases the levels of IL-18 [175]. It has been used in a dose of 20–40 mg/kg/day 
for 3–4 months with response rate ranging from 30 to 87% [176, 177]. There is no 
significant difference between cimetidine and placebo [178], and some author 
proposed a placebo effect for cimetidine [179].
7.8 Levamisole
Levamisole, an antihelminthic agent, is found to have immunomodulatory 
effects, making it effective in various dermatological disorders including viral warts 
at a dose of 2.5–5 mg/kg/day for 3 consecutive days every 2 weeks for 4–5 months 
[180–182]. The response to levamisole was approximately 60%. Side effects are 
rash, nausea, abdominal cramps, taste alteration, alopecia, arthralgia and a flu-like 
syndrome and rarely cause myopathy, leukocytoclastic vasculitis, lichenoid erup-
tions and leukoencephalopathy [183, 184].
7.9 HPV vaccines
Since 2006, two vaccines against Human papillomavirus (HPV) have been 
licenced in more than 100 countries [185]. Both vaccines target HPV types 16 and 
18, which account for about 70% of all cervical cancer cases, and the quadrivalent 
vaccine also targets HPV types 6 and 11, associated with 90% of genital warts (GWs) 
[186]. In Denmark, the quadrivalent HPV vaccine was introduced into the children’s 
vaccination programme in January 2009 for 12-year-old girls. In 2014 the European 
Medicines Agency and the World Health Organisation Strategic Advisory Group of 
Experts recommended a two-dose schedule for 9–13-year-old girls. However, three-
dose schedule offers better protection against genital warts than a two-dose schedule 
in a nationwide study. But, if the dosing interval extends (about six months), the 
two dose schedule came as effective as three. The quadrivalent HPV vaccine that 
comprises the L1 protein of HPV types 6, 11, 16 and 18 has been in use on a large scale 
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in countries like Denmark with a decline in the prevalence of genital warts [187]. 
Similar decline in genital warts has been noticed in the UK and Australia [188, 189].
7.10 Autoimplantation therapy
Autowart inoculation by means of homologous autoimplantation helping to 
induce specific cell-mediated immunity has been proposed as a treatment option for 
recalcitrant, extensive and genital wart [190]. About 83 patients with all types of 
wart lesions were included in a study. At 16 weeks of therapy, 69.5% of patients recov-
ered completely, and more than 75% improvement occurred in another 8.5% patients. 
No significant complication was documented. There was no recurrence within study 
period [191]. Another study also had noticed 73.3% total clearance of warts, with a 
majority of them (91%) within 2 months [190]. Inoculation site infection and post-
inflammatory hyperpigmentation and hypopigmentation are the side effects.
7.11 Contact sensitizers
Contact sensitizers are a mode of inducing a type IV hypersensitivity reaction, 
thus making them a form of topical immunotherapy [28]. Diphencyprone (DCP) 
is the preferred compound. DCP 2% solution is applied after every 10–14 days, 
on the medial side of upper arm—till there is appearance of local erythema and 
vesiculation—and this may be repeated up to three times. Warts were then first 
pared followed by application with stepwise concentration of DCP: 0.01, 0.05, 0.10, 
0.25, 0.50, 1.0, 1.5, 2.0, 3.0, 4.0 and 6.0%. Treatments are applied every 1–4 weeks. 
Resistant palmoplantar warts treated with DCP over 8 years [192] exhibited 88% 
clearance rate. However, a large percentage of patients developed adverse effects 
(56%), including painful blistering at the site of sensitization and near warts, 
pompholyx-like or generalised eczematous eruption, influenza-like symptoms, 
vesiculation elsewhere due to passive transfer of DCP and inguinal lymphadenopa-
thy. They concluded that patients with recalcitrant palmar, plantar, periungual and 
digital warts are good candidates for DCP therapy [193].
8. Others
There are various other agents being tried infrequently in the management of 
warts.
Historic folk remedies have included many variants.
Duct tape occlusion therapy involves placing a piece of duct tape over the wart. 
The mechanism of action of this technique still remains unknown [194].
Components of garlic (Allium sativum) have been shown to have antiviral activ-
ity and to inhibit cellular proliferation of virally infected cells, resulting clearance of 
wart with less recurrence [195].
Application of paste made of baking powder and castor oil is age old technique 
for warts.
Herbal preparations such as Echinacea and propolis are reported to boost 
the immunity when administered orally [196], act as immunomodulators and 
improve warts.
Sinecatechins are derived from green tea extract (Camellia sinensis) and are 
marketed as a 10% ointment, containing around eight catechins. A clearance rate of 
46–52% has been noticed in various studies [197].
Glycyrrhizic acid, obtained from the root of Glycyrrhiza glabra, has anti-
viral, anti-inflammatory and antiulcerative properties. When used with an 
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in countries like Denmark with a decline in the prevalence of genital warts [187]. 
Similar decline in genital warts has been noticed in the UK and Australia [188, 189].
7.10 Autoimplantation therapy
Autowart inoculation by means of homologous autoimplantation helping to 
induce specific cell-mediated immunity has been proposed as a treatment option for 
recalcitrant, extensive and genital wart [190]. About 83 patients with all types of 
wart lesions were included in a study. At 16 weeks of therapy, 69.5% of patients recov-
ered completely, and more than 75% improvement occurred in another 8.5% patients. 
No significant complication was documented. There was no recurrence within study 
period [191]. Another study also had noticed 73.3% total clearance of warts, with a 
majority of them (91%) within 2 months [190]. Inoculation site infection and post-
inflammatory hyperpigmentation and hypopigmentation are the side effects.
7.11 Contact sensitizers
Contact sensitizers are a mode of inducing a type IV hypersensitivity reaction, 
thus making them a form of topical immunotherapy [28]. Diphencyprone (DCP) 
is the preferred compound. DCP 2% solution is applied after every 10–14 days, 
on the medial side of upper arm—till there is appearance of local erythema and 
vesiculation—and this may be repeated up to three times. Warts were then first 
pared followed by application with stepwise concentration of DCP: 0.01, 0.05, 0.10, 
0.25, 0.50, 1.0, 1.5, 2.0, 3.0, 4.0 and 6.0%. Treatments are applied every 1–4 weeks. 
Resistant palmoplantar warts treated with DCP over 8 years [192] exhibited 88% 
clearance rate. However, a large percentage of patients developed adverse effects 
(56%), including painful blistering at the site of sensitization and near warts, 
pompholyx-like or generalised eczematous eruption, influenza-like symptoms, 
vesiculation elsewhere due to passive transfer of DCP and inguinal lymphadenopa-
thy. They concluded that patients with recalcitrant palmar, plantar, periungual and 
digital warts are good candidates for DCP therapy [193].
8. Others
There are various other agents being tried infrequently in the management of 
warts.
Historic folk remedies have included many variants.
Duct tape occlusion therapy involves placing a piece of duct tape over the wart. 
The mechanism of action of this technique still remains unknown [194].
Components of garlic (Allium sativum) have been shown to have antiviral activ-
ity and to inhibit cellular proliferation of virally infected cells, resulting clearance of 
wart with less recurrence [195].
Application of paste made of baking powder and castor oil is age old technique 
for warts.
Herbal preparations such as Echinacea and propolis are reported to boost 
the immunity when administered orally [196], act as immunomodulators and 
improve warts.
Sinecatechins are derived from green tea extract (Camellia sinensis) and are 
marketed as a 10% ointment, containing around eight catechins. A clearance rate of 
46–52% has been noticed in various studies [197].
Glycyrrhizic acid, obtained from the root of Glycyrrhiza glabra, has anti-
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immunostimulant [198], it was shown to have a slightly better efficacy than 
podophyllin (87%). The glycyrrhizic acid is a safe and effective treatment for the 
management of anogenital warts during pregnancy [199].
Intralesional injection of 0.2 ml of 15 mg/kg vitamin D3 led to complete reso-
lution [200] in 19 (82.60%) out of 23 patients with palmoplantar warts and 14 
(77.77%) of 18 patients with verruca vulgaris.
9. Conclusion
Numerous varieties of approaches for wart management are there. It is difficult 
to choose the best wart treatment. It should be determined by type of wart, whether 
old or new; site; immune status of the patient; pregnancy; the effects and side 
effects of the wart management procedure; its compliance with patient; and above 
all the availability of the planned modality of treatment. A rational consideration of 
all factors can provide an appreciable benefit.
© 2020 The Author(s). Licensee IntechOpen. This chapter is distributed under the terms 
of the Creative Commons Attribution License (http://creativecommons.org/licenses/
by/3.0), which permits unrestricted use, distribution, and reproduction in any medium, 
provided the original work is properly cited. 
49
Human Papillomavirus Infection: Management and Treatment
DOI: http://dx.doi.org/10.5772/intechopen.92397
References
[1] Bzhalava D, Guan P, Franceschi S, 
Dillner J, Clifford G. A systematic 
review of the prevalence of mucosal and 
cutaneous human papillomavirus types. 
Virology. 2013;445:224-231
[2] Abeck D, Tetsch L, Lüftl M, 
Biedermann T. Extragenital cutaneous 
warts—Clinical presentation, 
diagnosis and treatment. Journal of 
the German Society of Dermatology. 
2019;17(6):613-634
[3] Piaserico S, Sandini E, Pescerico A, 
et al. Cutaneous viral infections in 
organ transplant patients. Giornale 
Italiano di Dermatologia e Venereologia. 
2014;149:409-415
[4] Maor D, Brennand S, Goh MSY, 
Chong AH. Recalcitrant hyperkeratotic 
verrucae in a renal transplant 
recipient clearing with cessation of 
immunosuppression. JAAD Case 
Reports. 2018;24:471-473
[5] Grassegger A, Rollinger-Holzinger I, 
Zelger BW, et al. Spontaneous or 
interferon-y induced T cell infiltration, 
HLA-DR and ICAM1 expression in 
genitoanal warts are associated with 
TH1 or mixed TH1/TH2 cytokine 
mRNA expression profiles. Archives 
of Dermatological Research. 
1997;289:243-250
[6] Sterling JC, Gibbs S, Haque 
Hussain SS, Mohd Mustapa MF, 
Handfield-Jones SE. British 
Association of Dermatologists’ 
guidelines for the management 
of cutaneous warts 2014. The 
British Journal of Dermatology. 
2014;171(4):696-712. DOI: 10.1111/
bjd.13310. Epub 2014 October 1
[7] Kuykendall-Ivy TD, Johnson SM. 
Evidence-based review of management 
of nongenital cutaneous warts. Cutis. 
2003;71:213-222
[8] Lipke MM. An armamentarium of 
wart treatments. Clinical Medicine & 
Research. 2006;4(4):273-293
[9] Bedinghaus JM, Niedfeldt MW. 
Over-the-counter foot remedies. 
American Family Physician. 
2001;64:791-796
[10] Baumbach JL, Sheth PB. Topical 
and intralesional antiviral agents. In: 
Wolverton S, editor. Comprehensive 
Dermatologic Drug Therapy. 
Philadelphia, PA: W. B. Saunders 
Company; 2001. pp. 524-536
[11] Abdullah AN, Walzman M, 
Wade A. Treatment of external 
genital warts comparing cryotherapy 
(liquid nitrogen) and trichloroacetic 
acid. Sexually Transmitted Diseases. 
1993;20(6):344-345
[12] Hanif J, Tasca RA, Frosh A, 
Ghufoor K, Stirling R. Silver nitrate: 
Histological effects of cautery on 
epithelial surfaces with varying contact 
times. Clinical Otolaryngology and 
Allied Sciences. 2003;28:368-370
[13] Bray Healthcare. Silver Nitrate Pencil 
Instructions. Faringdon, Oxon, UK: Bray 
Group Ltd. Available at: http://www.
bray.co.uk/silver-nitrate-pencil.html
[14] Haddad V Jr et al. Tropical 
dermatology: Venomous arthropods and 
human skin: Part I. Insecta. Journal of 
the American Academy of Dermatology. 
2012;67(3):331.e1-331.14. [PubMed] 
[Google Scholar]
[15] Bertaux B et al. Cantharide 
acantholysis: Endogenous protease 
activation leading to desmosomal 
plaque dissolution. The British Journal 
of Dermatology. 1988;118(2):157-165. 
[PubMed] [Google Scholar]
[16] Torbeck R, Pan M, DeMoll E. 
Cantharidin: A comprehensive review 
49
Human Papillomavirus Infection: Management and Treatment
DOI: http://dx.doi.org/10.5772/intechopen.92397
References
[1] Bzhalava D, Guan P, Franceschi S, 
Dillner J, Clifford G. A systematic 
review of the prevalence of mucosal and 
cutaneous human papillomavirus types. 
Virology. 2013;445:224-231
[2] Abeck D, Tetsch L, Lüftl M, 
Biedermann T. Extragenital cutaneous 
warts—Clinical presentation, 
diagnosis and treatment. Journal of 
the German Society of Dermatology. 
2019;17(6):613-634
[3] Piaserico S, Sandini E, Pescerico A, 
et al. Cutaneous viral infections in 
organ transplant patients. Giornale 
Italiano di Dermatologia e Venereologia. 
2014;149:409-415
[4] Maor D, Brennand S, Goh MSY, 
Chong AH. Recalcitrant hyperkeratotic 
verrucae in a renal transplant 
recipient clearing with cessation of 
immunosuppression. JAAD Case 
Reports. 2018;24:471-473
[5] Grassegger A, Rollinger-Holzinger I, 
Zelger BW, et al. Spontaneous or 
interferon-y induced T cell infiltration, 
HLA-DR and ICAM1 expression in 
genitoanal warts are associated with 
TH1 or mixed TH1/TH2 cytokine 
mRNA expression profiles. Archives 
of Dermatological Research. 
1997;289:243-250
[6] Sterling JC, Gibbs S, Haque 
Hussain SS, Mohd Mustapa MF, 
Handfield-Jones SE. British 
Association of Dermatologists’ 
guidelines for the management 
of cutaneous warts 2014. The 
British Journal of Dermatology. 
2014;171(4):696-712. DOI: 10.1111/
bjd.13310. Epub 2014 October 1
[7] Kuykendall-Ivy TD, Johnson SM. 
Evidence-based review of management 
of nongenital cutaneous warts. Cutis. 
2003;71:213-222
[8] Lipke MM. An armamentarium of 
wart treatments. Clinical Medicine & 
Research. 2006;4(4):273-293
[9] Bedinghaus JM, Niedfeldt MW. 
Over-the-counter foot remedies. 
American Family Physician. 
2001;64:791-796
[10] Baumbach JL, Sheth PB. Topical 
and intralesional antiviral agents. In: 
Wolverton S, editor. Comprehensive 
Dermatologic Drug Therapy. 
Philadelphia, PA: W. B. Saunders 
Company; 2001. pp. 524-536
[11] Abdullah AN, Walzman M, 
Wade A. Treatment of external 
genital warts comparing cryotherapy 
(liquid nitrogen) and trichloroacetic 
acid. Sexually Transmitted Diseases. 
1993;20(6):344-345
[12] Hanif J, Tasca RA, Frosh A, 
Ghufoor K, Stirling R. Silver nitrate: 
Histological effects of cautery on 
epithelial surfaces with varying contact 
times. Clinical Otolaryngology and 
Allied Sciences. 2003;28:368-370
[13] Bray Healthcare. Silver Nitrate Pencil 
Instructions. Faringdon, Oxon, UK: Bray 
Group Ltd. Available at: http://www.
bray.co.uk/silver-nitrate-pencil.html
[14] Haddad V Jr et al. Tropical 
dermatology: Venomous arthropods and 
human skin: Part I. Insecta. Journal of 
the American Academy of Dermatology. 
2012;67(3):331.e1-331.14. [PubMed] 
[Google Scholar]
[15] Bertaux B et al. Cantharide 
acantholysis: Endogenous protease 
activation leading to desmosomal 
plaque dissolution. The British Journal 
of Dermatology. 1988;118(2):157-165. 
[PubMed] [Google Scholar]
[16] Torbeck R, Pan M, DeMoll E. 
Cantharidin: A comprehensive review 
Human Papillomavirus
50
of the clinical literature. Dermatology 
Online Journal. 2014;20(6):3. [PubMed] 
[Google Scholar]
[17] Recanati MA, Kramer KJ, Maggio JJ, 
Chao CR. Cantharidin is superior to 
trichloroacetic acid for the treatment 
of non-mucosal genital warts: A pilot 
randomized controlled trial. Clinical 
and Experimental Obstetrics & 
Gynecology. 2018;45(3):383-386
[18] Banihashemi M, Pezeshkpoor F, 
Yazdanpanah MJ, Family S. Efficacy 
of 80% phenol solution in comparison 
with cryotherapy in the treatment of 
common warts of hands. Singapore 
Medical Journal. 2008;49(12):1035
[19] Kubeyinje EP. Evaluation of the 
efficacy and safety of 0.05% tretinoin 
cream in the treatment of plane 
warts in Arab children. Journal of 
Dermatological Treatment. 1996;7:21-22
[20] Mizuki D, Kaneko T, Hanada K. 
Successful treatment of topical 
photodynamic therapy using 
5-aminolevulinic acid for plane warts. 
The British Journal of Dermatology. 
2003;149:1087-1088
[21] Lin MY, Xiang LH. Topical 
5-aminolevulinic acid photodynamic 
therapy for recalcitrant facial flat wart 
in Chinese subjects. The Journal of 
Dermatology. 2008;35:658-661
[22] Lu YG, Wu JJ, He Y, Yang HZ, 
Yang YD. Efficacy of topical 
aminolevulinic acid photodynamic 
therapy for the treatment of verruca 
planae. Photomedicine and Laser 
Surgery. 2010;28:561-563
[23] Morton CA, Szeimies RM, 
Sidoroff A, Braathen LR. European 
guidelines for topical photodynamic 
therapy part 2: Emerging indications—
Field cancerization, photorejuvenation 
and inflammatory/infective dermatoses. 
Journal of the European Academy 
of Dermatology and Venereology. 
2013;27:672-679
[24] Yang Y-l, Sang J, Liao N-x, 
Wei F, Liao W, Chen J-h. Off-label 
photodynamic therapy for recalcitrant 
facial flat warts using topical 
5-aminolevulinic acid. Lasers in Medical 
Science. 2016 Jul;31(5):929-936. DOI: 
10.1007/s10103-016-1925-8 Epub 2016 
April 8
[25] Sterling JC, Handfield-Jones S, 
Hudson PM, British Association of 
Dermatologists. Guidelines for the 
management of cutaneous warts. 
The British Journal of Dermatology. 
2001;144:4-11
[26] Gaspar ZS, Dawber RP. An 
organic refrigerant for cryosurgery: 
Fact or fiction? Australian Journal of 
Dermatology. 1997;38:71-72
[27] Caballero Martínez F et al. 
Dermatological cryosurgery in primary 
care with dimethyl ether propane spray 
in comparison with liquid nitrogen. 
Atencion Primaria. 1996;18(5):211-216
[28] Leman JA, Benton EC. Verrucas. 
Guidelines for management. American 
Journal of Clinical Dermatology. 
2000;1:143-149
[29] Connolly M, Bazmi K, O’Connell M, 
Lyons JF, Bourke JF. Cryotherapy of 
viral warts: A sustained 10-s freeze 
is more effective than the traditional 
method. The British Journal of 
Dermatology. 2001;145:554-557
[30] Berth-Jones J, Bourke J, Eglitis H, 
Harper C, Kirk P, Pavord S, et al. 
Value of a second freeze-thaw cycle 
in cryotherapy of common warts. 
The British Journal of Dermatology. 
1994;131:883-886
[31] Bourke JF, Berth-Jones J, 
Hutchinson PE. Cryotherapy of 
common viral warts at intervals of 1, 2 
and 3 weeks. The British Journal of 
Dermatology. 1995;132:433-436
[32] Zaza M, Grassi C, Mardjonovic A, 
Valli E, Farne C, Romanini C. The use 
51
Human Papillomavirus Infection: Management and Treatment
DOI: http://dx.doi.org/10.5772/intechopen.92397
of electrosurgery in the treatment of 
extra-cervical genital condylomatosis. 
Minerva Ginecologica. 1998;50:367-371
[33] Tosti A, Piraccini BM. Warts of 
the nail unit: Surgical and nonsurgical 
approaches. Dermatologic Surgery. 
2001;27:235-239
[34] Wyre HW Jr, Stolar R. Extirpation 
of warts by a loop electrode and cutting 
current. The Journal of Dermatologic 
Surgery and Oncology. 1977;3:520-522
[35] Ferenczy A, Bergeron C, 
Richart RM. Human papillomavirus 
DNA in fomites on objects used 
for the management of patients 
with genital human papillomavirus 
infections. Obstetrics and Gynecology. 
1989;74:950-954
[36] Dogra A, Gupta SK, Bansal A. 
Comparative efficacy of topical 5% 
FU with electrosurgey in treatment of 
warts. Indian Journal of Dermatology. 
2006;51:108-110
[37] Piskin S, Aksoz T, Gorgulu A. 
The treatment of common warts with 
infrared coagulation. The Journal of 
Dermatology. 2004;31:989-992
[38] Bekassy Z, Westrom L. Infrared 
coagulation in the treatment of 
condyloma acuminata in the female 
genital tract. Sexually Transmitted 
Diseases. 1987;14:209-212
[39] Apfelberg DB, Druker D, 
Maser MR, White DN, Lash H, 
Spector P. Benefits of the CO2 
laser for verruca resistant to other 
modalities of treatment. The Journal of 
Dermatologic Surgery and Oncology. 
1989;15(4):371-375
[40] Mancuso JE, Abramow SP, 
Dimichino BR, Landsman MJ. 
Carbon dioxide laser management of 
plantar verruca: A 6-year follow-up 
survey. The Journal of Foot Surgery. 
1991;30(3):238-243
[41] McBurney EI, Rosen DA. 
Carbon dioxide laser treatment of 
verrucae vulgares. The Journal of 
Dermatologic Surgery and Oncology. 
1984;10(1):45-48
[42] Serour F, Somekh E. Successful 
treatment of recalcitrant warts in 
pediatric patients with carbon dioxide 
laser. European Journal of Pediatric 
Surgery. 2003;13:219-223
[43] Logan RA, Zachary CB. Outcome 
of carbon dioxide laser therapy for 
persistent cutaneous viral warts. 
The British Journal of Dermatology. 
1989;121(1):99-105
[44] Takac S. The CO2 laser and verruca 
vulgaris [in Croatian]. Medicinski 
Pregled. 2000;53(7-8):389-393
[45] Hruza GJ. Laser treatment of 
warts and other epidermal and 
dermal lesions. Dermatologic Clinics. 
1997;15(3):487-506
[46] Sloan K, Haberman H, Lynde CW. 
Carbon dioxide laser-treatment 
of resistant verrucae vulgaris: 
Retrospective analysis. Journal of 
Cutaneous Medicine and Surgery. 
1998;2(3):142-145
[47] Lim JT, Goh CL. Carbon dioxide 
laser treatment of periungual 
and subungual viral warts. The 
Australasian Journal of Dermatology. 
1992;33(2):87-91
[48] Street ML, Roenigk RK. Recalcitrant 
periungual verrucae: The role of carbon 
dioxide laser vaporization. Journal of 
the American Academy of Dermatology. 
1990;23(1):115-120
[49] Oni G, Mahaffey PJ. Treatment 
of recalcitrant warts with the carbon 
dioxide laser using an excision 
technique. Journal of Cosmetic and 
Laser Therapy. 2011;13(5):231-236
[50] Serour F, Somekh E. Successful 
treatment of recalcitrant warts in 
51
Human Papillomavirus Infection: Management and Treatment
DOI: http://dx.doi.org/10.5772/intechopen.92397
of electrosurgery in the treatment of 
extra-cervical genital condylomatosis. 
Minerva Ginecologica. 1998;50:367-371
[33] Tosti A, Piraccini BM. Warts of 
the nail unit: Surgical and nonsurgical 
approaches. Dermatologic Surgery. 
2001;27:235-239
[34] Wyre HW Jr, Stolar R. Extirpation 
of warts by a loop electrode and cutting 
current. The Journal of Dermatologic 
Surgery and Oncology. 1977;3:520-522
[35] Ferenczy A, Bergeron C, 
Richart RM. Human papillomavirus 
DNA in fomites on objects used 
for the management of patients 
with genital human papillomavirus 
infections. Obstetrics and Gynecology. 
1989;74:950-954
[36] Dogra A, Gupta SK, Bansal A. 
Comparative efficacy of topical 5% 
FU with electrosurgey in treatment of 
warts. Indian Journal of Dermatology. 
2006;51:108-110
[37] Piskin S, Aksoz T, Gorgulu A. 
The treatment of common warts with 
infrared coagulation. The Journal of 
Dermatology. 2004;31:989-992
[38] Bekassy Z, Westrom L. Infrared 
coagulation in the treatment of 
condyloma acuminata in the female 
genital tract. Sexually Transmitted 
Diseases. 1987;14:209-212
[39] Apfelberg DB, Druker D, 
Maser MR, White DN, Lash H, 
Spector P. Benefits of the CO2 
laser for verruca resistant to other 
modalities of treatment. The Journal of 
Dermatologic Surgery and Oncology. 
1989;15(4):371-375
[40] Mancuso JE, Abramow SP, 
Dimichino BR, Landsman MJ. 
Carbon dioxide laser management of 
plantar verruca: A 6-year follow-up 
survey. The Journal of Foot Surgery. 
1991;30(3):238-243
[41] McBurney EI, Rosen DA. 
Carbon dioxide laser treatment of 
verrucae vulgares. The Journal of 
Dermatologic Surgery and Oncology. 
1984;10(1):45-48
[42] Serour F, Somekh E. Successful 
treatment of recalcitrant warts in 
pediatric patients with carbon dioxide 
laser. European Journal of Pediatric 
Surgery. 2003;13:219-223
[43] Logan RA, Zachary CB. Outcome 
of carbon dioxide laser therapy for 
persistent cutaneous viral warts. 
The British Journal of Dermatology. 
1989;121(1):99-105
[44] Takac S. The CO2 laser and verruca 
vulgaris [in Croatian]. Medicinski 
Pregled. 2000;53(7-8):389-393
[45] Hruza GJ. Laser treatment of 
warts and other epidermal and 
dermal lesions. Dermatologic Clinics. 
1997;15(3):487-506
[46] Sloan K, Haberman H, Lynde CW. 
Carbon dioxide laser-treatment 
of resistant verrucae vulgaris: 
Retrospective analysis. Journal of 
Cutaneous Medicine and Surgery. 
1998;2(3):142-145
[47] Lim JT, Goh CL. Carbon dioxide 
laser treatment of periungual 
and subungual viral warts. The 
Australasian Journal of Dermatology. 
1992;33(2):87-91
[48] Street ML, Roenigk RK. Recalcitrant 
periungual verrucae: The role of carbon 
dioxide laser vaporization. Journal of 
the American Academy of Dermatology. 
1990;23(1):115-120
[49] Oni G, Mahaffey PJ. Treatment 
of recalcitrant warts with the carbon 
dioxide laser using an excision 
technique. Journal of Cosmetic and 
Laser Therapy. 2011;13(5):231-236
[50] Serour F, Somekh E. Successful 
treatment of recalcitrant warts in 
Human Papillomavirus
52
pediatric patients with carbon dioxide 
laser. European Journal of Pediatric 
Surgery. 2003;13(4):219-223
[51] Läuchli S, Kempf W, Dragieva G, 
Burg G, Hafner J. CO2 laser treatment 
of warts in immunosuppressed patients. 
Dermatology. 2003;206(2):148-152
[52] Mitsuishi T, Sasagawa T, Kato T, 
et al. Combination of carbon dioxide 
laser therapy and artificial dermis 
application in plantar warts: Human 
papillomavirus DNA analysis after 
treatment. Dermatologic Surgery. 
2010;36(9):1401-1405
[53] Zeng Y, Zheng YQ , Wang L. 
Vagarious successful treatment of 
recalcitrant warts in combination with 
CO2 laser and imiquimod 5% cream. 
Journal of Cosmetic and Laser Therapy. 
2014;16(6):311-313
[54] Garden JM, O’Banion MK, 
Shelnitz LS, Pinski KS, Bakus AD, 
Reichmann ME, et al. Papillomavirus 
in the vapor of carbon dioxide 
laser-treated verrucae. JAMA. 
1988;259:1199-1202
[55] Garden JM, O’Banion MK, 
Bakus AD, Olson C. Viral disease 
transmitted by laser-generated plume 
(aerosol). Archives of Dermatology. 
2002;138:1303-1307
[56] Sawchuk WS, Weber PJ, 
Lowy DR, Dzubow LM. Infectious 
papillomavirus in the vapor of warts 
treated with carbon dioxide laser 
or electrocoagulation: Detection 
and protection. Journal of the 
American Academy of Dermatology. 
1989;21:41-49
[57] Kashima HK, Kessis T, Mounts P, 
Shah K. Polymerase chain reaction 
identification of human papillomavirus 
DNA in CO2 laser plume from 
recurrent respiratory papillomatosis. 
Otolaryngology and Head and Neck 
Surgery. 1991;104:191-195
[58] Gloster HM Jr, Roenigk RK. Risk 
of acquiring human papillomavirus 
from the plume produced by the carbon 
dioxide laser in the treatment of warts. 
Journal of the American Academy of 
Dermatology. 1995;32:436-441
[59] Ozluer SM, Chuen BY, Barlow RJ, 
Markey AC. Hypertrophic scar 
formation following carbon dioxide 
laser ablation of plantar warts in 
cyclosporin-treated patients. The 
British Journal of Dermatology. 
2001;145(6):1005-1007
[60] Hobbs ER, Bailin PL, Wheeland RG, 
Ratz JL. Superpulsed lasers: Minimizing 
thermal damage with short duration, 
high irradiance pulses. The Journal of 
Dermatologic Surgery and Oncology. 
1987;13(9):955-964
[61] Goldberg DJ, Beckford AN, 
Mourin A. Verruca vulgaris: Novel 
treatment with a 1064 nm Nd:YAG laser. 
Journal of Cosmetic and Laser Therapy. 
2015;17(2):116-119
[62] Wollina U. Erbium-YAG laser 
therapy—Analysis of more than 1200 
treatments. Global Dermatology. 
2016;3(2):268-272
[63] Park JH, Hwang ES, Kim SN, 
Kye YC. Er:YAG laser treatment of 
verrucous epidermal nevi. Dermatologic 
Surgery. 2004;30:378-381
[64] Wollina U. Er:YAG laser followed 
by topical podophyllotoxin for hard-
to-treat palmoplantar warts. Journal 
of Cosmetic and Laser Therapy. 
2003;5:35-37
[65] Hughes PS, Hughes AP. 
Absence of human papillomavirus 
DNA in the plume of erbium:YAG 
laser-treated warts. Journal of the 
American Academy of Dermatology. 
1998;38:426-428
[66] Drnovšek-Olup B, Vedlin B. Use of 
Er:YAG laser for benign skin disorders. 
53
Human Papillomavirus Infection: Management and Treatment
DOI: http://dx.doi.org/10.5772/intechopen.92397
Lasers in Surgery and Medicine. 
1997;21(1):13-19
[67] Wollina U, Konrad H, Karamfilov T. 
Treatment of common warts and 
actinic keratoses by Er:YAG laser. 
Journal of Cutaneous Laser Therapy. 
2001;3(2):63-66
[68] Trelles MA, Allones I, Mayo E. 
Er:YAG laser ablation of plantar 
verrucae with red LED therapy-assisted 
healing. Photomedicine and Laser 
Surgery. 2006;24(4):494-498
[69] Pfau A, Abd-el-Raheem TA, 
Baumler W, Hohenleutner U, 
Landthaler M. Nd:YAG laser 
hyperthermia in the treatment 




[70] Pfau A, Abd-El-Raheem TA, 
Baumler W, Hohenleutner U, 
Landthaler M. Treatment of recalcitrant 
verrucae vulgares with Nd: YAG laser 
hyperthermia (Regensburg’s technique): 
Preliminary results in 31 cases. 
Journal of Dermatological Treatment. 
1995;6:39-42
[71] El-Tonsy MH, Anbar TE, 
El-Domyati M, Barakat M. Density 
of viral particles in pre and post Nd: 
YAG laser hyperthermia therapy 
and cryotherapy in plantar warts. 
International Journal of Dermatology. 
1999;38:393-398
[72] Janda P, Leunig A, Sroka R, Betz CS, 
Rasp G. Preliminary report of endo-
laryngeal and endotracheal laser surgery 
of juvenile-onset recurrent respiratory 
papillomatosis by Nd:YAG laser and 
a new fiber guidance instrument. 
Otolaryngology and Head and Neck 
Surgery. 2004;131:44-49
[73] Buzalov S, Khristakieva E. 
Condylomata acuminata. The 
correlation between affecting sexual 
partners and the risk of developing 
preneoplasia of the cervix uteri, 
The therapeutic potentials of the 
Nd-Yag laser. Akush Ginekol (Sofiia). 
1999;38(3):36-38
[74] Izumi T, Kyushima N, Genda T, 
Kobayashi N, Kanai T, Wakita K, 
et al. Margin clearance and HPV 
infection do not influence the cure 
rates of early neoplasia of the uterine 
cervix by laser conization. European 
Journal of Gynaecological Oncology. 
2000;21:251-254
[75] Kimura U, Takeuchi K, Kinoshita A, 
Takamori K, Suga Y. Long-pulsed 1064-
nm neodymium:yttrium-aluminum-
garnet laser treatment for refractory 
warts on hands and feet. The Journal of 
Dermatology. 2014;41(3):252-257
[76] Han TY, Lee JH, Lee CK, Ahn JY, 
Seo SJ, Hong CK. Long-pulsed Nd:YAG 
laser treatment of warts: Report on a 
series of 369 cases. Journal of Korean 
Medical Science. 2009;24(5):889-893
[77] Bingol UA, Comert A, Cinar C. The 
overlapped triple circle pulse technique 
with Nd:YAG laser for refractory 
hand warts. Photomedicine and Laser 
Surgery. 2015;33(6):338-342
[78] Baczako A, Krautheim V, 
Biedermann T, Volz T. Combination 
of surgery and Nd:YAG laser 
therapy for recalcitrant viral warts: 
A successful therapeutic approach 
for immunosuppressed patients. 
Acta Dermato-Venereologica. 
2019;99:349-350
[79] El-Mohamady AE-S, Mearag I, 
El-Khalawany M, Elshahed A, 
Shokeir H, Mahmoud A. Pulsed 
dye laser versus Nd:YAG laser in 
the treatment of plantar warts: A 
comparative study. Lasers in Medical 
Science. 2014;29:1111-1116
[80] Robson KJ, Cunningham NM, 
Kruzan KL, et al. Pulsed-dye laser 
53
Human Papillomavirus Infection: Management and Treatment
DOI: http://dx.doi.org/10.5772/intechopen.92397
Lasers in Surgery and Medicine. 
1997;21(1):13-19
[67] Wollina U, Konrad H, Karamfilov T. 
Treatment of common warts and 
actinic keratoses by Er:YAG laser. 
Journal of Cutaneous Laser Therapy. 
2001;3(2):63-66
[68] Trelles MA, Allones I, Mayo E. 
Er:YAG laser ablation of plantar 
verrucae with red LED therapy-assisted 
healing. Photomedicine and Laser 
Surgery. 2006;24(4):494-498
[69] Pfau A, Abd-el-Raheem TA, 
Baumler W, Hohenleutner U, 
Landthaler M. Nd:YAG laser 
hyperthermia in the treatment 




[70] Pfau A, Abd-El-Raheem TA, 
Baumler W, Hohenleutner U, 
Landthaler M. Treatment of recalcitrant 
verrucae vulgares with Nd: YAG laser 
hyperthermia (Regensburg’s technique): 
Preliminary results in 31 cases. 
Journal of Dermatological Treatment. 
1995;6:39-42
[71] El-Tonsy MH, Anbar TE, 
El-Domyati M, Barakat M. Density 
of viral particles in pre and post Nd: 
YAG laser hyperthermia therapy 
and cryotherapy in plantar warts. 
International Journal of Dermatology. 
1999;38:393-398
[72] Janda P, Leunig A, Sroka R, Betz CS, 
Rasp G. Preliminary report of endo-
laryngeal and endotracheal laser surgery 
of juvenile-onset recurrent respiratory 
papillomatosis by Nd:YAG laser and 
a new fiber guidance instrument. 
Otolaryngology and Head and Neck 
Surgery. 2004;131:44-49
[73] Buzalov S, Khristakieva E. 
Condylomata acuminata. The 
correlation between affecting sexual 
partners and the risk of developing 
preneoplasia of the cervix uteri, 
The therapeutic potentials of the 
Nd-Yag laser. Akush Ginekol (Sofiia). 
1999;38(3):36-38
[74] Izumi T, Kyushima N, Genda T, 
Kobayashi N, Kanai T, Wakita K, 
et al. Margin clearance and HPV 
infection do not influence the cure 
rates of early neoplasia of the uterine 
cervix by laser conization. European 
Journal of Gynaecological Oncology. 
2000;21:251-254
[75] Kimura U, Takeuchi K, Kinoshita A, 
Takamori K, Suga Y. Long-pulsed 1064-
nm neodymium:yttrium-aluminum-
garnet laser treatment for refractory 
warts on hands and feet. The Journal of 
Dermatology. 2014;41(3):252-257
[76] Han TY, Lee JH, Lee CK, Ahn JY, 
Seo SJ, Hong CK. Long-pulsed Nd:YAG 
laser treatment of warts: Report on a 
series of 369 cases. Journal of Korean 
Medical Science. 2009;24(5):889-893
[77] Bingol UA, Comert A, Cinar C. The 
overlapped triple circle pulse technique 
with Nd:YAG laser for refractory 
hand warts. Photomedicine and Laser 
Surgery. 2015;33(6):338-342
[78] Baczako A, Krautheim V, 
Biedermann T, Volz T. Combination 
of surgery and Nd:YAG laser 
therapy for recalcitrant viral warts: 
A successful therapeutic approach 
for immunosuppressed patients. 
Acta Dermato-Venereologica. 
2019;99:349-350
[79] El-Mohamady AE-S, Mearag I, 
El-Khalawany M, Elshahed A, 
Shokeir H, Mahmoud A. Pulsed 
dye laser versus Nd:YAG laser in 
the treatment of plantar warts: A 
comparative study. Lasers in Medical 
Science. 2014;29:1111-1116
[80] Robson KJ, Cunningham NM, 
Kruzan KL, et al. Pulsed-dye laser 
Human Papillomavirus
54
versus conventional therapy in the 
treatment of warts: A prospective 
randomized trial. Journal of the 
American Academy of Dermatology. 
2000;43(2, pt 1):275-280
[81] Schellhaas U, Gerber W, Hammes S, 
Ockenfels HM. Pulsed dye laser 
treatment is effective in the treatment 
of recalcitrant viral warts. Dermatologic 
Surgery. 2008;34(1):67-72
[82] Tan OT, Hurwitz RM, Stafford TJ. 
Pulsed dye laser treatment of 
recalcitrant verrucae: A preliminary 
report. Lasers in Surgery and Medicine. 
1993;13(1):127-137
[83] Kenton-Smith J, Tan ST. Pulsed 
dye laser therapy for viral warts. 
British Journal of Plastic Surgery. 
1999;52(7):554-558
[84] Vargas H, Hove CR, Dupree ML, 
Williams EF. The treatment of facial 
verrucae with the pulsed dye laser. 
Laryngoscope. 2002;112(9):1573-1576
[85] Grillo E, Boixeda P, Ballester A, 
Miguel-Morrondo A, Truchuelo T, 
Jaén P. Pulsed dye laser treatment for 
facial flat warts. Dermatologic Therapy. 
2014;27(1):31-35
[86] van Brederode RL, Engel ED. 
Combined cryotherapy/70% salicylic 
acid treatment for plantar verrucae. 
The Journal of Foot and Ankle Surgery. 
2001;40:36-41
[87] Wu C, Langan S, Kilmurray M, 
Lawlor D, Watson R. Efficacy of 
pulsed-dye laser for viral warts—An 
internal audit. Irish Medical Journal. 
2003;96(80):82-83
[88] Kopera D. Verrucae vulgares: 
Flashlamp-pumped pulsed dye 
laser treatment in 134 patients. 
International Journal of Dermatology. 
2003;42:905-908
[89] Tuncel A, Gorgu M, Ayhan M, 
Deren O, Erdogan B. Treatment of 
anogenital warts by pulsed dye laser. 
Dermatologic Surgery. 2002;28:350-352
[90] Khandpur S, SharmaVK. Efficacy 
of pulsed dye laser in cosmetically 
distressing facial dermatoses in skin 
types. Indian Journal of Dermatology. 
2008;53(4):186-189
[91] Passeron T, Sebban K, Mantoux F, 
Fontas E, Lacour JP, Ortonne JP. 
Traitement des verrues palmo-plantaires 
par le laser à colorant pulsé à 595 nm: 
étude randomisée en simple insu contre 
placebo. Annales de Dermatologie et de 
Vénéréologie. 2007;134(2):135-139
[92] Akhyani M, Ehsani AH, 
Noormohammadpour P, Shamsodini R, 
Azizahari S, Sayanjali S. Comparing 
pulsed-dye laser with cryotherapy 
in the treatment of common warts. 
Journal of Lasers in Medical Sciences. 
2010;1(1):14-19
[93] Akarsu S, Ilknur T, Demirtaşoglu M, 
Özkan S. Verruca vulgaris: Pulsed dye 
laser therapy compared with salicylic 
acid + pulsed dye laser therapy. 
Journal of the European Academy 
of Dermatology and Venereology. 
2006;20(8):936-940
[94] Park HS, Choi WS. Pulsed dye laser 
treatment for viral warts: A study of 120 
patients. The Journal of Dermatology. 
2008;35(8):491-498
[95] Ross BS, Levine VJ, Nehal K, Tse Y, 
Ashinoff R. Pulsed dye laser treatment 
of warts: An update. Dermatologic 
Surgery. 1999;25(5):377-380
[96] Jain A, Storwick GS. Effectiveness 
of the 585 nm flashlamp-pulsed tunable 
dye laser (PTDL) for treatment of 
plantar verrucae. Lasers in Surgery and 
Medicine. 1997;21(5):500-505
[97] Sparreboom EF, Luiijks HG, 
Luiting-Welkenhuyzen HA, 
Willems PW, Groeneveld CP, 
Bovenschen HJ. Pulsed-dye laser 
55
Human Papillomavirus Infection: Management and Treatment
DOI: http://dx.doi.org/10.5772/intechopen.92397
treatment for recalcitrant viral warts: A 
retrospective case seriesof 227 patients. 
The British Journal of Dermatology. 
2014;171(5):1270-1273
[98] Pollock B, Sheehan-Dare R. Pulsed 
dye laser and intralesional bleomycin 
for treatment of resistant viol hand 
warts. Lasers in Surgery and Medicine. 
2002;30(2):135-140
[99] Sethuraman G, Richards KA, 
Hiremagalore RN, Wagner A. 
Effectiveness of pulsed dye laser in 
the treatment of recalcitrant warts 
in children. Dermatologic Surgery. 
2010;36(1):58-65
[100] Park HS, Kim JW, Jang SJ, 
Choi JC. Pulsed dye laser therapy for 
pediatric warts. Pediatric Dermatology. 
2007;24(2):177-181
[101] Jacobsen E, McGraw R, 
McCagh S. Pulsed dye laser efficacy 
as initial therapy for warts and 
against recalcitrant verrucae. Cutis. 
1997;59(4):206-208
[102] Kopera D. Verrucae vulgares: 
Flashlamp-pumped pulsed dye 
laser treatment in 134 patients. 
International Journal of Dermatology. 
2003;42(11):905-908
[103] Dobson JS, Harland CC. Pulsed dye 
laser and intralesional bleomycin for 
the treatment of recalcitrant cutaneous 
warts. Lasers in Surgery and Medicine. 
2014;46(2):112-116
[104] Gooptu C, James MP. Recalcitrant 
viral warts: Results of treatment with 
the KTP laser. Clinical and Experimental 
Dermatology. 1999;24:60-63
[105] Steele K, Irwin WG. Treatment 
options for cutaneous warts in family 
practice. Family Practice. 1988;5:314-319
[106] London ID. Buffered glutaraldehyde 
solution for warts. Archives of 
Dermatology. 1971;104:96-97
[107] Hirose R, Hori M, Shukuwa T, 
Udono M, Yamada M, Koide T, et al. 
Topical treatment of resistant warts 
with glutaraldehyde. The Journal of 
Dermatology. 1994;21:248-253
[108] Stonehill AA, Krop S, Borick PM. 
Buffered glutaraldehyde—A new 
chemical sterilizing solution. American 
Journal of Hospital Pharmacy. 
1963;20:458-465
[109] Arýcan Ö. Verrukalarda güncel 
tedavi. Dermatose. 2004;3:159-159
[110] Mapar MA, Maghsoodi M, 
Maghsoodi K, Kardooni A, Shafiee A. 
Comparison between efficacy of 
formalin 5% solution and placebo in 
treatment of plane warts. Biomedical & 
Pharmacology Journal. 2017;10(1):81-87
[111] Sutana R, Alam M, Khondker L, 
Ahmed RS. Safety in use of cryotherapy 
and topical salicylic acid with lactic 
acid combination in treating verruca 
vulgaris. Mymensingh Medical Journal. 
2012;21(4):715-722
[112] Bagwell A, Loy A, McFarland MS, 
Tessmer-Neubauer A. Oral acyclovir 
in the treatment of verruca. 
Journal of Drugs in Dermatology. 
2016;15(2):237-238
[113] Tandeter H, Tandeter ER. 
Treatment of plantar warts with oral 
valacyclovir. The American Journal of 
Medicine. 01 June 2005;118(6):689-690. 
DOI: 10.1016/j.amjmed.2004.12.029. 
PMID: 15922706
[114] Hivnor C, Shepard JW, 
Shapiro MS, Vittorio CC, et al. 
Intravenous cidofovir for recalcitrant 
verruca vulgaris in the setting of 
HIV. Archives of Dermatology. 
2004;140(1):13-14. DOI: 10.1001/
archderm.140.1.13
[115] Turnbull JR, Husak R, Treudler R, 
Zouboulis CC, Orfanos CE. Regression 
of multiple viral warts in a human 
immunodeficiency virus-infected 
55
Human Papillomavirus Infection: Management and Treatment
DOI: http://dx.doi.org/10.5772/intechopen.92397
treatment for recalcitrant viral warts: A 
retrospective case seriesof 227 patients. 
The British Journal of Dermatology. 
2014;171(5):1270-1273
[98] Pollock B, Sheehan-Dare R. Pulsed 
dye laser and intralesional bleomycin 
for treatment of resistant viol hand 
warts. Lasers in Surgery and Medicine. 
2002;30(2):135-140
[99] Sethuraman G, Richards KA, 
Hiremagalore RN, Wagner A. 
Effectiveness of pulsed dye laser in 
the treatment of recalcitrant warts 
in children. Dermatologic Surgery. 
2010;36(1):58-65
[100] Park HS, Kim JW, Jang SJ, 
Choi JC. Pulsed dye laser therapy for 
pediatric warts. Pediatric Dermatology. 
2007;24(2):177-181
[101] Jacobsen E, McGraw R, 
McCagh S. Pulsed dye laser efficacy 
as initial therapy for warts and 
against recalcitrant verrucae. Cutis. 
1997;59(4):206-208
[102] Kopera D. Verrucae vulgares: 
Flashlamp-pumped pulsed dye 
laser treatment in 134 patients. 
International Journal of Dermatology. 
2003;42(11):905-908
[103] Dobson JS, Harland CC. Pulsed dye 
laser and intralesional bleomycin for 
the treatment of recalcitrant cutaneous 
warts. Lasers in Surgery and Medicine. 
2014;46(2):112-116
[104] Gooptu C, James MP. Recalcitrant 
viral warts: Results of treatment with 
the KTP laser. Clinical and Experimental 
Dermatology. 1999;24:60-63
[105] Steele K, Irwin WG. Treatment 
options for cutaneous warts in family 
practice. Family Practice. 1988;5:314-319
[106] London ID. Buffered glutaraldehyde 
solution for warts. Archives of 
Dermatology. 1971;104:96-97
[107] Hirose R, Hori M, Shukuwa T, 
Udono M, Yamada M, Koide T, et al. 
Topical treatment of resistant warts 
with glutaraldehyde. The Journal of 
Dermatology. 1994;21:248-253
[108] Stonehill AA, Krop S, Borick PM. 
Buffered glutaraldehyde—A new 
chemical sterilizing solution. American 
Journal of Hospital Pharmacy. 
1963;20:458-465
[109] Arýcan Ö. Verrukalarda güncel 
tedavi. Dermatose. 2004;3:159-159
[110] Mapar MA, Maghsoodi M, 
Maghsoodi K, Kardooni A, Shafiee A. 
Comparison between efficacy of 
formalin 5% solution and placebo in 
treatment of plane warts. Biomedical & 
Pharmacology Journal. 2017;10(1):81-87
[111] Sutana R, Alam M, Khondker L, 
Ahmed RS. Safety in use of cryotherapy 
and topical salicylic acid with lactic 
acid combination in treating verruca 
vulgaris. Mymensingh Medical Journal. 
2012;21(4):715-722
[112] Bagwell A, Loy A, McFarland MS, 
Tessmer-Neubauer A. Oral acyclovir 
in the treatment of verruca. 
Journal of Drugs in Dermatology. 
2016;15(2):237-238
[113] Tandeter H, Tandeter ER. 
Treatment of plantar warts with oral 
valacyclovir. The American Journal of 
Medicine. 01 June 2005;118(6):689-690. 
DOI: 10.1016/j.amjmed.2004.12.029. 
PMID: 15922706
[114] Hivnor C, Shepard JW, 
Shapiro MS, Vittorio CC, et al. 
Intravenous cidofovir for recalcitrant 
verruca vulgaris in the setting of 
HIV. Archives of Dermatology. 
2004;140(1):13-14. DOI: 10.1001/
archderm.140.1.13
[115] Turnbull JR, Husak R, Treudler R, 
Zouboulis CC, Orfanos CE. Regression 




patient treated by triple antiretroviral 
therapy. The British Journal of 
Dermatology. 2002;146:330
[116] Shumer SM, O’Keefe EJ. Bleomycin 
in the treatment of recalcitrant warts. 
Journal of the American Academy of 
Dermatology. 1983;9:91-96. [PubMed] 
[Google Scholar]
[117] van der Velden EM, 
Ijsselmuiden OE, Drost BH, 
Baruchin AM. Dermatography with 
bleomycin as a new treatment for 
verrucae vulgaris. International Journal 
of Dermatology. 1997;36:145-150
[118] Stulberg DL, Hutchinson AG. 
Molluscum contagiosum and 
warts. American Family Physician. 
2003;67:1233-1240
[119] Stulberg DL, Hutchinson AG. 
Physicians need more evidence on 
treatments of warts: in reply. American 
Family Physician. 2003;68:1714-1716. 
Available from: http://www.aafp.org/
afp/20031101/letters.html [Accessed: 10 
May 2006]
[120] Sobh MA, Abd El-Razic MM, 
Rizc RA, Eid MM, Abd El-Hamid IA, 
Ghoneim MA. Intralesional injection of 
bleomycin sulphate into resistant warts 
in renal transplant recipients versus 
non-transplant warty patients. Acta 
Dermato-Venereologica. 1991;71:63-66
[121] James MP, Collier PM, 
Aherne W, Hardcastle A, Lovegrove S. 
Histologic, pharmacologic, and 
immunocytochemical effects of 
injection of bleomycin into viral warts. 
Journal of the American Academy of 
Dermatology. 1993;28:933-937
[122] Miller RA. Nail dystrophy following 
intralesional injections of bleomycin 
for aperiungual wart. Archives of 
Dermatology. 1984;120:963-964
[123] Yamamoto T. Bleomycin and 
the skin. The British Journal of 
Dermatology. 2006;155:869-875
[124] Abess A, Keel DM, Graham BS. 
Flagellate hyperpigmentation following 
intral-lesional bleomycin treatment 
of verruca plantaris. Archives of 
Dermatology. 2003;139:337-339
[125] Munn SE, Higgins E, Marshall M, 
et al. A new method of intralesional 
bleomycin therapy in the treatment of 
recalcitrant warts. The British Journal of 
Dermatology. 1996;135:969-971
[126] Loo S K-f, Tang W Y-m. Warts 
(non-genital). BMJ Clinical Evidence. 
2014;2014:1710. PMCID: PMC4054795. 
PMID: 24921240
[127] Dhar SB, Rashid MM, Islam A, 
Bhuiyan M. Intralesional bleomycin 
in the treatment of cutaneous warts: 
A randomized clinical trial comparing 
it with cryotherapy. Indian Journal 
of Dermatology, Venereology and 
Leprology. 2009;75:262-267
[128] Seif R. Factors which disorganize 
microtubules or microfilaments increase 
the frequency of cell transformation 
by polyoma virus. Journal of Virology. 
1980;36:421-428
[129] Krogh G. Penile condylomata 
acuminata an experimental model for 
evaluation of topical self-treatment with 
0.5%-1.0% ethanolic preparations of 
podophyllotoxin for three days. Sexually 
Transmitted Diseases. 1981;8:179-186
[130] Gabriel G, Thin RNT. Treatment 
of anogerital warts: Comparison of 
trichloroacetic acid and podophyllin vs 
podophyllin alone. The British Journal 
of Venereal Diseases. 1983;59:124-126
[131] Workowski KA, Bolan GA. 
Sexually transmitted diseases treatment 
guidelines. Morbidity and 
mortality weekly report (MMWR). 
Recommendations and Reports. 5 June 
2015;64(RR3):1-137. Available from: 
https://www.cdc.gov/mmwr/ 
[132] Briggs GC, Freeman RK, Yaffe SJ. 
Drugs in Pregnancy and Lactation. 
57
Human Papillomavirus Infection: Management and Treatment
DOI: http://dx.doi.org/10.5772/intechopen.92397
9th ed. Philadelphia, PA: Lippincott 
Williams & Wilkins; 2011
[133] Hellberg D, Svarrer T, Nilsson S, 
Valentin J. Self-treatment of female 
external genital warts with 0.5% 
podophyllotoxin cream (Condyline) vs 
weekly applications of 20% podophyllin 
solution. International Journal of STD 
& AIDS. 1995;6:257-261
[134] Thappa DM, Chiramel MJ. 
Evolving role of immunotherapy 
in the treatment of refractory 
warts. Indian Dermatology Online 
Journal. 2016;7(5):364-370. DOI: 
10.4103/2229-5178.190487
[135] Arndt KA, Bowers KE, Alam M, 
Reynolds R, Tsao S, editors. Warts. In: 
Manual of Dermatologic Therapeutics. 
6th ed. Philadelphia: Lippincott 
Williams & Wilkins; 2002. pp. 241-251
[136] Moore RA, Edwards JE, 
Hopwood J, Hicks D. Imiquimod 
for the treatment of genital warts: 
Aquantitative systematic review. BMC 
Infectious Diseases. 2001;1:3. [PMC free 
article] [PubMed] [Google Scholar]
[137] Ahn CS, Huang WW. Imiquimod 
in the treatment of cutaneous warts: 
An evidence-based review. American 
Journal of Clinical Dermatology. 
2014;15:387-399. [PubMed] [Google 
Scholar]
[138] Stefanaki C, Lagogiani I, Kouris A, 
Kontochristopoulos G, Antoniou C, 
Katsarou AJ. Cryotherapy versus 
imiquimod 5% cream combined with 
a keratolytic lotion in cutaneous warts 
in children: A randomized study. 
Journal of Dermatological Treatment. 
2016;27(1):80-82. [PubMed] [Ref list]
[139] Ciavattini A, Tsiroglou D, Vichi M, 
Di Giuseppe J, Cecchi S, Tranquilli AL. 
Topical Imiquimod 5% cream therapy 
for external anogenital warts in 
pregnant women: Report of four cases 
and review of the literature. Journal of 
Maternal-Fetal and Neonatal Medicine. 
2012;25(7):873-876. [PubMed] [Ref list]
[140] Garg S, Baveja S. Intralesional 
immunotherapy for difficult to treat 
warts with Mycobacterium w vaccine. 
Journal of Cutaneous and Aesthetic 
Surgery. 2014;7:203-208
[141] Singh S, Chouhan K, Gupta S. 
Intralesional immunotherapy with 
killed Mycobacterium indicus pranii 
vaccine for the treatment of extensive 
cutaneous warts. Indian Journal 
of Dermatology, Venereology and 
Leprology. 2014;80:509-514
[142] Gupta S, Malhotra AK, 
Verma KK, Sharma VK. Intralesional 
immunotherapy with killed 
Mycobacterium w vaccine for the 
treatment of ano-genital warts: 
An open label pilot study. Journal 
of the European Academy of 
Dermatology and Venereology: JEADV. 
2008;22:1089-1093
[143] Meena JK, Malhotra AK, 
Mathur DK, Mathur DC. Intralesional 
immunotherapy with Mycobacterium 
w vaccine in patients with multiple 
cutaneous warts: Uncontrolled 
open study. JAMA Dermatology. 
2013;149:237-239
[144] Dhakar AK, Dogra S, Vinay K, 
Sarangal R, Kanwar AJ, Singh MP. 
Intralesional Mycobacterium w vaccine 
versus cryotherapy in treatment 
of refractory extragenital warts: 
Arandomized, open-label, comparative 
study. Journal of Cutaneous Medicine 
and Surgery. 2016;20:123-129
[145] Kumar P, Dar L, Saldiwal S, 
Varma S, Datt Upadhyay A, Talwar D, 
et al. Intralesional injection of 
Mycobacterium w vaccine vs imiquimod, 
5%, cream in patients with anogenital 
warts: Arandomized clinical trial. JAMA 
Dermatology. 2014;150:1072-1078
[146] Singh S, Chouhan K, Gupta S. 
Intralesional immunotherapy with 
57
Human Papillomavirus Infection: Management and Treatment
DOI: http://dx.doi.org/10.5772/intechopen.92397
9th ed. Philadelphia, PA: Lippincott 
Williams & Wilkins; 2011
[133] Hellberg D, Svarrer T, Nilsson S, 
Valentin J. Self-treatment of female 
external genital warts with 0.5% 
podophyllotoxin cream (Condyline) vs 
weekly applications of 20% podophyllin 
solution. International Journal of STD 
& AIDS. 1995;6:257-261
[134] Thappa DM, Chiramel MJ. 
Evolving role of immunotherapy 
in the treatment of refractory 
warts. Indian Dermatology Online 
Journal. 2016;7(5):364-370. DOI: 
10.4103/2229-5178.190487
[135] Arndt KA, Bowers KE, Alam M, 
Reynolds R, Tsao S, editors. Warts. In: 
Manual of Dermatologic Therapeutics. 
6th ed. Philadelphia: Lippincott 
Williams & Wilkins; 2002. pp. 241-251
[136] Moore RA, Edwards JE, 
Hopwood J, Hicks D. Imiquimod 
for the treatment of genital warts: 
Aquantitative systematic review. BMC 
Infectious Diseases. 2001;1:3. [PMC free 
article] [PubMed] [Google Scholar]
[137] Ahn CS, Huang WW. Imiquimod 
in the treatment of cutaneous warts: 
An evidence-based review. American 
Journal of Clinical Dermatology. 
2014;15:387-399. [PubMed] [Google 
Scholar]
[138] Stefanaki C, Lagogiani I, Kouris A, 
Kontochristopoulos G, Antoniou C, 
Katsarou AJ. Cryotherapy versus 
imiquimod 5% cream combined with 
a keratolytic lotion in cutaneous warts 
in children: A randomized study. 
Journal of Dermatological Treatment. 
2016;27(1):80-82. [PubMed] [Ref list]
[139] Ciavattini A, Tsiroglou D, Vichi M, 
Di Giuseppe J, Cecchi S, Tranquilli AL. 
Topical Imiquimod 5% cream therapy 
for external anogenital warts in 
pregnant women: Report of four cases 
and review of the literature. Journal of 
Maternal-Fetal and Neonatal Medicine. 
2012;25(7):873-876. [PubMed] [Ref list]
[140] Garg S, Baveja S. Intralesional 
immunotherapy for difficult to treat 
warts with Mycobacterium w vaccine. 
Journal of Cutaneous and Aesthetic 
Surgery. 2014;7:203-208
[141] Singh S, Chouhan K, Gupta S. 
Intralesional immunotherapy with 
killed Mycobacterium indicus pranii 
vaccine for the treatment of extensive 
cutaneous warts. Indian Journal 
of Dermatology, Venereology and 
Leprology. 2014;80:509-514
[142] Gupta S, Malhotra AK, 
Verma KK, Sharma VK. Intralesional 
immunotherapy with killed 
Mycobacterium w vaccine for the 
treatment of ano-genital warts: 
An open label pilot study. Journal 
of the European Academy of 
Dermatology and Venereology: JEADV. 
2008;22:1089-1093
[143] Meena JK, Malhotra AK, 
Mathur DK, Mathur DC. Intralesional 
immunotherapy with Mycobacterium 
w vaccine in patients with multiple 
cutaneous warts: Uncontrolled 
open study. JAMA Dermatology. 
2013;149:237-239
[144] Dhakar AK, Dogra S, Vinay K, 
Sarangal R, Kanwar AJ, Singh MP. 
Intralesional Mycobacterium w vaccine 
versus cryotherapy in treatment 
of refractory extragenital warts: 
Arandomized, open-label, comparative 
study. Journal of Cutaneous Medicine 
and Surgery. 2016;20:123-129
[145] Kumar P, Dar L, Saldiwal S, 
Varma S, Datt Upadhyay A, Talwar D, 
et al. Intralesional injection of 
Mycobacterium w vaccine vs imiquimod, 
5%, cream in patients with anogenital 
warts: Arandomized clinical trial. JAMA 
Dermatology. 2014;150:1072-1078
[146] Singh S, Chouhan K, Gupta S. 
Intralesional immunotherapy with 
Human Papillomavirus
58
killed Mycobacterium indicus pranii 
vaccine for the treatment of extensive 
cutaneous warts. Indian Journal 
of Dermatology, Venereology and 
Leprology. 2014;80:509-514
[147] Zuo C, Huang J, Liao Z, Lu J, 
Chen J. Effects of BCG-PSN on serum 
levels of IL-4 and IL-12 in patients 
with condyloma acuminatum. Zhong 
Nan Da Xue Xue Bao. Yi Xue Ban. 
2004;29:690-692
[148] Sharquie KE, Al-Rawi JR, 
Al-Nuaimy AA, Radhy SH. Bacille 
Calmette-Guerin immunotherapy of 
viral warts. Saudi Medical Journal. 
2008;29:589-593
[149] Salem A, Nofal A, Hosny D. 
Treatment of common and plane 
warts in children with topical viable 
Bacillus Calmette-Guerin. Pediatric 
Dermatology. 2013;30:60-63
[150] Daulatabad D, Pandhi D, Singal A. 
BCG vaccine for immunotherapy in 
warts: Is it really safe in a tuberculosis 
endemic area? Dermatologic Therapy. 
2016;29:168-172
[151] Zamanian A, Mobasher P, Jazi GA. 
Efficacy of intralesional injection 
of mumps-measles-rubella vaccine 
in patients with wart. Advanced 
Biomedical Research. 2014;3:107
[152] Nofal A, Nofal E. Intralesional 
immunotherapy of common warts: 
Successful treatment with mumps, 
measles and rubella vaccine. 
Journal of the European Academy 
of Dermatology and Venereology. 
2010;24(10):1166-1170. DOI: 
10.1111/j.1468-3083.2010.03611.x
[153] Kus S, Ergun T, Gun D, Akin O. 
Intralesional tuberculin for treatment 
of refractory warts. Journal of the 
European Academy of Dermatology and 
Venereology. 2005;19:515-516
[154] Clifton MM, Johnson SM, 
Roberson PK, et al. Immunotherapy 
for recalcitrant warts in children 
using intralesional mumps or Candida 
antigens. Pediatric Dermatology. 
2003;20:268-271
[155] King M, Johnson SM, Horn TD. 
Intralesional immunotherapy for 
genital warts. Archives of Dermatology. 
2005;141:1606-1607
[156] Signore RJ. Candida albicans 
intralesional injection immunotherapy 
of warts. Cutis. 2002;70:185-192
[157] Horn TD, Johnson SM, 
Helm RM, Roberson PK. Intralesional 
immunotherapy of warts with mumps, 
Candida and trichophyton skin test 
antigens: A single-blinded, randomized 
and controlled trial. Archives of 
Dermatology. 2005;141:589-594
[158] Johnson SM, Horn TD. 
Intralesional immunotherapy for 
warts using a combination of skin test 
antigens: A safe and effective therapy. 
Journal of Drugs in Dermatology. 
2004;3:263-265
[159] Phillips RC, Ruhl TS, Pfenniger JL, 
Garber MR. Treatment of warts with 
Candida antigen injection. Archives of 
Dermatology. 2000;136:1274-1275
[160] Johnson SM, Roberson PK, 
Horn TD. Intralesional injection of 
mumps or Candida skin test antigens: A 
novel immunotherapy for warts. Archives 
of Dermatology. 2001;137:451-455
[161] Brunk D. Injection of Candida 
antigen works on warts. Skin Allergy 
News. 1999;30:5
[162] Majid I, Imran S. Immunotherapy 
with intralesional Candida Albicans 
antigen in resistant or recurrent warts: 
A study. Indian Journal of Dermatology. 
2013;58(5):360-365
[163] Maronn M, Salm C, Lyon V, 
Galbraith S. One-year experience 
with Candida antigen immunotherapy 
59
Human Papillomavirus Infection: Management and Treatment
DOI: http://dx.doi.org/10.5772/intechopen.92397
for warts and molluscum. Pediatric 
Dermatology. 2008;25:189-192
[164] Dianzani F. Viral interference and 
interferon. La Ricerca in Clinica e in 
Laboratorio. 1975;5:196-213. [PubMed] 
[Google Scholar]
[165] Turek LP, Byrne JC, Lowy DR, 
Dvoretzky I, Friedman RM, 
Howley PM. Interferon induces 
morphologic reversion with elimination 
of extrachromosomal viral genomes 
in bovine papillomavirus-transformed 
mouse cells. Proceedings of the National 
Academy of Sciences of the United 
States of America. 1982;79:7914-7918. 
DOI: 10.1073/pnas.79.24.7914. [PMC 
free article] [PubMed] [CrossRef] 
[Google Scholar]
[166] Yang J, Yu-guo P, Zeng Z-m, Yu Z-j, 
Huang N, Deng Q-w. Interferon for the 
treatment of genital warts: A systematic 
review. BMC Infectious Diseases. 
2009;9:156
[167] Ibs KH, Rink L. Zinc-altered 
immune function. The Journal of 
Nutrition. 2003;133:1452S-1526S
[168] Fraker PJ, King LE. 
Reprogramming of the immune system 
during zinc deficiency. Annual Review 
of Nutrition. 2004;24:277-298
[169] Sharquie KE, Khorsheed AA, 
Al-Nuaimy AA. Topical zinc sulphate 
solution for treatment of viral warts. 
Saudi Medical Journal. 2007;28(9):1418-
1421. View at Google Scholar; View at 
Scopus
[170] Khattar JA, Musharrafieh UM, 
Tamim H, Hamadeh GN. Topical 
zinc oxide vs salicylic acid-lactic acid 
combination in the treatment of warts. 
International Journal of Dermatology. 
2007;46(4):427-430. View at Publisher; 
View at Google Scholar
[171] Al-Gurairi FT, Al-Waiz M, 
Sharquie KE. Oral zinc sulphate in the 
treatment of recalcitrant viral warts: 
Randomized placebo-controlled clinical 
trial. British Journal of Dermatology. 
2002;146(3):423-431. View at Google 
Scholar
[172] Mun JH, Kim SH, Jung DS, et al. 
Oral zinc sulfate treatment for viral 
warts: An open-label study. Journal of 
Dermatology. 2011;38:541-545. View at 
Google Scholar
[173] Sharquine KA, Al-Nuaimy AA. 
Treatment of viral warts by intralesional 
injection of zinc sulphate. Annals of 
Saudi Medicine. 2002;22(1-2):26-28. 
View at Google Scholar; View at Scopus
[174] Paller AS. Cimetidine for the 
treatment of warts. The Western 
Journal of Medicine. 1996;164:520-521. 
[PMC free article] [PubMed] [Google 
Scholar]
[175] Mitsuishi T, Iida K, Kawana S. 
Cimetidine treatment for viral warts 
enhances IL-2 and IFN-gamma 
expression but not IL-18 expression 
in lesional skin. European Journal 
of Dermatology. 2003;13:445-448. 
[PubMed] [Google Scholar]
[176] Gooptu C, Higgins CR, James MP. 
Treatment of viral warts with 
cimetidine: An open-label study. 
Clinical and Experimental Dermatology. 
2000;25:183-185. [PubMed] [Google 
Scholar]
[177] Yilmaz E, Alpsoy E, Basaran E. 
Cimetidine therapy for warts: Aplacebo-
controlled, double-blind study. 
Journal of the American Academy 
of Dermatology. 1996;34:1005-1007. 
[PubMed] [Google Scholar]
[178] Rogers CJ, Gibney MD, 
Siegfried EC, Harrison BR, 
Glaser DA. Cimetidine therapy for 
recalcitrant warts in adults: Is it any 
better than placebo? Journal of the 
American Academy of Dermatology. 
1999;41:123-127
59
Human Papillomavirus Infection: Management and Treatment
DOI: http://dx.doi.org/10.5772/intechopen.92397
for warts and molluscum. Pediatric 
Dermatology. 2008;25:189-192
[164] Dianzani F. Viral interference and 
interferon. La Ricerca in Clinica e in 
Laboratorio. 1975;5:196-213. [PubMed] 
[Google Scholar]
[165] Turek LP, Byrne JC, Lowy DR, 
Dvoretzky I, Friedman RM, 
Howley PM. Interferon induces 
morphologic reversion with elimination 
of extrachromosomal viral genomes 
in bovine papillomavirus-transformed 
mouse cells. Proceedings of the National 
Academy of Sciences of the United 
States of America. 1982;79:7914-7918. 
DOI: 10.1073/pnas.79.24.7914. [PMC 
free article] [PubMed] [CrossRef] 
[Google Scholar]
[166] Yang J, Yu-guo P, Zeng Z-m, Yu Z-j, 
Huang N, Deng Q-w. Interferon for the 
treatment of genital warts: A systematic 
review. BMC Infectious Diseases. 
2009;9:156
[167] Ibs KH, Rink L. Zinc-altered 
immune function. The Journal of 
Nutrition. 2003;133:1452S-1526S
[168] Fraker PJ, King LE. 
Reprogramming of the immune system 
during zinc deficiency. Annual Review 
of Nutrition. 2004;24:277-298
[169] Sharquie KE, Khorsheed AA, 
Al-Nuaimy AA. Topical zinc sulphate 
solution for treatment of viral warts. 
Saudi Medical Journal. 2007;28(9):1418-
1421. View at Google Scholar; View at 
Scopus
[170] Khattar JA, Musharrafieh UM, 
Tamim H, Hamadeh GN. Topical 
zinc oxide vs salicylic acid-lactic acid 
combination in the treatment of warts. 
International Journal of Dermatology. 
2007;46(4):427-430. View at Publisher; 
View at Google Scholar
[171] Al-Gurairi FT, Al-Waiz M, 
Sharquie KE. Oral zinc sulphate in the 
treatment of recalcitrant viral warts: 
Randomized placebo-controlled clinical 
trial. British Journal of Dermatology. 
2002;146(3):423-431. View at Google 
Scholar
[172] Mun JH, Kim SH, Jung DS, et al. 
Oral zinc sulfate treatment for viral 
warts: An open-label study. Journal of 
Dermatology. 2011;38:541-545. View at 
Google Scholar
[173] Sharquine KA, Al-Nuaimy AA. 
Treatment of viral warts by intralesional 
injection of zinc sulphate. Annals of 
Saudi Medicine. 2002;22(1-2):26-28. 
View at Google Scholar; View at Scopus
[174] Paller AS. Cimetidine for the 
treatment of warts. The Western 
Journal of Medicine. 1996;164:520-521. 
[PMC free article] [PubMed] [Google 
Scholar]
[175] Mitsuishi T, Iida K, Kawana S. 
Cimetidine treatment for viral warts 
enhances IL-2 and IFN-gamma 
expression but not IL-18 expression 
in lesional skin. European Journal 
of Dermatology. 2003;13:445-448. 
[PubMed] [Google Scholar]
[176] Gooptu C, Higgins CR, James MP. 
Treatment of viral warts with 
cimetidine: An open-label study. 
Clinical and Experimental Dermatology. 
2000;25:183-185. [PubMed] [Google 
Scholar]
[177] Yilmaz E, Alpsoy E, Basaran E. 
Cimetidine therapy for warts: Aplacebo-
controlled, double-blind study. 
Journal of the American Academy 
of Dermatology. 1996;34:1005-1007. 
[PubMed] [Google Scholar]
[178] Rogers CJ, Gibney MD, 
Siegfried EC, Harrison BR, 
Glaser DA. Cimetidine therapy for 
recalcitrant warts in adults: Is it any 
better than placebo? Journal of the 




[179] Karabulut AA, Sahin S, 
Eksioglu M. Is cimetidine effective 
for nongenital warts: A double-blind, 
placebo-controlled study. Archives of 
Dermatology. 1997;133:533-534
[180] Amer M, Tosson Z, Soliman A, 
Selim AG, Salem A, Al-Gendy AA. 
Verrucae treated by levamisole. 
International Journal of Dermatology. 
1991;30:738-740. [PubMed] [Google 
Scholar]
[181] Moncada B, Rodriguez ML. 
Levamisole therapy for multiple warts. 
The British Journal of Dermatology. 
1979;101:327-330. [PubMed] [Google 
Scholar]
[182] Saúl A, Sanz R, Gomez M. 
Treatment of multiple viral warts 
with levamisole. International Journal 
of Dermatology. 1980;19:342-343. 
[PubMed] [Google Scholar]
[183] Parsad D, Pandhi R, Juneja A, 
Negi KS. Cimetidine and levamisole 
versus cimetidine alone for recalcitrant 
warts in children. Pediatric 
Dermatology. 2001;18:349-352. 
[PubMed] [Google Scholar]
[184] Scheinfeld N, Rosenberg JD, 
Weinberg JM. Levamisole in 
dermatology: A review. American Journal 
of Clinical Dermatology. 2004;5:97-104. 
[PubMed] [Google Scholar]
[185] Markowitz LE, Tsu V, Deeks SL, 
et al. Human papillomavirus vaccine 
introduction—The first five years. 
Vaccine. 2012;30(Suppl 5):F139-F148
[186] Giuliano AR, Tortolero-Luna G, 
Ferrer E, et al. Epidemiology of human 
papillomavirus infection in men, 
cancers other than cervical and benign 
conditions. Vaccine. 2008;26(Suppl 
10):K17-K28
[187] Blomberg M, Dehlendorff C, 
Sand C, Kjaer SK. Dose-related 
differences in effectiveness of human 
papillomavirus vaccination against 
genital warts: A nationwide study of 
550,000 young girls. Clinical Infectious 
Diseases. 2015;61:676-682. [PubMed] 
[Google Scholar]
[188] Blomberg M, Dehlendorff C, 
Sand C, Kjaer SK. Dose-related 
differences in effectiveness of human 
papillomavirus vaccination against 
genital warts: A nationwide study of 
550,000 young girls. Clinical Infectious 
Diseases. 2015;61:676-682. [PubMed] 
[Google Scholar]
[189] Chow EP, Read TR, Wigan R, 
Donovan B, Chen MY, Bradshaw CS, 
et al. Ongoing decline in genital warts 
among young heterosexuals 7 years after 
the Australian human papillomavirus 
(HPV) vaccination programme. 
Sexually Transmitted Infections. 
2015;91:214-219. [PubMed] [Google 
Scholar]
[190] Shivakumar V, Okade R, 
Rajkumar V. Autoimplantation therapy 
for multiple warts. Indian Journal 
of Dermatology, Venereology and 
Leprology. 2009;7:593-595
[191] Das S, Das S, Chowdhury J, Patra S, 
Ghoshal L, Banerjee S. Auto-wart 
inoculation: An easy and effective 
treatment of multiple, recalcitrant 
and genital warts. Journal of Pakistan 
Association of Dermatologists. 
2016;26(3):229-234
[192] Buckley DA, Keane FM, Munn SE, 
Fuller LC, Higgins EM, Du Vivier AW. 
Recalcitrant viral warts treated by 
diphencyprone immunotherapy. 
The British Journal of Dermatology. 
1999;141:292-296
[193] Upitis JA, Krol A. The use of 
diphenylcyclopropenone in the 
treatment of recalcitrant warts. Journal 
of Cutaneous Medicine and Surgery. 
2002;6:214-217
61
Human Papillomavirus Infection: Management and Treatment
DOI: http://dx.doi.org/10.5772/intechopen.92397
[194] Focht DR 3rd, Spicer C, 
Fairchok MP. The efficacy of duct tape 
vs cryotherapy in the treatment of 
verruca vulgaris (the common wart). 
Archives of Pediatrics & Adolescent 
Medicine. 2002;156:971-974
[195] Seki T, Tsuji K, Hayato Y, 
Moritomo T, Ariga T. Garlic and onion 
oils inhibit proliferation and induce 
differentiation of HL-60 cells. Cancer 
Letters. 2000;160:29-35
[196] Zedan H, Hofny ERM, Ismail SA. 
Propolis as an alternative treatment for 
cutaneous warts. International Journal 
of Dermatology. 2009;48:1246-1249. 
[PubMed] [Google Scholar]
[197] Gupta AK, Daigle D. Sinecatechins 
10% ointment: A green tea extract 
for the treatment of external genital 
warts. Skin Therapy Letter. 2015;20:6-8. 
[PubMed] [Google Scholar]
[198] Domínguez Gómez J, Simón RD,  
Abreu Daniel A, Zelenkova H. 
Effectiveness of glycyrrhizinic Acid 
(glizigen) and an immunostimulant 
(viusid) to treat anogenital warts. ISRN 
Dermatology. 2012;2012:863692. DOI: 
10.5402/2012/863692
[199] Kolev N, Bakardzhiev I. 
Glycyrrhizinic acid—An alternative 
treatment of anogenital warts 
during pregnancy. European Journal 
of Obstetrics, Gynecology, and 
Reproductive Biology. 2016;206:e86
[200] Kavya M, Shashikumar BM, et al. 
Safety and efficacy of intralesional 
vitamin D3 in cutaneous warts: An open 
uncontrolled trial. Journal of Cutaneous 
and Aesthetic Surgery. 2017;10(2):90-94
61
Human Papillomavirus Infection: Management and Treatment
DOI: http://dx.doi.org/10.5772/intechopen.92397
[194] Focht DR 3rd, Spicer C, 
Fairchok MP. The efficacy of duct tape 
vs cryotherapy in the treatment of 
verruca vulgaris (the common wart). 
Archives of Pediatrics & Adolescent 
Medicine. 2002;156:971-974
[195] Seki T, Tsuji K, Hayato Y, 
Moritomo T, Ariga T. Garlic and onion 
oils inhibit proliferation and induce 
differentiation of HL-60 cells. Cancer 
Letters. 2000;160:29-35
[196] Zedan H, Hofny ERM, Ismail SA. 
Propolis as an alternative treatment for 
cutaneous warts. International Journal 
of Dermatology. 2009;48:1246-1249. 
[PubMed] [Google Scholar]
[197] Gupta AK, Daigle D. Sinecatechins 
10% ointment: A green tea extract 
for the treatment of external genital 
warts. Skin Therapy Letter. 2015;20:6-8. 
[PubMed] [Google Scholar]
[198] Domínguez Gómez J, Simón RD,  
Abreu Daniel A, Zelenkova H. 
Effectiveness of glycyrrhizinic Acid 
(glizigen) and an immunostimulant 
(viusid) to treat anogenital warts. ISRN 
Dermatology. 2012;2012:863692. DOI: 
10.5402/2012/863692
[199] Kolev N, Bakardzhiev I. 
Glycyrrhizinic acid—An alternative 
treatment of anogenital warts 
during pregnancy. European Journal 
of Obstetrics, Gynecology, and 
Reproductive Biology. 2016;206:e86
[200] Kavya M, Shashikumar BM, et al. 
Safety and efficacy of intralesional 
vitamin D3 in cutaneous warts: An open 
uncontrolled trial. Journal of Cutaneous 
and Aesthetic Surgery. 2017;10(2):90-94
63
Chapter 4
Human Papillomavirus Infections 
in Pregnant Women and Its Impact 
on Pregnancy Outcomes: Possible 
Mechanism of Self-Clearance
Sanchita Roy Pradhan, Sutapa Mahata, Dipanwita Ghosh, 
Pranab Kumar Sahoo, Sinjini Sarkar, Ranita Pal  
and Vilas D. Nasare
Abstract
Young women are at the maximum risk of Human papillomavirus (HPV) infection 
which are asymptomatic in a majority of cases and spontaneously get cleared. Women 
in the age between 20 and 35 years are more active sexually and especially in the devel-
oping nations, this age group forms a major cohort among the population of pregnant 
women. The changed hormonal milieu and immune response during pregnancy 
might favor presence or persistence of HPV infection, while at the same time natural 
clearance also takes place during pregnancy with an unknown mechanism. Various 
HPVs have been reported to be associated with preterm rupture of membranes 
(PROM), fetal growth restriction (FGR), preeclampsia, placental abnormalities and 
preterm delivery in several populations. The risk factors involved in the intrauterine 
environment affects fetal development and thus increase the development risk of 
specific diseases in adult life as per the hypothesis of the fetal origins of adult disease 
(FOAD). The structural and molecular changes in the feto-maternal interface support 
and protect the semiallogeneic fetus from immune-mediated or inflammatory injury. 
On the other hand, the trophoblast cells of placenta facilitate the replication of HPV 
and the affliction of placenta and the vaginal infection can directly be associated 
with pregnancy outcomes. So, to optimize better child health care and reproductive 
outcomes, HPV screening might help during pregnancy. It is therefore important to 
understand how the HPV is affecting the early pregnancy and immune cells within 
the feto-maternal interface are educated for self-clearance to fulfill their biological 
functions or prevalence to affect the pregnancy outcomes and how the persistence of 
HR-HPV infection overtime increases the development of cervical cancer risk.
Keywords: pregnancy, self clearance, feto-maternal cell trafficking, HPV vaccine, 
cervical cancer
1. Introduction
The most common sexually transmitted infectious conditions across the 
globe are Human papillomavirus (HPV) infections which is responsible for the 
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development of cervical cancer. The infection of HPV does not always lead towards 
the neoplastic disease which suggests that the clearance or acquisition of HPV infec-
tions may depend on the interpersonal variations in the immune system as well as 
environmental or viral factors. For example, a well-established cervical cancer risk 
factor is parity. However, the influence of pregnancy in the natural history of HPV 
infection and thus the development of cervical neoplasia and its exact mechanism is 
not known [1].
At the beginning of the pregnancy, immune modulation and induction of 
tolerance are required for successful implantation allowance but as the pregnancy 
progresses a responsive immune system is responsible for a successful pregnancy 
which can protect both the fetus and the mother against environmental insults 
whenever there is a necessity arises. Indeed the maternal immune system reinforces 
networks that can respond according to the recognized danger signals and eliminate 
them appropriately promoting repair when needed. Not only the maternal immune 
system but also the actively developing immune system in the fetal-placental unit 
can modify further the maternal immune response and the reaction of the mater-
nal immune system to the environment. So, the immunity during pregnancy is 
dynamic and unique which can be modulated as per the requirement and definitely 
not suppressed [2].
Several studies have proven the idea incorrect that constant immunosuppres-
sion is crucial for a successful pregnancy which demonstrates that inhibition of key 
signaling pathways such as pathways mediated by FAS; FAS ligand and deletion of 
immune cells at the implantation site are detrimental to pregnancy which may lead 
to pregnancy loss [3, 4]. The deletion of specific decidual NK cells leads to poor 
endometrial vascularity and obstruct the invasion of the trophoblast [5]. Thus, for a 
successful pregnancy the presence of immune infiltrates is required which suggests 
that the immune cells are not recruited to the decidua as a response to a ‘non-self ’ or 
‘foreign’ fetus but recruited actively to facilitate proper implantation and promote 
successful pregnancy.
During pregnancy and postpartum, different levels of hormonal changes and 
changes in the immunity may be responsible for the modulation of the natural 
history of the HPV infection. There are differences in the status of HPV infec-
tion during pregnancy and reduction in the number of HPV positive cases during 
postpartum period have been reported by various authors [6]. Though the dynam-
ics of HPV infection during pregnancy is not well understood and the information 
remains controversial. The clearance and persistence of HPV during and after 
pregnancy have been studied by very few authors [7].
HPV infection in most cases naturally disappears in a short relative time period 
and risk of disease development in that case is very less. As pregnancy affects the 
host immune system, it is believed that pregnancy reduces the seroreactivity against 
infection of HPV. The upstream regulatory region of HPV18 has been reported to be 
activated by estrogen and progesterone which alters the clearance rate of HPV com-
pared to non-pregnant women [8]. HPV genotypes and viral characteristics such as 
population distribution and evasive ability play an important role during persistent 
infection. However, how the HPV genotype specific reaction of the host immune 
system and the sexual behavior of pregnant women affect the rates of infection in 
case of persistent cases and how it is related to the host in not clear [9].
In pregnancy, the pregnant mother which is an adult organism is exposed to 
the fetus which is partly an extremely young organism and this phenomenon can 
be viewed similar to a natural state known as parabiosis in which organisms share 
partly blood systems. However, the fetus may have restoring effect on the maternal 
system. It has been reported that the regenerative capacity of the aged liver and 
other organs in mice model is restored by pregnancy [10].
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There are controversial results on the risk of HPV infection in pregnant 
women. A higher HPV prevalence has been reported in few studies in pregnant 
women, whereas, some claimed there are no statistical difference among the age 
matched non-pregnant women [9]. Moreover, there are no studies on estimating 
the trimester, age and type specific prevalence of cervical HPV DNA in pregnant 
women.
This chapter will focus on the incidence of HPV infection in pregnant women 
population, the reason behind higher incidence rates in early pregnancy, the 
possible mechanisms responsible for self-clearance and non-clearance of HPV in 
pregnant women, immune mechanisms playing role in pregnancy, feto-maternal 
cell trafficking and how HPV affects the pregnancy outcomes. Furthermore, we 
will also discuss the potential of HPV infection during pregnancy can lead to the 
development of cervical cancer and therapeutic strategies.
2. Incidence of HPV infection in pregnant women population
Highest incidence rates have been reported in young adults just after the onset 
of their sexual activity [11]. In young women between the age group of 17 and 
24 years, longitudinal studies reported incidence rates of HPV infection ranging 
from 15.7 to 29.4 of all types per 1000 women-months [12]. Women in their thir-
ties showed a lower incidence rate in cohort studies which is between 5.2 and 13.4 
any type HPV infection per 1000 women-months [12]. The prevalence is likewise 
higher in younger age groups than older. The global HPV prevalence estimated by 
a multi-country meta-analysis is 11.7% (with confidence interval 95% 11.6–11.7%) 
with normal cytology in women with an important variation within and between 
geographic regions. At round 25 years the prevalence peaks and decreases thereaf-
ter. It has been reported that at around 45 years a smaller second peak is observed 
[13, 14]. It has also been reported in various studies that within 1–2 years of HPV 
infection almost 80% of them resolve spontaneously [15]. Various studies suggested 
that during pregnancy it is more likely to acquire and progress HPV infection [16] 
which regresses after delivery [6, 7, 17, 18].
Whereas, Liu et al. [16] reported that in pregnant women the HPV prevalence 
varies from 9.58 to 46.67% and in age-matched non-pregnant women the preva-
lence varies from 8.9 to 23.5%, with a summary estimate of 16.82 and 12.25% 
respectively and there are significant differences between the summary estimates. 
In Asia, North America and Europe, it has been reported that the HPV prevalence 
rates are significantly higher in pregnant women as compared to those in non-
pregnant women and the pregnant women in North America as compared to those 
in Europe and Asia are more susceptible to HPV infection [16]. As per the meta-
analytical data showed by Liu et al. [16], the prevalence rates of HPV infection in 
pregnant women in North America, Australia, Europe and Asia were 30.37, 36.60, 
13.19 and 15.72% respectively which showed a worldwide significant difference. 
In pregnant women aged 25, 25–29 and ≥ 30 years the prevalence rates of HPV 
infection were 23.94, 13.34 and 14.79% respectively and in non-pregnant women 
the prevalence rates were 18, 12.08 and 11.43% in respective three age groups [16]. 
The most frequently identified HPV types in pregnant women have been reported 
are HPV-16 with 3.86% prevalence rate, HPV-6 with 2.45% prevalence rate, HPV-
18 with 1.80% prevalence rate and HPV-11 with 1.76% prevalence rate which is as 
same as the prevalence rates in non-pregnant women of these HPV types. In the 
three trimesters the HPV prevalence rates reported are 18.20, 14.38 and 19.32% and 
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Studies conducted in Hong Kong and Hungary showed that in asymptomatic 
pregnant women HPV-16 is the most common type and HPV-6,-18,-11,-58,-31 
and − 33 are the other common HPV types [19]. Whereas, in non-pregnant women 
the sequence is bit different such as HPV-16, -6, -11, -18, -58, -33 and -31 and in 
women with normal cytology worldwide the sequence reported is HPV-16, -18, -31, 
-58 and -52 [16].
Specific to genital tract infections, HPV types are classified into three risk 
categories based on their relative malignant potential such as HPV-6, -11, -40, -42, 
-43, -44 are low risk; HPV-31, -33, -35, -51, -52 are intermediate and HPV-16, -18, 
-45, -56 are high risk types. Young women between the ages of 10 and 35 years are 
reported to be at the maximum risk of HPV infection which are asymptomatic 
in majority of the cases and spontaneously get cleared may be due to the strong 
immune system. The reason being this is the age when women are sexually more 
active. A major cohort of the pregnant population is formed by this age group in the 
developing nations. The changed immune response and hormonal milieu during 
pregnancy might favor the presence or persistence of the HPV infection. Niyibizi 
et al. [18] reported the prevalence of HPV infection in pregnant women with a 
wide variation from 5.5 to 65%. Various HPVs in several populations have been 
reported to be associated with adverse pregnancy outcomes such as preeclamsia, 
preterm rupture of membranes (PROM), preterm delivery, fetal growth restriction 
and placental abnormalities. However, no such data on the association of the HPV 
infection in pregnancy and its outcome from the Indian subcontinent is available 
till date [20].
3. The reason behind higher incidence rates in early pregnancy
3.1 Maternal immunity during pregnancy
Starting at the conception and towards the course of completion with labor and 
birth enormous transformations the uterus has to undergo in pregnancy. In order 
to achieve blastocyst stage embryo development for a newly fertilized egg and 
successful invasion into the uterine tissue, there is a requirement of finely balanced 
subsets of immune cells and their soluble mediators. Mainly genetics determine the 
developmental potential of the blastocyst. However, the optimal environment of 
the uterus determines the viability and competence of the blastocyst to become a 
fully developed fetus and on-time delivery achievements which in turn reflects the 
maternal immune response quality.
It has been claimed that pregnancy is a state of mild immunosuppression due 
to the reduction in the helper T-cell type 1 cell mediated response or decrease in 
natural killer cells. Sillman and Sedlis in the year 1987 reported that a higher inci-
dence of cervical neoplasia is found in immunosuppressed women [15]. A steroidal 
hormone receptor binding element present on the transcriptional promotor of 
HPV-16 as reported by Gloss et al. is responsible for promotion of HPV transcrip-
tion which suggests an involvement of hormonal activation of replication of HPV 
[21]. Observation from various studies indicated that the temporary altered immu-
nity state and the increased steroidal hormonal levels during pregnancy might have 
an influence of the subsequence progression of the disease development effecting 
on HPV replication [16].
Fetus inherits 50% genome from the father that leads to the expressing of anti-
gens which are acknowledged as foreign by the maternal immune system. To accom-
modate the semi-allogeneic fetus within the immunocompetent mother’s body a 
range of complex processes take place [22]. The physiological and immunological 
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changes during pregnancy marks it a unique condition that makes the mother 
and the fetus more susceptible to certain infectious diseases, risk of congenital 
anomalies and the risk of more serious outcomes in other diseases. These changes 
are mainly driven by the cytokines, hormones and immune cells that lead to the 
modification of the immune system as well as the structural changes by remodeling 
of the endometrium [23]. In the 1950s, it was initially proposed that the induction 
of general immunosuppression during pregnancy allows the tolerance of the semi-
allogeneic fetus and since then several hypotheses has been proposed explaining the 
reason why the fetus is not rejected by the maternal immune system (Figure 1).
On the contrary, after the natural infection pregnant women are capable 
of inducing immune responses and immune memory which is similar to non-
pregnant women which proves the above hypothesis wrong [24]. Various studies 
have reported that the modulation of the immune system rather than active 
suppression is observed during pregnancy. Over the course of pregnancy, the 
progressive increase of the concentrations of steroidal hormones such as proges-
terone and estrogens induce a shift in the balance of pro and anti-inflammatory 
responses. During the first trimester of pregnancy which is called “open wound 
phase” the pro-inflammatory responses are prominent and in the second and the 
third trimester phases where the body prepared for deliver the anti-inflammatory 
responses are prominent [22]. Thus, it is clear that why the severity of certain 
diseases such as multiple sclerosis, rheumatoid arthritis induced by the inflam-
matory responses are often gets reduced during the third trimester of pregnancy 
and diseases which are controlled by the inflammatory responses such as malaria, 
influenza and lupus are increased during this phase [25]. There is a shift from Th1, 
which is oriented towards cell-mediated immunity, towards Th2, which is oriented 
towards the hormonal immunity, responses is observed which is associated with an 
alteration of the balance between type1 and type 2T helper cells and this transition 
is needed for the development of a healthy fetus. The suppression of cytotoxic T 
lymphocytes and stimulation of B lymphocytes to further increase the production 
of antibodies that are potential to be transferred to the fetus is controlled by these 
Th2-skewed responses. The findings of Mor et al. [22] and Chaouat et al. [24] 
suggested that the placenta is capable of interaction and response to pathogens 
which makes it an active immunological site. At the feto-maternal interphase, 
the immune mechanisms contribute to protect the fetus from rejection provid-
ing required cytokines and growth factors for implantation of the fetus in the 
Figure 1. 
Accommodation of the semi-allogenic fetus in the maternal system.
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Studies conducted in Hong Kong and Hungary showed that in asymptomatic 
pregnant women HPV-16 is the most common type and HPV-6,-18,-11,-58,-31 
and − 33 are the other common HPV types [19]. Whereas, in non-pregnant women 
the sequence is bit different such as HPV-16, -6, -11, -18, -58, -33 and -31 and in 
women with normal cytology worldwide the sequence reported is HPV-16, -18, -31, 
-58 and -52 [16].
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responses. During the first trimester of pregnancy which is called “open wound 
phase” the pro-inflammatory responses are prominent and in the second and the 
third trimester phases where the body prepared for deliver the anti-inflammatory 
responses are prominent [22]. Thus, it is clear that why the severity of certain 
diseases such as multiple sclerosis, rheumatoid arthritis induced by the inflam-
matory responses are often gets reduced during the third trimester of pregnancy 
and diseases which are controlled by the inflammatory responses such as malaria, 
influenza and lupus are increased during this phase [25]. There is a shift from Th1, 
which is oriented towards cell-mediated immunity, towards Th2, which is oriented 
towards the hormonal immunity, responses is observed which is associated with an 
alteration of the balance between type1 and type 2T helper cells and this transition 
is needed for the development of a healthy fetus. The suppression of cytotoxic T 
lymphocytes and stimulation of B lymphocytes to further increase the production 
of antibodies that are potential to be transferred to the fetus is controlled by these 
Th2-skewed responses. The findings of Mor et al. [22] and Chaouat et al. [24] 
suggested that the placenta is capable of interaction and response to pathogens 
which makes it an active immunological site. At the feto-maternal interphase, 
the immune mechanisms contribute to protect the fetus from rejection provid-
ing required cytokines and growth factors for implantation of the fetus in the 
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placenta. The placenta can generate signals which may modulate the responses 
of the maternal immune system to pathogens which leads to a new paradigm that 
there is a combination of signals and responses originating both from the feto-
placental unit and the maternal immune system which decides the overall immu-
nological responses during pregnancy (Figure 2) [26].
3.2 Anatomical changes during pregnancy
The increased susceptibility to infection of pregnant women during pregnancy 
may be due to the immunological and anatomical changes of the uterine canal. Like 
other human viruses, the placenta or the cells of the fetal origin may get infected by 
HPV. The presence of HPV has been reported in the polymorphonuclear cells which 
suggest that the passage of virus through feto-maternal barrier may be allowed by 
the transfer of the maternal cells [27]. It has also been reported that the trophoblast 
cells are broadly permissive in vitro for HPV and within the trophoblast cell cultures 
this virus is able to complete its life cycle [28, 29].
In the uterine mucosa, especially in the postovulatory phase there is an increase 
in the circulating progesterone levels which initiates a cascade of molecular and 
cellular events that allows the initial anchor of the embryo to the epithelial layer of 
the endometrial surface further leading to the coordination of the invasion of the 
extra-embryonic trophoblast lineages. The proliferative activity of estrogen-primed 
endometrium is inhibited by progesterone which induces the secretory activity in 
the glandular compartment followed by triggering the influx of specialized uterine 
natural killer cells such as uNK; CD16/CD56bright in response to the production 
of local chemokines such as CXCL9, CCL4 and CXCL10. The Uterine natural killer 
(uNK) cells which are a rich source of angiogenic and growth factors, has been 
reported to have critical role in remodeling of the endometrial spiral arteries during 
and prior to pregnancy [5, 30]. The contractile activity of the myocytes of the 
junctional zone is strongly reduced by the progesterone which is a crucial process 
for the apposition of the blastocyst to the luminal epithelium. The most outstand-
ing aspect of the maternal response during pregnancy is the transformation of the 
endometrial stromal fibroblasts into epithelioid-like, secretory decidual cells.
Upon implantation of a blastocyst, decidualization of the stromal compartment 
is observed in most species. On the other hand, in humans decidualization is initi-
ated without the involvement of a pregnancy in the midsecretory phase of the cycle. 
It is progressive process which is at first initiated around the terminal spiral arteries 
Figure 2. 
HPV clearance and non-clearance during pregnancy and postpartum.
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of the superficial endometrial layer which continues in pregnancy involving the 
entire endometrium as the pregnancy progresses [23]. The invasive or extravillous 
trophoblastic cells mediate the attachment of the placenta to the maternal uterine 
wall and they are responsible for the establishment of a low-resistance, high-flow 
supply of the maternal circulation to the fetus and the placenta. The placental 
dysfunction occurs due to the failed invasion of the extravillous trophoblast cells 
leading to the adverse obstetric outcomes such as spontaneous preterm delivery 
and pre-eclampsia. There are controversial reports on the HPV infection of the 
invasive trophoblast cells and their effects. There are reports showing the evidence 
of detection of HPV in trophoblast tissue from early pregnancy losses where HPV 
was more prominently found in spontaneous abortion cases than in cases of elective 
terminations of pregnancy. The genomes of the four different HPV types such as 
11, 18, 16 and 31 are reported to undergo complete life cycle in 3A trophoblast cell 
lines and the HPV-31 in an in vitro system are shown to decrease cell number of the 
trophoblast cell and their adhesion [31].
Impaired placental function is associated with pregnancy loss or complications 
such as abruption, fetal growth restriction and pre-eclampsia. In this case we have 
to consider that the uterine remodeling during pregnancy is required to accom-
modate deep trophoblast invasion and the decidual process is not primary under 
the embryonic control which makes the implantation process more vulnerable to 
perturbations in the mother [23].
4.  The possible mechanisms responsible for self-clearance  
and non-clearance of HPV in pregnant women
4.1 Role of maternal immunity
Between the maternal decidua and the blastocyst the first point of contact is 
represented by the trophoblast. It has been reported by current studies that the 
trophoblast plays an active role during implantation and early placentation in 
shaping the immunological milieu by educating and attracting immune cells at the 
implantation site and thus modeling the subsequent response of the immune cells to 
external stimuli. Cytokines such as transforming growth factor-β (TGF β), CXCL12 
which is also known as SDF1, CXCL8 which is also known as IL-8 and CCL2 which 
is also known as MCP1 are constitutively secreted by trophoblast cells. The secre-
tion of these cytokines by trophoblast cells upon establishment at the implantation 
site, promotes the recruitment of neutrophils, peripheral monocytes, T cells, NK 
cells and Treg cells [32]. After decidualization although immune infiltrates are 
already present, studies have shown that for successful pregnancy, immune cell 
trafficking is crucial and any disruption in these chemokines signaling pathways 
leads to reduced infiltration of the immune cells and adverse pregnancy outcomes. 
Cytokines are also secreted by trophoblast cells that can act on immune cells 
after their recruitment. These secreted cytokines have been reported to stimulate 
the unique differentiation of the earlier recruited immune cells in such as a way 
that they acquire phenotypes which are collectively essential for the successful 
 pregnancy [33].
Decidual NK cells are less cytotoxic, thus they are different from peripheral NK 
cells and TGFβ12 and trophoblast-derived IL-15 induces this type of phenotypes. 
Decidual vascular remodeling which is crucial for development of the placenta 
targeted by these specialized NK cells [34]. CD14+ monocytes upon recruitment to 
the maternal-fetal interface acquire a unique phenotype that is M2-like macrophage 
which might be induced by the trophoblast-derived macrophage colony-stimulating 
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of the superficial endometrial layer which continues in pregnancy involving the 
entire endometrium as the pregnancy progresses [23]. The invasive or extravillous 
trophoblastic cells mediate the attachment of the placenta to the maternal uterine 
wall and they are responsible for the establishment of a low-resistance, high-flow 
supply of the maternal circulation to the fetus and the placenta. The placental 
dysfunction occurs due to the failed invasion of the extravillous trophoblast cells 
leading to the adverse obstetric outcomes such as spontaneous preterm delivery 
and pre-eclampsia. There are controversial reports on the HPV infection of the 
invasive trophoblast cells and their effects. There are reports showing the evidence 
of detection of HPV in trophoblast tissue from early pregnancy losses where HPV 
was more prominently found in spontaneous abortion cases than in cases of elective 
terminations of pregnancy. The genomes of the four different HPV types such as 
11, 18, 16 and 31 are reported to undergo complete life cycle in 3A trophoblast cell 
lines and the HPV-31 in an in vitro system are shown to decrease cell number of the 
trophoblast cell and their adhesion [31].
Impaired placental function is associated with pregnancy loss or complications 
such as abruption, fetal growth restriction and pre-eclampsia. In this case we have 
to consider that the uterine remodeling during pregnancy is required to accom-
modate deep trophoblast invasion and the decidual process is not primary under 
the embryonic control which makes the implantation process more vulnerable to 
perturbations in the mother [23].
4.  The possible mechanisms responsible for self-clearance  
and non-clearance of HPV in pregnant women
4.1 Role of maternal immunity
Between the maternal decidua and the blastocyst the first point of contact is 
represented by the trophoblast. It has been reported by current studies that the 
trophoblast plays an active role during implantation and early placentation in 
shaping the immunological milieu by educating and attracting immune cells at the 
implantation site and thus modeling the subsequent response of the immune cells to 
external stimuli. Cytokines such as transforming growth factor-β (TGF β), CXCL12 
which is also known as SDF1, CXCL8 which is also known as IL-8 and CCL2 which 
is also known as MCP1 are constitutively secreted by trophoblast cells. The secre-
tion of these cytokines by trophoblast cells upon establishment at the implantation 
site, promotes the recruitment of neutrophils, peripheral monocytes, T cells, NK 
cells and Treg cells [32]. After decidualization although immune infiltrates are 
already present, studies have shown that for successful pregnancy, immune cell 
trafficking is crucial and any disruption in these chemokines signaling pathways 
leads to reduced infiltration of the immune cells and adverse pregnancy outcomes. 
Cytokines are also secreted by trophoblast cells that can act on immune cells 
after their recruitment. These secreted cytokines have been reported to stimulate 
the unique differentiation of the earlier recruited immune cells in such as a way 
that they acquire phenotypes which are collectively essential for the successful 
 pregnancy [33].
Decidual NK cells are less cytotoxic, thus they are different from peripheral NK 
cells and TGFβ12 and trophoblast-derived IL-15 induces this type of phenotypes. 
Decidual vascular remodeling which is crucial for development of the placenta 
targeted by these specialized NK cells [34]. CD14+ monocytes upon recruitment to 
the maternal-fetal interface acquire a unique phenotype that is M2-like macrophage 
which might be induced by the trophoblast-derived macrophage colony-stimulating 
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factor (M-CSF) and IL-10 [2118]. These M2-like macrophages participate in 
clearance of apoptotic cells and phagocytosis of degraded extracellular matrix and 
play a crucial role in tissue remodeling [35]. Trophoblast-educated M2 like macro-
phages on the contrary to other tissue-resident macrophages, maintain their CD14 
expression and capable of immunomodulatory cytokine secretions such as type I 
interferons and TGFβ [35]. Trophoblast-derived TGFβ furthermore is able to induce 
the naive CD4+ cell differentiation into FOXP3+ Treg cells [36]. In addition to the 
trophoblast cells, a substantial amount of data have shown that the decidual cells 
also have vital role in regulation of the immune cell trafficking which is mostly  
T cells towards the site of implantation (Figure 3) [37, 38].
In addition to chemokines and cytokines secretion which attract and educate 
immune cells, numerous studies have shown that the trophoblast cells have the abil-
ity to sense and respond according to the microenvironment. Cell-surface receptors 
expressed by the trophoblast cells such as NOD-like receptors (NLRs) and TLRs 
can recognize specific molecular patterns within the microenvironment. These 
receptors have also the ability to recognize DAMPs which are basically released from 
damaged tissues and dying cells as well as PAMPs (Pathogen-associated molecular 
patterns) from viruses, bacteria and other microorganisms and thus permit the 
trophoblast cells to sense and response to these signals [39, 40]. Thus, the placental 
and fetal development is supported by the trophoblast cells attracting and educat-
ing immune cells and responding to the signals within the microenvironment in a 
unique way such as decidual differentiation followed by trophoblast migration and 
invasion, angiogenesis and finally spiral artery remodeling [41].
4.2 How pregnancy responses to viral infections
During pregnancy the consequences of viral infection can vary being a benign 
asymptomatic event which is undetected mostly and it can either cause the occur-
rence of fetal congenital malformations or pregnancy loss [42]. Like bacteria, the 
TLRs and NLRs expressed by the immune cells as well as those expressed by the 
trophoblast cells can be engaged by the viruses. Viral replication as well as vertical 
transmission of a virus to the developing fetus from the mother can also controlled 
by the trophoblast cells [43, 44]. Commensal bacteria which are present at the 
Figure 3. 
Immune modulation during pregnancy at the feto-maternal interface.
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feto-maternal interface can induce the secretion of IFNβ by trophoblast cells which 
supports the decidual receptivity by exerting immunomodulatory effects. It has been 
reported that the antiviral responses can be exerted by the IFNβ [45] and thus one of 
the molecular pathways that is type I IFN pathway is actively inhibited by the viruses 
as they establish as infection. Various studies in mouse model have demonstrated 
that by inhibiting IRF3 phosphorylating in the placenta, viral infection can decrease 
IFNβ expression which leads to the decreased antiviral responses [46]. TLR4 induced 
responses are modified by viral infections to commensal bacteria leading to the con-
version of pro-inflammatory from anti-inflammatory in nature [47]. The receptivity 
and tolerance at the feto-maternal interface is promoted by the IFNβ which suggests 
that blunted response of IFNβ secondary to viral infection is responsible for the det-
rimental pregnancy consequences. The reduced receptivity of the immune cells at the 
feto-maternal interface due to the loss of IFNβ also reduces their capacity to control 
and respond to other microorganisms. Thus, the association of the overwhelming 
inflammation with pregnancy complications suggests that there may be an involve-
ment of an undetected viral infection which can change the response pattern of the 
feto-maternal interface to commensal bacteria. This hypothesis has been supported 
by the study results of Cardenas et al. [48] using an animal model. In that study, 
pregnant C57BL/6 mice was infected with MHV68 on 8.5 embryonic day and a low 
dose of LPS subsequent administration on E15.5 day leads to a cytokine storm which 
was characterized by high levels of G-CSF, CXCL1, IL-8 and TNF which is associated 
with parturition, a reduced production of IFNβ followed by preterm birth. These 
changes in the cytokine profile leading to preterm birth is not induced alone either by 
LPS treatment or MHV68 infection but by a ‘double-hit hypothesis’ proposed by Mor 
et al. [41] which suggests that how trophoblast cells respond to bacterial products are 
changed by a viral infection which abolishes the normal microbiota immunomodula-
tory effects. In response of the commensal microbiota, the trophoblastic cells in 
the absence of a viral infection secret IFNβ, whereas IFNβ signaling is abolished in 
the presence of a viral infection leading to eradicate its immunomodulatory effects 
which in turn changes the response of the trophoblastic cells to commensal bacteria 
shifting IFNβ response to a cytokine storm which promotes preterm birth. However, 
it has been reported that the inflammation and preterm labour is also promoted 
either by an increased response of IFNβ or inhibition of the IFNβ regulators [49]. 
Thus, the original milieu which has a setting of immune-tolerance, during viral 
infection, is shifted into a state of pro-inflammatory condition [41].
4.3 Role of feto-maternal cell trafficking
During pregnancy there is a bidirectional cell passage exists between fetus 
and mother which is called feto-maternal cell trafficking. It is known as fetal 
microchimerism when there is a presence of fetal cells in the maternal circulation 
and maternal microchimerism when the maternal cells are present in the fetal 
circulation. Georg Schmorl in the year 1893 first reported about fetal microchi-
merism after identifying the placental trophoblast cells in a mother who died due 
to eclampsia [50]. The persistence of fetal cells in the maternal circulation [51, 52] 
and other maternal organs such as liver, heart, kidney [52] and bone marrow [53] 
has been reported decades after pregnancy. In 1963, with the identification of the 
maternal platelets and leukocytes in the cord blood the maternal microchimerism 
was described for the first time [54]. In healthy, immunocompetent individuals 
these maternal cells have been found to circulate into adult life [55].
At 7 weeks of pregnancy the bidirectional trafficking of the cells begins and 
increases throughout the gestation steadily and peaks at parturition [56]. In nor-
mal pregnancies, maternal microchimerism and fetal microchimerism has been 
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feto-maternal interface can induce the secretion of IFNβ by trophoblast cells which 
supports the decidual receptivity by exerting immunomodulatory effects. It has been 
reported that the antiviral responses can be exerted by the IFNβ [45] and thus one of 
the molecular pathways that is type I IFN pathway is actively inhibited by the viruses 
as they establish as infection. Various studies in mouse model have demonstrated 
that by inhibiting IRF3 phosphorylating in the placenta, viral infection can decrease 
IFNβ expression which leads to the decreased antiviral responses [46]. TLR4 induced 
responses are modified by viral infections to commensal bacteria leading to the con-
version of pro-inflammatory from anti-inflammatory in nature [47]. The receptivity 
and tolerance at the feto-maternal interface is promoted by the IFNβ which suggests 
that blunted response of IFNβ secondary to viral infection is responsible for the det-
rimental pregnancy consequences. The reduced receptivity of the immune cells at the 
feto-maternal interface due to the loss of IFNβ also reduces their capacity to control 
and respond to other microorganisms. Thus, the association of the overwhelming 
inflammation with pregnancy complications suggests that there may be an involve-
ment of an undetected viral infection which can change the response pattern of the 
feto-maternal interface to commensal bacteria. This hypothesis has been supported 
by the study results of Cardenas et al. [48] using an animal model. In that study, 
pregnant C57BL/6 mice was infected with MHV68 on 8.5 embryonic day and a low 
dose of LPS subsequent administration on E15.5 day leads to a cytokine storm which 
was characterized by high levels of G-CSF, CXCL1, IL-8 and TNF which is associated 
with parturition, a reduced production of IFNβ followed by preterm birth. These 
changes in the cytokine profile leading to preterm birth is not induced alone either by 
LPS treatment or MHV68 infection but by a ‘double-hit hypothesis’ proposed by Mor 
et al. [41] which suggests that how trophoblast cells respond to bacterial products are 
changed by a viral infection which abolishes the normal microbiota immunomodula-
tory effects. In response of the commensal microbiota, the trophoblastic cells in 
the absence of a viral infection secret IFNβ, whereas IFNβ signaling is abolished in 
the presence of a viral infection leading to eradicate its immunomodulatory effects 
which in turn changes the response of the trophoblastic cells to commensal bacteria 
shifting IFNβ response to a cytokine storm which promotes preterm birth. However, 
it has been reported that the inflammation and preterm labour is also promoted 
either by an increased response of IFNβ or inhibition of the IFNβ regulators [49]. 
Thus, the original milieu which has a setting of immune-tolerance, during viral 
infection, is shifted into a state of pro-inflammatory condition [41].
4.3 Role of feto-maternal cell trafficking
During pregnancy there is a bidirectional cell passage exists between fetus 
and mother which is called feto-maternal cell trafficking. It is known as fetal 
microchimerism when there is a presence of fetal cells in the maternal circulation 
and maternal microchimerism when the maternal cells are present in the fetal 
circulation. Georg Schmorl in the year 1893 first reported about fetal microchi-
merism after identifying the placental trophoblast cells in a mother who died due 
to eclampsia [50]. The persistence of fetal cells in the maternal circulation [51, 52] 
and other maternal organs such as liver, heart, kidney [52] and bone marrow [53] 
has been reported decades after pregnancy. In 1963, with the identification of the 
maternal platelets and leukocytes in the cord blood the maternal microchimerism 
was described for the first time [54]. In healthy, immunocompetent individuals 
these maternal cells have been found to circulate into adult life [55].
At 7 weeks of pregnancy the bidirectional trafficking of the cells begins and 
increases throughout the gestation steadily and peaks at parturition [56]. In nor-
mal pregnancies, maternal microchimerism and fetal microchimerism has been 
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reported to be 42 and 51% respectively at the time of delivery [57]. In human blood 
and tissues the detection of maternal-fetal microchimerism is done by in situ 
hybridization for identification of whole cells and the identification of the origin 
of the DNA whether it is from mother or the fetus is done by polymerase chain 
reaction (PCR) to identify Y-chromosome DNA sequences in mother [58]. As the Y 
chromosome is easier to distinguish it is used as a biomarker to detect microchime-
rism and it does not require the fetus to be male. However, male microchimerism 
has been reported to be found in a fifth of women with no birth of a male child. The 
possible reason of the phenomenon can be a vanished male twin; early miscarriage 
of a male embryo; transfer of male cell through the maternal circulation from an 
older sibling to a later pregnancy; or due to an unexplored possibility of transfer of 
male DNA into the maternal circulation during sexual intercourse [59]. In females, 
male fetal cells have reported to show increased antigenicity. As the fetus carries 
paternal genes among which some are expressed on the cell surface that may induce 
potent allogeneic responses the mother confronts an immunological challenge 
during pregnancy. However, in spite of the immunologic differences of the cells, the 
fetus does not get rejected frequently (Figure 4) [60].
In pregnancy, the maternal and fetal cell exchange is common. During gesta-
tion, placenta allows the fetal and maternal reciprocal transport of cells in a state of 
mutual tolerance which proves placenta is not an immunologically inert barrier. It 
is not necessary to continue a pregnancy and deliver a child to develop mirochime-
rism. Up to 500,000 nucleated fetal cells can be delivered into the maternal circula-
tion even early terminations from surgical abortion [61, 62]. The cellular movement 
across the placental barrier is controlled by the maternal, fetal, or/and placental sig-
nals rather than nonspecific leakiness. The involvements of integrin-dependent and 
VEGF pathways are associated with the trans-placental cell trafficking mechanism 
but the initiation of the processes by the exact molecular signals are yet unknown 
[63]. In case of preeclampsia, fetal surgery and pregnancy termination where there 
is a disruption of the feto-maternal interface, association of altered feto-maternal 
cell trafficking has been reported which suggests that the placenta has a role in the 
cell migration regulation. The altered microchimerism levels are also associated 
with histocompatibility differences which suggests that the cell trafficking and 
the survival of the trafficked cells is either promoted or hindered by the immune 
response between the fetus and the mother [64, 65]. During pregnancy, the biologi-
cal role of the bidirectional movement of cells is unknown, although it has implica-
tions in the fetal immune system development [66]; repair of tissue in autoimmune 
disease [67–70] tolerance mechanisms during pregnancy [71]; immune surveillance 
Figure 4. 
Feto-maternal cell trafficking during pregnancy.
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[72] and cancer [73]. It is also involved in the maintenance of balance between the 
tolerance [74] and immunologic priming [75] which can influence the occurrence of 
autoimmune disease and transplantation outcomes. The utility of the feto-maternal 
cell trafficking has been identified clinically in the prediction of pregnancy compli-
cations [76, 77] and in prenatal testing for aneuploidies [78].
The research on microchimerism is still in its infancy, more specifically on the 
fetomaternal microchimerism. In women with autoimmune diseases, the long-term 
existence of the fetal cells and its speculative role has not yet been studied well. It 
has been reported by some of the researchers that the microchimeric cell popula-
tions occur due to pregnancy may have stem cell like properties which have the 
potential to home in damaged tissues and organs and further differentiate as part of 
the maternal repair response [62].
5. How HPV affects the pregnancy outcomes
Merckx et al. [79] reported that children born to HPV-positive mothers are 
at a significantly higher risk of becoming HPV positive which further results in 
infantile genital and anal condyloma acuminatum and juvenile laryngeal papillo-
matosis. However, by the age of 6 months some HPV infections are almost cleared. 
Hence, the question regarding susceptibility of pregnant women to HPV infection 
and its prevalence as compared to non-pregnant women population are crucial to 
answer [16].
Various studies reported that spontaneous abortion occurs in up to 30% of 
all pregnancies and it constitutes one of the most frequently occurring adverse 
pregnancy outcomes worldwide. In 5–13% of deliveries, spontaneous preterm birth 
is also observed [80]. As per the reports of recent investigations, the human papil-
lomavirus infection of the placenta may be involved with placental abnormalities, 
spontaneous preterm delivery and spontaneous abortion.
Trophoblast cells as discussed earlier constitute the prime target for HPV in 
placenta which is responsible for placentation abnormality. Various studies showed 
that in pregnant women the prevalence of HPV infection ranges widely from 6 to 
65% and the HPV DNA has been detected in amniotic fluid, placenta, fetal mem-
branes and umbilical cord blood [81].
Delivery before 37 weeks of gestation is defined as preterm birth and it is an 
important complication worldwide for both multifetal and singleton pregnancies. 
As compared to children born at term, the preterm children are more likely to 
develop log-term neurological and developmental disorders and are at an increased 
risk of mortality. The highest rates of preterm delivery have been reported to be 
found in South-eastern and South Asia with a percentage of 13.4%. Especially 
in low-income countries, the morbidity and mortality are highest among these 
preterm children [80].
As per the fetal origin of adult disease (FOAD) hypothesis, the specific changes 
in the fetus are caused by the intrauterine environmental exposures which lead 
to the risk of developing diseases in adult life. Depending on the environmental 
interaction, these risks may lead to adult diseases. Coronary heart disease was 
documented earlier to support this hypothesis [82] but a range of chronic condi-
tions has also now been included to expand the framework [83]. While, the ‘thrifty 
phenotype’ hypothesis states that low birth weight babies should not be at high risk 
of non-insulin dependent diabetes development when they grow with a scarcity 
of food [84, 85] but growing up in an area of affluence of the same babies would 
increase the risk and hence the intrauterine exposure plays an important role in 
inheriting the harmful potential in interaction with exposures later. Thus, the 
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reformulated FOAD hypothesis included epigenetics and the life –course epidemiol-
ogy as an important factor which includes social and physical exposures during ges-
tation, adolescence, childhood, young adulthood and adult life. To understand the 
development of chronic diseases, history specific and inter-generational elements 
of individual’s life is also important [86]. The timing of exposure variables and how 
the outcome of interest is related to each other is the basis of life-course perspective. 
Hence, the effects of intrauterine exposures can be modified by the entire lifespan 
of an individual through the life-events, behavioral, biological and socioeconomic 
processes [87].
Infection with HPV (Human papillomavirus) is generally regarded as sexually 
transmitted disease. However, the detection of HPV in the oral mucosa of newborn 
babies who are sexually inexperienced has been reported in various studies which 
suggests plausible non-sexual alternative route of HPV infection. Detection of 
HPV genotypes and their similarities in the offspring’s oral sample and in mother’s 
genital tract suggests that the probable source of HPV infection in the newborn is 
the HPV infected mother. In the mother-baby pair, the reported vertical transmis-
sion rates are between 18.2 and 53.3% [88].
The possible mode of vertical transmission of HPV to infant from a mother 
is still under debate. However, during fertilization, or pregnancy or delivery the 
possible mode of transmission has been implicated. Evidence of prenatal transmis-
sion of HPV has been provided by Koskimaa et al. [89] and the presence of HPV in 
cord blood and placenta has been shown to increase the risk of carrying HPV DNA 
in the oral mucosa which suggests that in the transmission of HPV, unlike several 
other human viruses, placenta may play an important role [27]. Recent studies 
reported that the placenta and the maternal microbiomes have role in regulating 
the neonatal microbiomes which suggests during pregnancy the fetal exposure of 
microbiota has long-term outcomes in their health [90]. The translocated maternal 
oral microbes are presented to the fetal immune system at the placenta which 
acts as a site leading to the development of prenatal tolerance to the maternal 
 microbiome [91].
The encounter with HPV and its significance in pre or perinatal period is not 
clear. Early exposure of HPV might have a significant impact in the HPV-specific 
immunity development, subsequent HPV infection and progression due to the 
immaturity of the immune system of the fetus and infant [92]. However, practically 
in children the HPV-specific immunity has remained an unknown area. As reported 
by Koskimaa et al. [88] and Koskimaa et al. [93], children aged 12–14 years had 
immunoreactivity specific to HPV 16 E2-, E6-, and E7. Whereas, various studies 
reported that the HPV-16 specific cell mediated immunity is much lower in adults 
[94, 95]. Between HPV positive and negative subjects, differences have been found 
in the memory Th cell (T Helper) reactivity against HPV16 E2, E7 and E6 oncopro-
teins in adults. Against HPV16 E2 and E6, the Th responsiveness is accompanied by 
the type 1 and type 2 cytokine secretions in a mixed pattern and seems to be more 
common in healthy individuals as compared to individuals with HPV16 induced 
disease.
Koskimaa et al. [89] reported that children those are exposed to HPV via cord 
blood or Oral HPV or placenta might have HPV16 specific T helper cell responses 
similar to the adults having HPV induced lesions which are highly different from 
negative HPV controls.
Though some studies have reported HPV infection to be associated with 
spontaneous preterm delivery and spontaneous abortion, controversy continues 
in this field due to the reason that some studies were unable to confirm this 
association.
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6.  Potential of HPV infection during pregnancy can lead to the 
development of cervical cancer and therapeutic strategies
Cervical cancer ranks as the 3rd most frequently diagnosed cancer with an 
estimated 569,847 incident cases and 311,365 deaths reported in the year 2018 
(GLOBOCAN) worldwide and in women it is the fourth leading cause of death 
due to cancer. After breast cancer it ranks second in incidence and mortality rates 
in lower HDI settings. Worldwide in 28 countries it is the mostly diagnosed cancer 
and leading cause of cancer death in 42 countries which includes vast majority in 
South-Eastern Asia and Sub-Saharan Africa [96]. It has been reported that around 
530,000 women get affected every year by cervical cancer and the HPV related 
cancer burden in women worldwide add up to 6% of total cancer cases.
In India, the diagnosis of new cervical cancer is about 96,922 cases annually 
making it the 2nd leading cause of female cancer. Women aged between 15 and 
44 years, cervical cancer is the second most common female cancer in India [97].
The development of cervical cancer and its precursor lesions are reported 
through several epidemiological and biological studies to be associated with high-
risk Human papillomavirus (HPV) infection. The development of high grade 
cervical lesions is reported to be associated with positive high-risk HPV test results 
in women with or without abnormal cervical smears [66, 98–100]. It has been 
reported in various studies on immunocompromised patients such as transplant 
recipients and AIDs patients that the increased persistence of high-risk HPV and 
HPV-mediated carcinogenesis is associated with compromised immunosurveil-
lance [101, 102]. In pregnancy, the immune-response is altered in women and some 
studies concluded that there is no effect of pregnancy on CIN [103], whereas few 
reported high relapse rates of cervical dysplasia in the postpartum period [104]. 
Likewise, few studies reported high-risk HPV prevalence rate to be higher in preg-
nant women and others reported there is no difference of HPV prevalence between 
non-pregnant and pregnant women. However, on the natural course of high-risk 
HPV types infection the influence of pregnancy is not yet known. There are few 
questions need to be answered in this area: (1) what is the difference between the 
clearance of HPV in pregnant and non-pregnant women? (2) During pregnancy 
how does the high-risk HPV rate change? [6].
The Food and Drug Administration (FDA) has approved three vaccines such 
as the first-generation Human papillomavirus (HPV) vaccines, Gardasil (Merck, 
Kenilworth, NJ, USA) which is a quadri valent vaccine; Cervarix (GlaxoSmithKline, 
London, UK) which is a bivalent vaccine, have the potential to prevent about 70 and 
84% of the cervical cancer cases respectively. Gardasil 9 (Merck), which is a next-
generation nonavalent HPV vaccine, can prevent cervical cancer approximately 
90%. However, pre-existing infections and their related cervical abnormalities 
cannot be treated by these vaccines. The American Society of Clinical Oncology 
(ASCO) in the year 2016 released cervical screening guidelines which recom-
mend the screening for women aged between 30 and 49 years, one to three times 
in a lifetime in lower resource settings [105]. The screening should be done with 
primary HPV testing via the use of self-collected specimens as it has been reported 
to be more effective, adaptable and reliable method of screening as compared to 
traditional cytological methods and thus the effective cervical cancer screening can 
be done in several generations of women [106].
In terms of HPV vaccination and coverage rates of cervical screening, consider-
able inconsistencies exist worldwide between countries and within countries. In 
low-income and middle-income countries (LMICs), in the year 2008 the reported 
overall screening uptake was 19%, while in high-income regions it was 63% [107]. 
Human Papillomavirus
74
reformulated FOAD hypothesis included epigenetics and the life –course epidemiol-
ogy as an important factor which includes social and physical exposures during ges-
tation, adolescence, childhood, young adulthood and adult life. To understand the 
development of chronic diseases, history specific and inter-generational elements 
of individual’s life is also important [86]. The timing of exposure variables and how 
the outcome of interest is related to each other is the basis of life-course perspective. 
Hence, the effects of intrauterine exposures can be modified by the entire lifespan 
of an individual through the life-events, behavioral, biological and socioeconomic 
processes [87].
Infection with HPV (Human papillomavirus) is generally regarded as sexually 
transmitted disease. However, the detection of HPV in the oral mucosa of newborn 
babies who are sexually inexperienced has been reported in various studies which 
suggests plausible non-sexual alternative route of HPV infection. Detection of 
HPV genotypes and their similarities in the offspring’s oral sample and in mother’s 
genital tract suggests that the probable source of HPV infection in the newborn is 
the HPV infected mother. In the mother-baby pair, the reported vertical transmis-
sion rates are between 18.2 and 53.3% [88].
The possible mode of vertical transmission of HPV to infant from a mother 
is still under debate. However, during fertilization, or pregnancy or delivery the 
possible mode of transmission has been implicated. Evidence of prenatal transmis-
sion of HPV has been provided by Koskimaa et al. [89] and the presence of HPV in 
cord blood and placenta has been shown to increase the risk of carrying HPV DNA 
in the oral mucosa which suggests that in the transmission of HPV, unlike several 
other human viruses, placenta may play an important role [27]. Recent studies 
reported that the placenta and the maternal microbiomes have role in regulating 
the neonatal microbiomes which suggests during pregnancy the fetal exposure of 
microbiota has long-term outcomes in their health [90]. The translocated maternal 
oral microbes are presented to the fetal immune system at the placenta which 
acts as a site leading to the development of prenatal tolerance to the maternal 
 microbiome [91].
The encounter with HPV and its significance in pre or perinatal period is not 
clear. Early exposure of HPV might have a significant impact in the HPV-specific 
immunity development, subsequent HPV infection and progression due to the 
immaturity of the immune system of the fetus and infant [92]. However, practically 
in children the HPV-specific immunity has remained an unknown area. As reported 
by Koskimaa et al. [88] and Koskimaa et al. [93], children aged 12–14 years had 
immunoreactivity specific to HPV 16 E2-, E6-, and E7. Whereas, various studies 
reported that the HPV-16 specific cell mediated immunity is much lower in adults 
[94, 95]. Between HPV positive and negative subjects, differences have been found 
in the memory Th cell (T Helper) reactivity against HPV16 E2, E7 and E6 oncopro-
teins in adults. Against HPV16 E2 and E6, the Th responsiveness is accompanied by 
the type 1 and type 2 cytokine secretions in a mixed pattern and seems to be more 
common in healthy individuals as compared to individuals with HPV16 induced 
disease.
Koskimaa et al. [89] reported that children those are exposed to HPV via cord 
blood or Oral HPV or placenta might have HPV16 specific T helper cell responses 
similar to the adults having HPV induced lesions which are highly different from 
negative HPV controls.
Though some studies have reported HPV infection to be associated with 
spontaneous preterm delivery and spontaneous abortion, controversy continues 
in this field due to the reason that some studies were unable to confirm this 
association.
75
Human Papillomavirus Infections in Pregnant Women and Its Impact on Pregnancy Outcomes…
DOI: http://dx.doi.org/10.5772/intechopen.90197
6.  Potential of HPV infection during pregnancy can lead to the 
development of cervical cancer and therapeutic strategies
Cervical cancer ranks as the 3rd most frequently diagnosed cancer with an 
estimated 569,847 incident cases and 311,365 deaths reported in the year 2018 
(GLOBOCAN) worldwide and in women it is the fourth leading cause of death 
due to cancer. After breast cancer it ranks second in incidence and mortality rates 
in lower HDI settings. Worldwide in 28 countries it is the mostly diagnosed cancer 
and leading cause of cancer death in 42 countries which includes vast majority in 
South-Eastern Asia and Sub-Saharan Africa [96]. It has been reported that around 
530,000 women get affected every year by cervical cancer and the HPV related 
cancer burden in women worldwide add up to 6% of total cancer cases.
In India, the diagnosis of new cervical cancer is about 96,922 cases annually 
making it the 2nd leading cause of female cancer. Women aged between 15 and 
44 years, cervical cancer is the second most common female cancer in India [97].
The development of cervical cancer and its precursor lesions are reported 
through several epidemiological and biological studies to be associated with high-
risk Human papillomavirus (HPV) infection. The development of high grade 
cervical lesions is reported to be associated with positive high-risk HPV test results 
in women with or without abnormal cervical smears [66, 98–100]. It has been 
reported in various studies on immunocompromised patients such as transplant 
recipients and AIDs patients that the increased persistence of high-risk HPV and 
HPV-mediated carcinogenesis is associated with compromised immunosurveil-
lance [101, 102]. In pregnancy, the immune-response is altered in women and some 
studies concluded that there is no effect of pregnancy on CIN [103], whereas few 
reported high relapse rates of cervical dysplasia in the postpartum period [104]. 
Likewise, few studies reported high-risk HPV prevalence rate to be higher in preg-
nant women and others reported there is no difference of HPV prevalence between 
non-pregnant and pregnant women. However, on the natural course of high-risk 
HPV types infection the influence of pregnancy is not yet known. There are few 
questions need to be answered in this area: (1) what is the difference between the 
clearance of HPV in pregnant and non-pregnant women? (2) During pregnancy 
how does the high-risk HPV rate change? [6].
The Food and Drug Administration (FDA) has approved three vaccines such 
as the first-generation Human papillomavirus (HPV) vaccines, Gardasil (Merck, 
Kenilworth, NJ, USA) which is a quadri valent vaccine; Cervarix (GlaxoSmithKline, 
London, UK) which is a bivalent vaccine, have the potential to prevent about 70 and 
84% of the cervical cancer cases respectively. Gardasil 9 (Merck), which is a next-
generation nonavalent HPV vaccine, can prevent cervical cancer approximately 
90%. However, pre-existing infections and their related cervical abnormalities 
cannot be treated by these vaccines. The American Society of Clinical Oncology 
(ASCO) in the year 2016 released cervical screening guidelines which recom-
mend the screening for women aged between 30 and 49 years, one to three times 
in a lifetime in lower resource settings [105]. The screening should be done with 
primary HPV testing via the use of self-collected specimens as it has been reported 
to be more effective, adaptable and reliable method of screening as compared to 
traditional cytological methods and thus the effective cervical cancer screening can 
be done in several generations of women [106].
In terms of HPV vaccination and coverage rates of cervical screening, consider-
able inconsistencies exist worldwide between countries and within countries. In 
low-income and middle-income countries (LMICs), in the year 2008 the reported 
overall screening uptake was 19%, while in high-income regions it was 63% [107]. 
Human Papillomavirus
76
As compared to high-income countries, in low-income and middle-income coun-
tries the HPV vaccination coverage is much lower. In the high-income countries an 
estimated 33.6% of girls and women aged between 10 and 20 years had received 
the full course of HPV vaccine by the year 2014 as compared to low-income and 
middle-income countries which was 2.7% of the same age group of females [108]. 
Though studies are still in progress on the long-term vaccine efficacies to under-
stand the total duration of protection, it has been reported that with Gardasil the 
protection against targeted HPV types last for at least 10 years [109], with Cervarix 
at least 9 years [110] and with Gardasil 9 a least 6 years [111]. But these vaccines 
have not sufficiently been tested during pregnancy and hence it is not used in 
pregnant women.
The Centers for Disease Control and Prevention (CDC) recommends HPV 
vaccination for women having either an HPV infection or an abnormal Pap test or 
both if they are in the appropriate age group as that may protect them against the 
high-risk HPV types which have not been acquired by them. However, the vaccina-
tion has not the potential to treat the abnormal results of the Pap test or cure the 
current HPV infections [112]. Though, the vaccines have been reported to be safe 
when given to people with pre-existing HPV infection, it gives maximum benefit 
if given to people before being sexually active [113, 114]. However, some residual 
benefit from the vaccination will still be there for people already exposed to HPV 
even though infections with one or more HPV types which are included in the vac-
cines. Currently, there is no specific test available to detect past exposure of HPV in 
individuals and the approved HPV tests detect only current infection with high-risk 
HPV types at the cervix region without any information on past infection.
Even after the vaccination, the screening for cervical cancer need to be done as 
all HPV types which has the potential to cause cancer are not covered by the HPV 
vaccines. Therefore, in cervical cells to detect precancerous changes before the 
development of cancer, screening is essential. Additionally, women with exist-
ing HPV infection or who are not vaccinated the cervical screening is critically 
important. However, the screening recommendations may be changed in future for 
women given HPV vaccination.
Research works are in progress to develop therapeutic HPV vaccines which 
would prevent cancer development among women with previous history of HPV 
infection. The immune system will be stimulated by these vaccines which will result 
in specifically targeting and killing infected cells. The safety and efficacy of a thera-
peutic DNA vaccine are being tested by ongoing clinical trials to treat HPV related 
cervical and vulvar lesions [115–117]. A combination of preventive and therapeutic 
vaccine would be an ideal strategy in this case.
Topical microbicides is another preventive strategy which is being explored. 
In various studies, carrageenan which is an extracted compound from seaweed 
widely used in foods and other products has been reported to inhibit infection 
with HPV. Clinical trial in healthy individuals with a gel containing carrageenan is 
underway to test its efficacy to prevent genital HPV infections.
6.1 Immunization of the pregnant women
The response of the adaptive immune system of the infants cannot be protective 
to many pathogens in the first months of life. The T cells of both fetal and neonatal 
origin are shewed towards Th2 responses which are ineffective against intracellular 
pathogens. Ineffectiveness has also been reported for bacterial polysaccharides 
by antibody responses. Infants rely on additional protection during this period 
which is acquired from maternal antibodies during gestation passively transported 
through the placenta. At the time of birth, the antibody levels present in the infants 
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are correlated with the maternal antibody levels and the therefore, there is an 
interconnection between the antibody levels present in the maternal circulation 
and the degree of transfer of antibodies. However, the suboptimal maternal specific 
antibodies may not be sufficient to provide full protective immunity or can provide 
protection only for a limited period of time to the infants. Moreover, the maternal 
antibody levels decrease over a periods of approximately 6 months after birth. 
Therefore, the aim of the maternal immunization is to increase the concentration 
of maternal specific antibody and their passive transport to the fetus which will 
reduce the window of vulnerability for infants. IgG (Immunoglobulin G) is the only 
isotype among the five antibody classes that has the ability to efficiently cross the 
human placenta. Syncytiotrophoblast cells of the placenta, are responsible for the 
transfer of the IgG antibodies from mother to the fetus, which are located in contact 
with the maternal blood. In the circulation maternal IgG are internalized in endo-
somes and bind to Fc receptors (FcRn) of the neonatal cells which are expressed 
on the surface of the internal endosomes. On membrane of the fetal side of the 
syncytiotrophoblasts, the endosomes fuse and the IgG are released from FcRn. 
Passing through the villous stroma and fetal capillary endothelium, IgG enters the 
fetal circulation through an unknown mechanism. With the largest transferred 
proportion during the third trimester of pregnancy, the transfer of IgG through 
placenta increases over time especially within the last 4 weeks. Consistent with an 
active transport process, the IgG concentration in the fetal circulation are gener-
ally greater than the maternal circulation at full term of pregnancy [118, 119]. This 
transfer is influenced by several factors such as maternal non-infectious diseases, 
placental integrity, total maternal IgG concentration, FcRn availability, IgG sub-
type, timing of infection or vaccination and nature of the antigen [120]. IgG4, IgG3 
and IgG2 are the least efficiently transferred to the fetus as compared to IgG1 which 
is the most efficiently transferred antibody subtype to the fetus.
Approximately after 2 weeks of maternal immunization, the concentration 
of specific antibodies starts increasing which suggests that if the vaccination is 
provided between 28 and 32 weeks of pregnancy, the optimal amount of specific 
IgG may be achieved in full-term infants at birth, but may not be the same for 
preterm infants. Diphtheria toxoid-acellular pertussis vaccine (Tdap) in the second 
trimester is reported to be reduced by the vaccination with tetanus toxoid which 
results in higher neonatal anti-pertussis antibody titers as compared to vaccina-
tion in the third trimester both in preterm and term neonates [121, 122]. The total 
longer transfer time may be a reason for the accumulation of antibodies in the fetal 
circulation. In addition to the maternal IgG antibodies which is transferred through 
placenta and known for providing protection, lesser concentration of IgG, IgM 
and high concentration of maternal IgA are also excreted in the breast milk and 
colostrum [123]. Immediately after delivery or in the second or third trimester of 
pregnancy, vaccination with Tdap reported to increase the pertussis-specific IgA 
antibody levels in the breast milk [124]. Therefore, another mode of transferring 
antibodies to the new born is breastfeeding. The maternal IgA transferred through 
the breast milk helps protecting the infants against enteric infections and respira-
tory illness with fever in infants born to influenza-vaccinated mothers for at least 
6 months after birth [42, 123]. Though, there are evidences highlighting the mater-
nal immunization benefits, few studies have also shown controversial interferences 
between the maternal IgG antibodies and the infant antibody responses [125].
The “immunological blunting”, a phenomenon is observed after the primary 
vaccination series in early infancy when the maternal IgG antibodies can inhibit 
the immune responses against the same or related antigens. While after the booster 
dose, this blunting effect dissipates [119, 126]. Blunting has been reported to be 
observed with polio and measles vaccines after natural infection or maternal 
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As compared to high-income countries, in low-income and middle-income coun-
tries the HPV vaccination coverage is much lower. In the high-income countries an 
estimated 33.6% of girls and women aged between 10 and 20 years had received 
the full course of HPV vaccine by the year 2014 as compared to low-income and 
middle-income countries which was 2.7% of the same age group of females [108]. 
Though studies are still in progress on the long-term vaccine efficacies to under-
stand the total duration of protection, it has been reported that with Gardasil the 
protection against targeted HPV types last for at least 10 years [109], with Cervarix 
at least 9 years [110] and with Gardasil 9 a least 6 years [111]. But these vaccines 
have not sufficiently been tested during pregnancy and hence it is not used in 
pregnant women.
The Centers for Disease Control and Prevention (CDC) recommends HPV 
vaccination for women having either an HPV infection or an abnormal Pap test or 
both if they are in the appropriate age group as that may protect them against the 
high-risk HPV types which have not been acquired by them. However, the vaccina-
tion has not the potential to treat the abnormal results of the Pap test or cure the 
current HPV infections [112]. Though, the vaccines have been reported to be safe 
when given to people with pre-existing HPV infection, it gives maximum benefit 
if given to people before being sexually active [113, 114]. However, some residual 
benefit from the vaccination will still be there for people already exposed to HPV 
even though infections with one or more HPV types which are included in the vac-
cines. Currently, there is no specific test available to detect past exposure of HPV in 
individuals and the approved HPV tests detect only current infection with high-risk 
HPV types at the cervix region without any information on past infection.
Even after the vaccination, the screening for cervical cancer need to be done as 
all HPV types which has the potential to cause cancer are not covered by the HPV 
vaccines. Therefore, in cervical cells to detect precancerous changes before the 
development of cancer, screening is essential. Additionally, women with exist-
ing HPV infection or who are not vaccinated the cervical screening is critically 
important. However, the screening recommendations may be changed in future for 
women given HPV vaccination.
Research works are in progress to develop therapeutic HPV vaccines which 
would prevent cancer development among women with previous history of HPV 
infection. The immune system will be stimulated by these vaccines which will result 
in specifically targeting and killing infected cells. The safety and efficacy of a thera-
peutic DNA vaccine are being tested by ongoing clinical trials to treat HPV related 
cervical and vulvar lesions [115–117]. A combination of preventive and therapeutic 
vaccine would be an ideal strategy in this case.
Topical microbicides is another preventive strategy which is being explored. 
In various studies, carrageenan which is an extracted compound from seaweed 
widely used in foods and other products has been reported to inhibit infection 
with HPV. Clinical trial in healthy individuals with a gel containing carrageenan is 
underway to test its efficacy to prevent genital HPV infections.
6.1 Immunization of the pregnant women
The response of the adaptive immune system of the infants cannot be protective 
to many pathogens in the first months of life. The T cells of both fetal and neonatal 
origin are shewed towards Th2 responses which are ineffective against intracellular 
pathogens. Ineffectiveness has also been reported for bacterial polysaccharides 
by antibody responses. Infants rely on additional protection during this period 
which is acquired from maternal antibodies during gestation passively transported 
through the placenta. At the time of birth, the antibody levels present in the infants 
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antibodies may not be sufficient to provide full protective immunity or can provide 
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antibody levels decrease over a periods of approximately 6 months after birth. 
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transfer of the IgG antibodies from mother to the fetus, which are located in contact 
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somes and bind to Fc receptors (FcRn) of the neonatal cells which are expressed 
on the surface of the internal endosomes. On membrane of the fetal side of the 
syncytiotrophoblasts, the endosomes fuse and the IgG are released from FcRn. 
Passing through the villous stroma and fetal capillary endothelium, IgG enters the 
fetal circulation through an unknown mechanism. With the largest transferred 
proportion during the third trimester of pregnancy, the transfer of IgG through 
placenta increases over time especially within the last 4 weeks. Consistent with an 
active transport process, the IgG concentration in the fetal circulation are gener-
ally greater than the maternal circulation at full term of pregnancy [118, 119]. This 
transfer is influenced by several factors such as maternal non-infectious diseases, 
placental integrity, total maternal IgG concentration, FcRn availability, IgG sub-
type, timing of infection or vaccination and nature of the antigen [120]. IgG4, IgG3 
and IgG2 are the least efficiently transferred to the fetus as compared to IgG1 which 
is the most efficiently transferred antibody subtype to the fetus.
Approximately after 2 weeks of maternal immunization, the concentration 
of specific antibodies starts increasing which suggests that if the vaccination is 
provided between 28 and 32 weeks of pregnancy, the optimal amount of specific 
IgG may be achieved in full-term infants at birth, but may not be the same for 
preterm infants. Diphtheria toxoid-acellular pertussis vaccine (Tdap) in the second 
trimester is reported to be reduced by the vaccination with tetanus toxoid which 
results in higher neonatal anti-pertussis antibody titers as compared to vaccina-
tion in the third trimester both in preterm and term neonates [121, 122]. The total 
longer transfer time may be a reason for the accumulation of antibodies in the fetal 
circulation. In addition to the maternal IgG antibodies which is transferred through 
placenta and known for providing protection, lesser concentration of IgG, IgM 
and high concentration of maternal IgA are also excreted in the breast milk and 
colostrum [123]. Immediately after delivery or in the second or third trimester of 
pregnancy, vaccination with Tdap reported to increase the pertussis-specific IgA 
antibody levels in the breast milk [124]. Therefore, another mode of transferring 
antibodies to the new born is breastfeeding. The maternal IgA transferred through 
the breast milk helps protecting the infants against enteric infections and respira-
tory illness with fever in infants born to influenza-vaccinated mothers for at least 
6 months after birth [42, 123]. Though, there are evidences highlighting the mater-
nal immunization benefits, few studies have also shown controversial interferences 
between the maternal IgG antibodies and the infant antibody responses [125].
The “immunological blunting”, a phenomenon is observed after the primary 
vaccination series in early infancy when the maternal IgG antibodies can inhibit 
the immune responses against the same or related antigens. While after the booster 
dose, this blunting effect dissipates [119, 126]. Blunting has been reported to be 
observed with polio and measles vaccines after natural infection or maternal 
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immunization for maternal antibodies [119, 127]. Though, the clinical importance 
of this blunting effect is unknown, the epidemiological data of implemented 
maternal immunization from various countries have not shown any negative impact 
on the protection against the diseases targeted [26, 128].
6.2 HPV vaccination during pregnancy
Gardasil and Cervarix both HPV vaccines are recombinant which contains 
virus-like particles (VLP’s) and enhanced by an adjuvant which is responsible for 
triggering an immune response higher than a natural infection [129]. Gardasil 9, a 
9-valent HPV vaccine was only licensed for use in the USA in December 2014.
Depending on age, full coverage by the HPV vaccine is obtained by 2 or 3 
doses with the first dose administered at time o, followed by the second dose 
after 1–2 months and the third dose after 6 months [130]. While, all doses are not 
received by many girls [131]. In order to achieve long-term duration of immunity, 
the repeat doses of vaccine are given which boost the immune system.
Worldwide, millions of doses of HPV vaccine since its introduction have been 
administered and involuntary administration also occurs during pregnancy as the 
young fertile women are the main recipients of the vaccines. Potentially harmful 
adverse effects (AE) to the unborn child such as preterm birth, miscarriage, con-
genital malformations, fetal death or fears of teratogenicity raise concern among 
both the health care providers and recipients. The development of sensitive organs 
such as the heart, the central nervous system takes place in the first trimester of 
pregnancy and in this period the environmental factors like medications and drugs 
theoretically might cause damage the developing fetus which is the main reason of 
concern. The vaccine manufacturers (Merck and GlaxoSmithKline) and the World 
Health Organization recommend avoiding HPV vaccination during pregnancy [36]. 
However, in case of accidental vaccination of pregnant women there are no inter-
ventions and no mandatory pregnancy testing before vaccination recommended so 
far. Moreover, conducting studies to investigate the pregnancy outcomes by admin-
istering HPV vaccines to pregnant women are not ethically feasible. In pregnancy, 
the true safety of the HPV vaccination has not yet been established through ran-
domized controlled trial. Hence, the HPV vaccine administration to the pregnant 
women has not yet been approved [132].
7. Conclusion
In pregnant women, many observational studies reported the HPV infection risk 
but there are controversial results too. Higher HPV prevalence has been reported in 
few studies, whereas several studies reported lower prevalence in pregnant women 
or there is no statistical difference between pregnant and age matched non-preg-
nant controls [16].
For a successful pregnancy, a modulated, dynamic and responsive immune 
system is required but definitely not a suppressive one and this has been sup-
ported by an increasing number of studies. At the feto-maternal interface, the 
trophoblastic cells are important for the receptive immune system establishment 
which is achieved as a part of response mechanism to the normal microbiota which 
highlights the complexity of the regulatory pathways involved during pregnancy. 
Moreover, there are evidences on the effects that changed the modulated immune 
system and the receptive feto-maternal interface by a clinically silent viral infection 
emphasizes the necessity of better detection, treatment and prevention of the viral 
infections during pregnancy. This will further lead not only to the better outcomes 
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of pregnancy but also the postnatal development can be affected in a better way as 
these viral infections and the subsequent inflammations reported to be associated 
with mental health issues and diseases of the immune system such as asthma and 
allergies. The effects of viral infections on fetal development during pregnancy can 
more be exemplified by the recent Zika virus outbreak and its teratogenic effect on 
the development of brain [22]. Therefore, it is important to understand the complex 
immune responses during pregnancy, with the continued risk of pandemics and the 
emergence of newer diseases associated as secondary to the viral infection, which 
will lead to the development of appropriate approaches and tools to protect both the 
fetus and the mother [41].
Moreover, there are very limited data is available due to the very limited number 
of investigations have been performed on materials from spontaneous abortions 
and spontaneous preterm deliveries due to HPV infection and the heterogeneous 
study groups making it difficult to come to a reliable conclusion. A proper study 
design, selection of proper controls is very essential in this case and a strict control 
of the similarity in patients/samples is needed for a valuable comparison between 
studies. Furthermore, the simple detection of a virus cannot be a real causative role 
for diseases in general or adverse pregnancy outcomes. Therefore, for this particular 
situation it is important to study the cellular localization and the viral activity to 
come to a realistic conclusion.
Therefore, we recommend more investigations on materials of adverse preg-
nancy outcomes including spontaneous abortion and spontaneous preterm delivery 
and the molecular mechanism of HPV infections on it which is the need of the hour 
and researchers need to conduct new studies to clarify the exact molecular mecha-
nisms involved on the HPV infection in early pregnancy and how the self-clearance 
takes place during the course of pregnancy.
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Chapter 5
HPV Vaccines: Myths and Facts
Mehmet Faruk Kose and Emine Karabuk
Abstract
Many types of HPV virus found in nature are known to cause anogenital diseases 
and cancers in both of men and women. Genital condylomas caused by some types 
of HPV can cause important dermocosmetic, social, and psychological problems. 
On the other hand, cervical cancers caused by high-risk HPV types can be detected 
and treated in early stage or preinvasive period by using effective screening pro-
grams. But the main goal is to fight with the viruses causing the disease. Therefore, 
protective and preventive HPV virus vaccines are important. However, for effec-
tive administration of vaccines, it is necessary to know the effects of the vaccines, 
to whom it is applicable, any adverse effects, and to overcome prejudices against 
the vaccines and to clarify misinformation. In this chapter, in the light of current 
information about HPV vaccines, known facts and myths about vaccines are shared.
Keywords: HPV vaccines, cervical cancer, anogenital cancer, anogenital warts, 
efficacy, side effects
1. Introduction
The discovery of HPV (human papillomavirus) was awarded by Nobel Prize. 
Since 2008, when Prof. Dr. Harald zur Hausen (German Cancer Research Centre, 
Heidelberg, Germany) found the relationship between HPV and cervical cancer, 
the debate on HPV and its vaccine never ended (Figure 1).
Figure 1. 
HPV and cervical cancer (the Nobel Prize in Physiology or Medicine 2008).
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There are more than 200 known types of HPV and 35–40 types are responsi-
ble for anogenital diseases. Fifteen high-risk types were also related to cancer. In 
order of their level of connection to cancer, the HPV types are: 16, 18, 45, 31, 33, 
52, 58, 35, 59, 56, 51, 39, 68, 73, and 82. Out of those, 16 and 18 are responsible 
for 71–80% of the cancers and are five times more oncogenic than the other 13 
types. From the low-risk types, 6 and 11 are responsible for 90% of the anogeni-
tal wart [1].
Looking geographically, 16, 18, 45, 31, 33, 52, and 58 are the seven most preva-
lent types, with little variation between locations [1]. In Turkey, Usubütün et al. 
found that types 16 and 18 had 76% prevalence in cervical cancers. The first six 
types (16, 18, 45, 31, 33, and 52) are responsible for 90.6% of the cancers [2].
In Figure 2, the full structure of both early (E) and late (L) proteins of HPV are 
shown, as well as their functions.
In their lifetime, women have 80–85% chance to have an HPV infection, 
which means it is a widespread sexually transmitted disease. Speaking of sexually 
transmitted, 99% of all types are transmitted via sex, and using condoms do not 
protect from it (although some studies show that it protects up to 60%, theoreti-
cally any contact between testicals and the vulva is enough for transmission); 
it can spread even if a finger that had contact with the infected organ touches 
the opposite gender’s genetelia (less than 0.1% of all cases), and since the virus 
requires body heat; it cannot be transmitted via pools, toilets, baths, saunas, or 
any other non-living surface.
So is HPV a cervical cancer factor, and are there other HPV-related diseases? 
HPV-related diseases are: cervix, anus, vulva, penis, oropharynx, and oral cav-
ity cancers. The main reason for cervical cancer is HPV. In other words, cervical 
cancer cannot happen without HPV. HPV is also related to other diseases to some 
extent (Figure 3).
Figure 2. 
L and E proteins of HPV and their functions.
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Recently, its association with lung cancer has been shown. In a study by Xiong 
et al. in 17 countries with 6890 cases and 7474 control groups, squamous cell 
carcinoma, adenocarcinoma and small-cell carcinoma types showed an increase 
post-HPV infection (Total OR 3.64 (95% CI: 2.60–5.08) for HPV 16: 3.14 (95% CI: 
2.07–4.76) for HPV 18: 2.25 (95% CI: 1.49–3.40)) [4].
Apart from cancer, anogenital wart is one of the most important social prob-
lems. As seen in Figure 4 for England and the Wales, anogenital wart increases with 
a country’s level of development.
In Turkey, anogenital wart prevalence was found as 154/100,000 and in another 
study that was adjusted for age, point prevalence (lifetime incidence rate) was 3.8% 
for the full group, and 2.4% for the pregnant population. Prevalence study revealed 
similar results of recurrence with USA and Europe by 15–37% [5, 6].
The question, then, arises: Is HPV only for females? What about HPV in males? 
HPV has been shown to be associated with anogenital wart, anal and penile cancers 
in men [7, 8].
Figure 3. 
HPV-related cancers and their HPV prevalence [3].
Figure 4. 
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Males are the carriers of this sexual-transmitted disease; however, the disease 
burden is mostly present in females.
So, is there any vaccine developed against this infectious disease, can this disease 
be eliminated?
First ever vaccination study was developed as a monovalent (for a single type) 
against 16 with a 100% protection rate [9]. This vaccine was not commercialized.
A bivalent (for 2-types) vaccine against the most cancer-linked types 16 and 18 
based on the previous study, as well as a quadrivalent (for four-types) vaccine based 
on recombinant virus-like particle (VLPs) were developed by the world-leader 
companies GSK and MSD [10, 11]. Then, a nonavalent (for nine-types) vaccine was 
developed and commercialized in order to protect against even more cancer-linked 
HPV types [12].
Since anogenital warts are one of the substantial social problems, it has not been 
available and bivalent vaccine against HPV 6 and 11 is still in progress. The current 
vaccines in use do not provide protection against HPV types associated with non-
wart anogenital warts and non-melanoma skin cancers (NMSC). Therefore, vaccina-
tion studies against L2 proteins are in progress in the phase of animal experiments.
The International Papillomavirus Society, in an excerpt in the Guardian, pointed 
to Australia as a model for eradicating cervical cancer; they discussed results in 
between 2005 and 2015 and showed vaccination rates at 78.6% for girls below the 
age of 15 and 72.9% for boys below the age of 15, since 2016 [13].
World Health Organization (WHO) has developed a strategy plan to eliminate 
cervical cancer. According to the strategy, to provide a total elimination from 
cervical cancer, up to 15 years of age 90% of the girls should be vaccinated, 70% of 
females aged between 35 and 45 should be screened via high sensitivity tests and 
90% of women should be successfully treated of cervical diseases (precancerous 
lesions and invasive cancers). World Health Organization stated that if these goals 
are reached by 2030, the elimination of cervical cancer would be possible in 2090 
(Figure 5) (https://www.who.int/docs/defaultsource/documents/cervical-cancer-
elimination-draft-strategy.pdf?sfvrsn=380979d6_4).
In Turkey, however, the situation is highly controversial. As of the last months 
of 2019, nonavalent is not licensed let alone being included in a vaccination pro-
gramme. Unfortunately, two of our worst examples for vaccination; polio and 
hepatitis B; shows a 17-year delay in adapting vaccination programs behind the rest 
of the world. In 1955, there were statements on Milliyet Journal’s columns such as 
Figure 5. 
Timeline for eliminating cervical cancer.
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“The discovery of Polio vaccine caused a stir in Turkey” and “The news of Polio 
caused an excitement in our country but Turkish practitioners do not want to make 
any statement before getting informed from authorities.” Seventeen years after 
these statements, polio was eliminated to be included in the vaccination programme 
of Turkey.
2. Myths
• Natural infection protects so there is no need for vaccination.
• Vaccinated children never experience HPV infection and never have HPV 
associated cancer throughout their lives.
• Vaccination cures their related disease.
• Antibody levels in blood are quite important; the protection loses its effect if 
the levels drop.
• Herd immunity (protection of the unvaccinated population) does not exist.
• Vaccinations are not effective when done at later ages.
• Smear or other HPV tests should be performed before the vaccination.
• If a pregnancy occurs during vaccination, it should be terminated.
• Vaccinated young girls have higher rates of sexually transmitted diseases since 
they feel more sexually comfortable.
• Autoimmune diseases such as primary ovarian deficiency and Guillain-Barre 
have higher rates among the vaccinated girls.
• There is cross-protection so vaccinations of HPV 16 and 18 are sufficient.
• If there is total protection against types in vaccinations, then cancer prevalence 
of other types will increase.
• Vaccines are not safe, there are deaths associated with the vaccine.
• Vaccines are not cost-effective, protected patients are not worth the cost.
3. Facts
3.1 Natural infection protects so there is no need for vaccination
HPV slithers through the cervical cracks and reaches basal cells in about 30 min-
utes and enters the cells to infect them. Since it does not stay in the vascular system, 
the antibody response does not form. Inside the cell, DNA is located episomally at 
first. Episomally located DNA causes a temporary infection and gets excreted with 
the cell when the cell is visible on the surface. If the DNA of the HPV gets integrated 
into the cell DNA, persistent infection will occur and some of them advance to 
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Males are the carriers of this sexual-transmitted disease; however, the disease 
burden is mostly present in females.
So, is there any vaccine developed against this infectious disease, can this disease 
be eliminated?
First ever vaccination study was developed as a monovalent (for a single type) 
against 16 with a 100% protection rate [9]. This vaccine was not commercialized.
A bivalent (for 2-types) vaccine against the most cancer-linked types 16 and 18 
based on the previous study, as well as a quadrivalent (for four-types) vaccine based 
on recombinant virus-like particle (VLPs) were developed by the world-leader 
companies GSK and MSD [10, 11]. Then, a nonavalent (for nine-types) vaccine was 
developed and commercialized in order to protect against even more cancer-linked 
HPV types [12].
Since anogenital warts are one of the substantial social problems, it has not been 
available and bivalent vaccine against HPV 6 and 11 is still in progress. The current 
vaccines in use do not provide protection against HPV types associated with non-
wart anogenital warts and non-melanoma skin cancers (NMSC). Therefore, vaccina-
tion studies against L2 proteins are in progress in the phase of animal experiments.
The International Papillomavirus Society, in an excerpt in the Guardian, pointed 
to Australia as a model for eradicating cervical cancer; they discussed results in 
between 2005 and 2015 and showed vaccination rates at 78.6% for girls below the 
age of 15 and 72.9% for boys below the age of 15, since 2016 [13].
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females aged between 35 and 45 should be screened via high sensitivity tests and 
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lesions and invasive cancers). World Health Organization stated that if these goals 
are reached by 2030, the elimination of cervical cancer would be possible in 2090 
(Figure 5) (https://www.who.int/docs/defaultsource/documents/cervical-cancer-
elimination-draft-strategy.pdf?sfvrsn=380979d6_4).
In Turkey, however, the situation is highly controversial. As of the last months 
of 2019, nonavalent is not licensed let alone being included in a vaccination pro-
gramme. Unfortunately, two of our worst examples for vaccination; polio and 
hepatitis B; shows a 17-year delay in adapting vaccination programs behind the rest 
of the world. In 1955, there were statements on Milliyet Journal’s columns such as 
Figure 5. 
Timeline for eliminating cervical cancer.
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“The discovery of Polio vaccine caused a stir in Turkey” and “The news of Polio 
caused an excitement in our country but Turkish practitioners do not want to make 
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• Vaccination cures their related disease.
• Antibody levels in blood are quite important; the protection loses its effect if 
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• Herd immunity (protection of the unvaccinated population) does not exist.
• Vaccinations are not effective when done at later ages.
• Smear or other HPV tests should be performed before the vaccination.
• If a pregnancy occurs during vaccination, it should be terminated.
• Vaccinated young girls have higher rates of sexually transmitted diseases since 
they feel more sexually comfortable.
• Autoimmune diseases such as primary ovarian deficiency and Guillain-Barre 
have higher rates among the vaccinated girls.
• There is cross-protection so vaccinations of HPV 16 and 18 are sufficient.
• If there is total protection against types in vaccinations, then cancer prevalence 
of other types will increase.
• Vaccines are not safe, there are deaths associated with the vaccine.
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preinvasive lesions. Only 15 of 100 HPV-infected women will develop cervical 
intraepithelial neoplasia (CIN) while 60% of them will have regression and 25% of 
them continue as infection.
In a study by Viscidi et al. with the National Cancer Institute (NCI) on the 
“Guanacaste, Costa Rica NCI Program,” that included 10,049 women examined 
for over a 5-year period; natural HPV infection occurred on women independent 
of the type-based serological state. HPV infections from types 16, 18, and 31 rates 
were equal for both seronegative and seropositive cases. This is the clearest evidence 
which proves that natural infections do not protect against HPV [14].
3.2 Vaccinated children cannot get HPV or HPV-linked cancer in the future
Many patients as well as physicians have misinterpreted this issue. HPV-
vaccinated patients that develop HPV-related diseases are shown as exemplary 
cases. What is the right information, then? Considering the cervical cancer, only 15 
high-risk types can cause cancer. Types 16 and 18 that are included in the vaccines 
are responsible for 71–76% and the seven high-risk types in the nonavalent vac-
cines are responsible for 88–90% of all cervical cancer. Naturally, even nonavalent 
vaccines do not protect against all HPV types, and HPV infection can develop in the 
rest. Furthermore, we know that LSIL (low-grade squamous intraepithelial lesion) 
may develop not only through high-risk HPV types but also it can be caused by 
other types of HPV.
In the end, naïve (no prior contact with HPV) group children are protected close 
to 100% against the types included in the vaccine. Adults who have not developed the 
same type HPV before are also protected close to 100%. If they developed it before, 
they are instead protected against the other included types.
However, FUTURE III study shows us that the chance of developing both types 16 
and 18 infections is less than 1% [15]. In addition to this, Kang et al. studied the effi-
cacy of quadrivalent vaccines in 737 cases treated for CIN 3 over the course of 3 years. 
In this randomized controlled study, 360 vaccinated cases and 377 non-vaccinated 
cases were monitored in terms of recurrent diseases associated with certain HPV 
types. In the vaccinated group, recurrent infection rate was 2.5% while in the non-
vaccinated group, the rate was 8.5% (HR = 2.840; CI: 1.335–6.042; p < 0.01) [16].
As a summary, both vaccinated girls and boys can develop HPV infections, 
which can lead to cancer, with types that are not included in the vaccine. Anogenital 
warts can occur with HPV types other than 6 and 11, hence the quadrivalent and 
nonavalent vaccinated group can develop anogenital warts at a rate lower than 10%.
3.3 Vaccination cures their related disease
Vaccines do not treat HPV-associated diseases. They are not therapeutic. 
However, as stated in previous section, vaccines are effective in preventing recur-
rent infections.
3.4  Antibody levels in blood are quite important; the protection loses its effect if 
the levels drop
Both bivalent and quadrivalent HPV vaccines’ fundamental studies, FUTURE 
[15] and PATRICIA [17], recorded related blood antibody levels. In these studies, 
neutralizing antibody levels were measured for four different age groups: 15–25, 
26–35, 36–45, and 46–55 years old. For per protocol groups, both HPV 16 and 18 
neutralizing antibodies separately showed a peak at 7 months (after the third dose).
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Antibody levels were found to be at least 8 times higher compared to natural 
infections, even in the youngest age group. HPV vaccines were found to have a 
general characteristic to be effective when done in both childhood and later ages. 
Neutralizing antibody level of 4V HPV vaccine for type 18 started to fall starting at 
24 months and fell to the natural infection level at 55 months. Neutralizing antibod-
ies showed 76% decrease at 24 weeks and 56% at 36 weeks.
Does this decrease in antibody level correspond to a decrease in protection level 
against type 18? In a 2008 RCT study by Joura et al., the protection level against 
HPV type 18 was steady at 98.4% (95% CI: 90.5–100) even when the antibody levels 
fell [18]. Ault et al. also showed that at 4 years mark, CIN 2/3 protection levels were 
at 100% even when seropositivity dropped to 60% [19]. When we consider the 
HPV vaccinated population that did not follow the full protocol; or had one or two 
doses only, by the 15th year mark hepatitis B vaccine shows a similar result. One or 
two dose vaccination was shown to provide comparable protection to three-dose 
regimes [20]. Even though hepatitis B vaccinated population’s neutralizing antibody 
level was not measurable, the protection level was known to be still at 100%. This 
goal is presumed to be reflected on HPV vaccination soon. As in, changes in the 
neutralizing antibody levels do not affect the protection, which will stay at 100%.
3.5 Herd immunity does not exist
Herd immunity, or the increase in protection rate of the unvaccinated popula-
tion as the overall vaccination rate increases, is a well-known fact for all types of 
vaccines. In Sweden, even though quadrivalent HPV vaccination rates are very 
low, 15–44 years old unvaccinated men and women had significant decrease on the 
annual rate-of-change percentage [21]. Therefore, as the community vaccination 
rate increases, those who are not vaccinated with HPV-related vaccines will develop 
HPV-related diseases at a lower rate.
3.6 Vaccinations are not effective when done at later ages
It was shown that HPV vaccination generates high neutralizing antibody levels 
when done in early childhood as well as at later ages. PATRICIA and FUTURE studies, 
at four age groups of 15–25, 26–35, 36–45 and 46–55 years old, shows consistent anti-
body levels for all of them. Even if there is not a statistical significance on vaccination 
of the naïve population, it is expected to be more effective. However, for all three 
vaccinations, EMA (European Medicine Agency) does not provide a set age limit. 
After considering the available data and studies, EMA decided to lift the age limit on 
women. However, there is a soft 25 years-old upper limit for men. This age limit is due 
to follow-up case series not being available yet.
3.7 Smear or other HPV tests should be performed before the vaccination
Vaccination will not protect against infections that occurred prior to it. FUTURE 
III study shows us that developing both HPV 16 and 18 together has a chance less 
than 1%. According to abnormal smear results, HSIL and cancer are only correlated 
with high-risk HPV types. On the other hand, LSIL is correlated with both high-risk 
HPV types as well as others. Hence, HPV DNA test prior to vaccination can only tell 
for less than 1% of women if the vaccine cannot protect against the most prevalent 
types 16 and 18. Studies also show that vaccinations help reduce reinfection rate for 
prior type 16 and/or 18 infections. On top of the infections, a randomized control 
study on LEEP treated cases due to HSIL, shows us that vaccinated group had a 
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reduced reinfection rate at 2.5% compared to 8.5% [16]. According to this data, 
smear or HPV DNA tests are not required prior to vaccination.
3.8 If a pregnancy occurs during vaccination, it should be terminated
There are limited number of cases about uses of bivalent and quadrivalent HPV 
vaccination during pregnancy. Both vaccines are classified as category B due to prior 
data. Comparison between vaccinated and unvaccinated group did not show an 
increase in the infant’s congenital anomaly rates. However, due to unavailability of 
more data, vaccination during pregnancy is not recommended. This does not mean 
that the vaccination is done without knowledge of the pregnancy, that it should be 
aborted [22].
3.9  Due to decreased sexual fear, sexually transmitted disease rates increase 
among vaccinated girls
From a social, psychologic, and religious angle; parents of vaccinated girls 
wonder if the protection of the vaccine would urge them to be more sexually active 
at a younger age. It would be an issue if it was true. In order to answer this, a study 
published at Pediatrics reported sexually transmitted infections (STI) history of 
vaccinated girls. Mayhew et al. found that between the 42.5% cases without prior 
sexual relations and 57.5% cases with prior sexual relations, there was only a differ-
ence of OR 0:13 (95% CI: 0.03–0.69) which shows that vaccination did not change 
their sexual behavior [23].
3.10  Autoimmune diseases such as primary ovarian insufficiency and  
Guillain-Barre have higher rates among the vaccinated girls
In order to claim that a vaccination developed a disease, it needs to be within 
3 years. At the 9th-year mark of HPV vaccines, 170,000,000 doses of vaccines had 
been done. Out of this large sample size, only six cases in the literature show primer 
ovarian insufficiency. Looking closer, we see that three of these cases had irregular 
periods up to 15 years before vaccination. The other three cases had their diagnosis 
more than 3 years after vaccination [24].
In the placebo-controlled FUTURE III (quadrivalent HPV vaccine) study, in 
both the vaccinated and AAHS (regular saline, placebo) groups, autoimmune 
disease rates were at 2.3%. This is the clearest study that shows autoimmune disease 
rate does not increase in vaccinated population. In addition, in a large meta-analysis 
study by Genovese et al. (243,289 vaccinated and 248,820 control group) there was 
no correlation between HPV vaccines and autoimmune diseases [25].
3.11  Vaccines that include types 16 and 18 are enough for the rest due  
to cross-protection effect
The difference between cross-protection and cross-reaction is an important issue. 
Bivalent and quadrivalent HPV vaccines both show cross-reaction. Especially in biva-
lent HPV vaccines, researchers argued for cross-protection due to common ancestry 
of types 16 and 31 as well as 18 and 45. In bivalent vaccinated girls, HPV 31 and 45 
immune response, as well as GMTs and seropositivity rates were considered. Serum 
GMTs were 20 times higher than natural infections for HPV 31 and 45. This effect, 
however, is cross-reaction. Because the vaccinated girls and women lose the protection 
against HPV 31 and 45 by the end of 4th year in these bivalent HPV studies [26–28].
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In a report by the Centers for Disease Control and Prevention (CDC) in the USA, 
as of 2018, there are no bivalent or quadrivalent HPV vaccines in the market; only 
nonavalent HPV vaccine is sold [29].
3.12  If the vaccines include full protection against some types, cancer rates in 
the rest of the types will increase
This is a baseless theory from anti-vaccination group. Is it necessary to prove 
the opposite of this theory? Even so, there have been studies on the matter. In 1180 
vaccinated cases, anogenital non-vaccinated type HPV and genetic-related HPV 
16 and 18 types prevalence are studied. There was no change in the non-vaccinated 
HPV type prevalence [30].
3.13 Vaccines are not safe; there are deaths associated with the vaccine
Three independent institutes on the CDC Website are continuously monitor-
ing the safety of vaccines and the data is available for both experts and the com-
munity. Because in the USA, every drug that is on the market has an obligation for 
routine control. These vaccine-monitoring systems are: the Vaccine Adverse Event 
Reporting System (VAERS), the Vaccine Safety Datalink (VSD), and the Clinical 
Immunization Safety Assessment (CISA) Network; and any person who had an 
adverse effect from a vaccine can report to them freely.
Vaccines consist of VLPs (virus-like particles) made with recombinant technol-
ogy, that do not include any DNA but are identical to HPV in terms of structure. 
They cannot develop HPV infections or HPV-related cancer, as they do not include 
any DNA to reproduce. On the other hand, weakened or killed bacteria or virus 
vaccines do have a minute risk [31].
Side effects include redness in the vaccination site, minor pain, inflammation, 
and mild fever; like all childhood vaccinations. It could also cause nausea and diz-
ziness. Due to this, vaccinated people are recommended to rest for 15 minutes after. 
VAERS records show that when divided into critical side effects and non-critical 
side effects; side effect rates were on a steady decline since 2007. In theory, autoim-
mune diseases are the most common side effect claims. In a quadrivalent HPV 
vaccine in 1000 cases of 9–26 year-old girls and women, there were no differences 
in autoimmune diseases between the vaccine group and the adjuvant or physiologic 
serum group. Both groups reported a rate of 2.3%.
When nonavalent HPV vaccine was introduced after the quadrivalent vaccine, 
which had twice the amount of aluminum (500 μg = 0.5 mg) of the latter, several 
anti-vaccination physicians theorized that this would worsen the side effects. 
However, any side effect of the 0.5 mg AAHS in hepatitis B, which has been used for 
25 years, has never been proven. In a new study on the safety of aluminum in vac-
cines, the aluminum in the immunity-booster adjuvants had a high safety factor and 
did not cause any neurotoxicity [32]. Furthermore, we ingest more aluminum from 
drinking water (<0.2 ml/L), from many foods such as potatoes and spinach (<5 mg/
kg), from aluminum folio to preserve food, from food with aluminum supplements, 
and soy-based food (0.4–6 mg/L) compared to the vaccines (https://www.cfs.gov.
hk/…/files/RA35_Aluminium_in_Food_e.pdf).
Theory that quadrivalent and nonavalent HPV vaccines can cause primary 
ovarian insufficiency (POI) has been claimed by experts in many places including 
the social media. As described in detail in the previous section, there have been 
only 6 POI cases out of 170,000,000 doses of HPV vaccines in over 9 years. What 
is the incidence rate of POI in a normal population? Spontaneous POI for under 
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serum group. Both groups reported a rate of 2.3%.
When nonavalent HPV vaccine was introduced after the quadrivalent vaccine, 
which had twice the amount of aluminum (500 μg = 0.5 mg) of the latter, several 
anti-vaccination physicians theorized that this would worsen the side effects. 
However, any side effect of the 0.5 mg AAHS in hepatitis B, which has been used for 
25 years, has never been proven. In a new study on the safety of aluminum in vac-
cines, the aluminum in the immunity-booster adjuvants had a high safety factor and 
did not cause any neurotoxicity [32]. Furthermore, we ingest more aluminum from 
drinking water (<0.2 ml/L), from many foods such as potatoes and spinach (<5 mg/
kg), from aluminum folio to preserve food, from food with aluminum supplements, 
and soy-based food (0.4–6 mg/L) compared to the vaccines (https://www.cfs.gov.
hk/…/files/RA35_Aluminium_in_Food_e.pdf).
Theory that quadrivalent and nonavalent HPV vaccines can cause primary 
ovarian insufficiency (POI) has been claimed by experts in many places including 
the social media. As described in detail in the previous section, there have been 
only 6 POI cases out of 170,000,000 doses of HPV vaccines in over 9 years. What 
is the incidence rate of POI in a normal population? Spontaneous POI for under 
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30-years old is about 0.1%, and for under 40-years old is about 1%. In Australia, 
out of 5,800,000 doses for 83% school-age girls, there was no relation between 
HPV and POI [33].
In Japan, there is a two-staged national vaccine program; quadrivalent HPV 
vaccine was implemented to the first stage in 2010 and was moved to the second 
stage in April 2013. This allowed only anyone that wanted to be vaccinated. The 
reason was abnormal uterus bleeding, excessive uterus bleeding, and headache. To 
address this, 71,117 women were studied and no relation between the symptoms 
and vaccination were found. As a result, vaccines were reimplemented into the first 
stage in June 2013 [34].
Considering mortality, CDC Website reports 117 deaths for the 80,000,000 
doses of vaccines from the related institutes and 51 of them had a known cause. 
These known causes were unrelated to vaccines. Recorded death causes included: 
traffic accident, homicide, epilepsy crisis for epilepsy diagnosed patients, pul-
monary embolism, drug overdose for drug abuse patients, acute myocarditis, 
and meningoencephalitis, influenza B, and diabetic ketoacidosis. There were five 
reported deaths after nonavalent vaccines were introduced: car accident, suicide, 
acute lymphoblastic leukemia, septic shock, and an unknown cause. There are 
many meta-analysis and reviews about vaccine safety readily available. There are 
no differences in between vaccinated and unvaccinated groups in terms of critical 
side effects.
3.14 Vaccines are not cost-effective; protected patients are not worth the cost
This is an interesting claim. Every single patient protected is worth the effort. 
Looking through a scientific perspective, many studies found that even the vaccines 
based on HPV 6/11 related warts, HPV 16/18 related precancerous lesions, and 
cervical cancer are cost effective [35–37].
4. Conclusion
HPV vaccines are recommended by WHO, CDC that are the world’s leading 
organizations, and related associations of all other developed countries, have not 
yet reached the deserved coverage rate. WHO described HPV vaccination as an 
essential part of its program when talking about the elimination of cervical cancer. 
The most well-known topic of all medical staff is “The worst vaccine is better than 
the best treatment.” As such, there are numbers of myths about HPV vaccines that 
we mentioned above. These issues should be well known to all of our community, 
especially health professionals, so that HPV vaccination can become widespread. 
We wanted to share the truths of these myths with you in the light of the evidences 
of today. In this article, neither of us have any conflict of interest.
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Chapter 6
HPV and Cervical Cancer Control




Cervical cancer is a major cancer affecting 5.3 million women annually,
worldwide, and is responsible for about 2.7 million deaths per year. More than 85%
of the incident cases occur in developing countries. Cervical cancer is a totally
preventable cancer, if diagnosed in the precancer stages and treated effectively.
HPV vaccination has been introduced in many countries. Effective screening and
treatment programs are available in many health settings. Posttreatment histopath-
ological follow-up is done for 3–5 years. Cure from precancer condition and pre-
vention of invasive cervical cancer are thus attained. But the main hurdle in
achieving the above ambitious goal is the lacunae and deficiencies in conversion of
knowledge into practice by the women who are otherwise well informed about the
prevention of cervical cancer, as result of massive inputs in the field of health
education. Thus, the screening participation and compliance to precancer treatment
remain low. This barrier in translational knowledge should be overcome efficiently.
The author, from his vast experience in planning and implementing one of the
largest cervical cancer screening programs in India, has conceptualized “the
STAR model P6 principles of Raj” for successful conversion of “knowledge into
practice.”
Keywords: cervical cancer, screening, treatment, low participation,
translational knowledge to practice
1. Introduction
Cervical cancer is the fourth common cancer among women in the world, and
it accounts for about 530,000 new cases and 270,000 deaths annually, as reported
in 2012. About 85% of these cases occur in developing countries. It represents 12%
of incident cancers in women and 7.5% deaths due to cancer in women.
In a developing country like India, about 122,000 new cases of cervical cancer
and about 67,400 deaths due cervical cancer are reported, every year, as per data
of 2017. It is the second most frequent cancer among women of reproductive age
group.
India also has the highest age standardized incidence of cervical cancer in South
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Chapter 6
HPV and Cervical Cancer Control




Cervical cancer is a major cancer affecting 5.3 million women annually,
worldwide, and is responsible for about 2.7 million deaths per year. More than 85%
of the incident cases occur in developing countries. Cervical cancer is a totally
preventable cancer, if diagnosed in the precancer stages and treated effectively.
HPV vaccination has been introduced in many countries. Effective screening and
treatment programs are available in many health settings. Posttreatment histopath-
ological follow-up is done for 3–5 years. Cure from precancer condition and pre-
vention of invasive cervical cancer are thus attained. But the main hurdle in
achieving the above ambitious goal is the lacunae and deficiencies in conversion of
knowledge into practice by the women who are otherwise well informed about the
prevention of cervical cancer, as result of massive inputs in the field of health
education. Thus, the screening participation and compliance to precancer treatment
remain low. This barrier in translational knowledge should be overcome efficiently.
The author, from his vast experience in planning and implementing one of the
largest cervical cancer screening programs in India, has conceptualized “the
STAR model P6 principles of Raj” for successful conversion of “knowledge into
practice.”
Keywords: cervical cancer, screening, treatment, low participation,
translational knowledge to practice
1. Introduction
Cervical cancer is the fourth common cancer among women in the world, and
it accounts for about 530,000 new cases and 270,000 deaths annually, as reported
in 2012. About 85% of these cases occur in developing countries. It represents 12%
of incident cancers in women and 7.5% deaths due to cancer in women.
In a developing country like India, about 122,000 new cases of cervical cancer
and about 67,400 deaths due cervical cancer are reported, every year, as per data
of 2017. It is the second most frequent cancer among women of reproductive age
group.
India also has the highest age standardized incidence of cervical cancer in South
Asia at 22, compared to 19.2 in Bangladesh, 13 in Sri Lanka, and 2.8 in Iran [1, 2].
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2. The role of HPV
HPV is a necessary cause for cervical cancer [3].
More than 115 types of HPV are present and 18 are high-risk carcinogenic types
for cervical cancer. Other than this, HPV-16 is the most common high risk in
cervical cancer [4].
In cervical cancer cases, HPV prevalence was in the range of 87.8 to 96.67%,
in a study in India. In women without cervical cancer, HPV prevalence varied from
7.5 to 16.9%.
The worldwide prevalence of HPV infection, in normal woman, is between 9%
and 13%.
3. HPV infection worldwide
HPV is associated with 50,000 new cases of cervical cancer and 250,000
associated cervical cancer deaths, worldwide, each year [5]. It also causes vulvar,
vaginal, anal, and penile cancers and precancerous lesions of vulva/vagina, genital
warts, and respiratory papilomatosis [5–7]. HPV infections are asymptomatic,
and generally, individuals are not aware of being infected, thus facilitating the
spread easily and unknowingly [5].
At least 50% of men and women will acquire genital HPV infection during their
lifetime [8].
All sexually active women are infected with HPV at least once during their
lifetime, and the highest prevalence is seen soon after the onset of sexual activities
[9, 10].
A majority of episodes of type-specific HPV infection resolve spontaneously
within 2 years, but this may be followed by an infection with a new type [7].
HPV transmission exclusively occurs following skin-to-skin contact with an
infected partner. Sexual intercourse is not necessary, and the virus can be
transmitted through sexual foreplay [5].
HPV can only replicate in the stratified squamous epithelium. HPV infection
is the most common sexually transmitted diseases [11]. The major risk factor for
HPV infection is sexual behavior, including early age of onset of sexual activity,
multiple sexual partners, and coinfection with HIV [12].
Although the determinants of risk for persistent infection and progression to
invasive diseases are not fully understood, persistence appears to be related to HPV
type and concurrent infection with multiple virus types [12].
The prevalence and distribution of HPV types in the general population as well
as in cervical neoplasia vary with geographic region and by the grade of disease [13].
4. Screening for cervical cancer
Secondary prevention involves screening for precancerous lesions and treating
them. The three screening modalities are cytology, visual inspection, and HPV test.
5. Prevention of cervical cancer
HPV is necessary for the development of cervical cancer. Therefore, preventing
HPV infection can prevent cervical cancer. This can be achieved by complete
abstinence from sexual activity or by a vaccine [14].
106
Human Papillomavirus
Primary prevention involves a risk reduction approach through behavioral
intervention for sexual and healthcare-seeking behavior or through mass immuni-
zation against high-risk HPV [15].
The objective of cervical screening/secondary prevention is to prevent invasive
cervical cancer from developing by detecting and treating women with CIN2/3
lesions, and the effectiveness is determined by reduction in incidence and mortality.
The critical components of a screening program are an acceptable good-quality
screening test, prompt diagnostic investigations, appropriate treatment, and
posttreatment follow-up [16].
There is a strong support from nonexperimental studies in developed countries
such as Denmark and Finland that the incidence and mortality of cervical cancer
can be reduced by screening [17].
Ensuring high levels of participation and sufficient healthcare infrastructure and
human resources are important for a screening program to succeed [18]. It is also
important for screening to be guided by equity considerations for those who are
more vulnerable or with lesser access to healthcare services because of social,
economic, or demographic factors [19].
Recent screening recommendations for specific age groups as per the American
Cancer Society (ACS) screening guidelines are as follows: [1, 2].
• At the age of 21 years: Screening is recommended.
• At the age of 21–29 years: Cytology (Pap smear) alone every 3 years.
• At the age of 30–65 years: Human papillomavirus virus (HPV) and cytology
contesting every 5 years or cytology alone every 3 years.
• At the age of >65 years: No screening recommended if adequate prior
screening has been negative and high risk is not present.
HPV Vaccines that aims to prevent cervical cancer are:
• A bivalent vaccine which protects against subtypes 16 and 18.
• A quadrivalent vaccine which protects against subtypes 16 and 18 plus
6 and 11.
• A 9-valent vaccine which protects against the same subtypes as the
quadrivalent plus subtypes 31, 33, 45, 52, and 58 (which cause about 15% of
cervical cancers).
• The HPV vaccine is ideally recommended to vaccinate boys and girls at age
11–12 years, but vaccination can begins at age 9.
6. The effect of HPV vaccination
1.Population-level impact and herd effects following the introduction of human
papillomavirus vaccination programs
From the abstract:We did a systematic review and meta-analysis of the population-
level impact of vaccinating girls and women against human papillomavirus on HPV
infections, anogenital wart diagnoses, and cervical intraepithelial neoplasia grade 2+
(CIN2+). Our results show compelling evidence of the substantial impact of HPV
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vaccination programs on HPV infections and CIN2+ among girls and women, and
on anogenital warts diagnoses among girls, women, boys, and men, programs with
multi-cohort vaccination and high vaccination coverage had a greater direct impact
and herd effects.
Ref: Population-level impact and herd effects following the introduction of human
papillomavirus vaccination programmes: updated systematic review and meta-analysis
Drolet M, Bénard É, Pérez N, Brisson M, on behalf of the HPV Vaccination Impact
Study Group. The Lancet. Open access
2.Human papillomavirus (HPV) vaccination significantly reduces the frequency
of genital HPV 16 and 18 infections and cervical intraepithelial neoplasia grade
2+ (CIN2+) in young women and shows signs of herd effects with a reduced
frequency of anogenital warts in both young women and men, a recent study
showed.
As cited in infectious diseases.
9/16/2019 HPV vaccination programmes reduce HPV infection, precancerous




7. KAP studies reveal the presence of adequate knowledge but
inadequate “practice “in the community
7.1 Recent study in India
Results: We observed that despite good knowledge and perception, less than 10
percent of workers have undergone screening. Significant association was seen
between the level of knowledge and practice of screening.
Conclusion: It is of utmost importance narrowing of existing gap between the
perception and practice of cervical cancer.
Screening should be initiated through introducing more educational programs
for workers and encouraging them to participate.
The study cited is from: Khanna D, Khargekar N, Budukh A. Knowledge, atti-
tude, and practice about cervical cancer and its screening among community
healthcare workers of Varanasi district, Uttar Pradesh, India. J Family Med Prim
Care 2019;8:1715–9.
8. How to translate “knowledge” in to “practice”
Author’s experiences in a cervical cancer screening program of the IARC/WHO,
In India.
8.1 The development of the STAR model P-6 principles of raj©
The author, having been successful in planning and implementing, such a
model, and achieving a reduction in the incidence rate of cervical cancer by 25% and
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mortality due to cervical cancer by 35%, in a period of 7 years—2000 to 2007,
strongly recommends the STAR model P-6 principles of Raj©.
He has served as the principal investigator for the first 3 years, and the project
was done at the Christian Fellowship Community Health Centre Society,
Ambilikkai, Dindigul district, Tamil Nadu, India, and was in technical collaboration
with the International Agency for Research on Cancer (IARC), WHO.
9. Background
Proof of concept (POC)—The Lancet Publication 2007, the author’s paper.
Quote:
Effect of visual screening on cervical cancer incidence and mortality in Tamil
Nadu, India: a cluster-randomized trial.
Lancet 2007; 370(9585):398-406.
Rengaswamy Sankaranarayanan, Pulikkottil Okkuru Esmy, Rajamanickam
Rajkumar, et al.
10. Summary
Cervical cancer is the most common cancer among women in developing coun-
tries. We assessed the effect of screening using visual inspection with 4% acetic acid
(VIA) on cervical cancer incidence and mortality in a cluster-randomized con-
trolled trial in India.
11. Methods
Of the 114 study clusters in Dindigul district, India, 57 were randomized to one
round of VIA by trained nurses and 57 to a control group. Healthy women aged 30–
59 years were eligible for the study. Screen-positive women had colposcopy,
directed biopsies, and, where appropriate, cryotherapy by nurses during the
screening visit. Those with larger precancerous lesions or invasive cancers were
referred for appropriate investigations and treatment.
Cervical cancer incidence and mortality in the study groups were analyzed and
compared using Cox regression taking the cluster design into account, and analysis
was by intention to treat. The primary outcome measures were cervical cancer
incidence and mortality.
12. Results
Of the 49,311 eligible women in the intervention group, 31,343 (636%) were
screened during 2000–2003; 30,958 control women received the standard care. Of
the 3088 (99%) screened positive, 3052 had colposcopy and 2539 directed biopsy.
Of the 1874 women with precancerous lesions in the intervention group, 72%
received treatment. In the intervention group, 274,430 person years, 167 cervical
cancer cases, and 83 cervical cancer deaths were accrued compared with 178,781
person years, 158 cases, and 92 deaths and in the control group during 2000–2006
(incidence hazard ratio 075 [95% CI 055–095] and mortality hazard ratio 065
[047–089]).
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13. Interpretation
HPV vaccination and organized screening, in the presence of good training
and sustained quality assurance, are effective methods, for HPV and cervical
cancer prevention and control, in developing countries. New and innovative
models and effective strategies for health education need to be developed to
strengthen the “knowledge translation to action” component of the healthcare
delivery systems,
14. Health education: for HPV prevention and control
The STAR model P-6 principles of Raj©.
Health education, with special strategies to effect the “practice” in a suc-
cessful way, is the key, for prevention and control of HPV infections and
cervical cancer.
Proposed strategy:
Knowledge transformation through p6 pathway©
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15. The P6 principles
15.1 P1. Projection
15.1.1 Health education process
It is very important that all the health-related programs have a very strong
foundation with the component of health education, may it be to an individual,
family, or a community. The healthcare planners, administrators, and providers are
responsible for developing various methods, tools, strategies for the delivery of
effective health education. In some health programs, it is called information, edu-
cation, communication strategies. In this process, an idea, theme, concept, facts and
figures, health topics, health problems, and solutions are being projected.
15.1.2 Negative projections
These are usually warning projections. For example, tobacco products have scary
pictures of lung cancers, and head and neck cancers are printed on the packs. These
are meant to arouse a sense of fear and discourage the consumer from using it. But,
the feelings and its effect are temporary, resulting in continued habits. The con-
sumers may not like the “advertisement” but likes the advertised. Such “dramatic
“projections,” are not ideal for health education on sensitive issues like HPV.
Negative projections
15.1.3 Positive/pleasant projections
The messages to be delivered are projected in a positive, attractive way. This is
also a temporary appeal to their emotions. Without in-depth analysis, the con-
sumers patronize the messages but on the long run has no permanent implications.
The advertisements on the health drinks are such “positive and pleasant projec-
tions.” Such projections are not suitable for behavior change targeted HP health
education messages.
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Positive/pleasant projections
15.1.4 Permanent behavior change projections
These projections are prosperous, progressive, peaceful, and productive. They
imply that acceptance and adoption of the advertised message would lead to happy,
healthy future. Health education messages in family planning are designed and
developed like this. The example of one such advertisement shows a happy family
with two children joyfully bonded with love and affection.
The consumer is highly impressed, inspired, and convinced to consider adopting
family planning methods to have a small and self-sufficient family, in the future.
Likewise, in HPV-related health education messages, we should have permanent
behavior change projections like HPV vaccination, menstrual hygiene, sexual
hygiene, and regular periodic screening for cervix cancer, and these are the ideal
and apt projections.
Permanent behavior change projections






It is the formation of an idea or concept, depending upon the effects of various
stimuli received, to perform an act.
15.2.1 Perception process: the i5
Ignite Imagine Interest Inspire Implement
Ignition: “Don’t let cervical cancer stop you.”
Imagine: End cervical cancer.
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Interest: Easy two ways—“get vaccinated, get screened.”
Inspire: Peer group inspires.
Implement: Get vaccination/screening done.
15.3 P3. Promotion
15.3.1 Health promotion model
Successful and productive past experiences; beliefs getting renewed and ratio-
nalized; benefits accrued both temporarily and permanently; breaking of barriers
by several inputs and interventions; positive influence from family, friends, peers,
and society; esthetic situations favoring and promoting empowerment by self-
efficacy, all these factors serve as a diving plank, providing strong and sustained





This is a continuous process where each step is evaluated and replanned for
better implementation in the next step.
Therefore in every performance, there is a betterment of the next practice. This
is depicted in the performance enhancement cycle (PEC).
Performance enhancement cycle (PEC)
15.5 P5. Perseverance
Perseverance is constant, continued efforts and attempts, amidst of many
difficulties, until the desired goal is achieved. This is an important process in
healthcare delivery, where the health providers make sustained efforts to
convince the healthcare recipients to adopt the desired behavior in order to
achieve the appropriate and relevant goals. The act of “perseverance” largely
depends upon the level and depth of perception of the health problem; the
support given by family, peers, and society; and the evaluation of the eventual
results and benefits. In the community, we can see the example of a pregnant
woman in a family, where everyone realizes the preciousness of pregnancy and
has in-depth perception and the family, relatives, community, and society offer
all the support needed for the pregnant woman, amidst of many problems and
difficulties, for a long period of maternity, and these acts of perseverance
eventually result in the successful outcome of a safe delivery, healthy mother,
and a healthy child.
In HPV control measures, perseverance is needed for effecting behavioral
changes like menstrual hygiene, sexual health, adoption of HPV vaccine and most
importantly screening and treatment for precancer status and regular follow-up as
needed. Hence,“perseverance” in health education, healthcare delivery, and follow-
up is a very important component of the goal-oriented system.
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Perseverance is constant, continued efforts and attempts, amidst of many
difficulties, until the desired goal is achieved. This is an important process in
healthcare delivery, where the health providers make sustained efforts to
convince the healthcare recipients to adopt the desired behavior in order to
achieve the appropriate and relevant goals. The act of “perseverance” largely
depends upon the level and depth of perception of the health problem; the
support given by family, peers, and society; and the evaluation of the eventual
results and benefits. In the community, we can see the example of a pregnant
woman in a family, where everyone realizes the preciousness of pregnancy and
has in-depth perception and the family, relatives, community, and society offer
all the support needed for the pregnant woman, amidst of many problems and
difficulties, for a long period of maternity, and these acts of perseverance
eventually result in the successful outcome of a safe delivery, healthy mother,
and a healthy child.
In HPV control measures, perseverance is needed for effecting behavioral
changes like menstrual hygiene, sexual health, adoption of HPV vaccine and most
importantly screening and treatment for precancer status and regular follow-up as
needed. Hence,“perseverance” in health education, healthcare delivery, and follow-
up is a very important component of the goal-oriented system.
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Perseverance in care during pregnancy for safe delivery
The common example of a pregnant woman and her family, community, and
society, being offered all support and help for a successful outcome, amidst many
difficulties, by acts of perseverance.
15.6 P6. Pursuit
The yacht in pursuit of destination amidst problems
In pursuit of excellence is a requirement by one and all for success and achieve-
ments. In the field of healthcare planning, delivery, and implementation, one is in
pursuit of excellence in technologies, techniques, strategies, skills, and scientific—
social achievements.
Goals, objectives, and indicators to reach are already fixed, defined, and
targeted, in a well-planned health program. The health providers are in “pursuit” of
attaining these goals. There would be many difficulties, obstacles, shortcomings,
and hurdles in the entire process. But, the goal is clear, and all efforts are made to
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overcome these, and the aim is ultimately achieved. The yacht travel which over-
comes all difficulties like the sun, rain, storm, and many others, to reach its desti-
nation safely, and it’s a symbolism of “pursuit.”
In the HPV control programs, many such draw backs are seen. For example,
illiteracy, ignorance, and poverty, prevent the usage of sanitary napkins. This is
overcome by health education and mobilization of resources. The HPV vaccine has
obstacles like differing policies, cost of the vaccine, lack of infrastructure to reach
the vaccine to the community, and illiteracy and ignorance among the target
groups. Screening programs suffer from problems like ignorant community; lack of
infrastructure; deficient manpower; nonavailability of techniques, technology, and
technicians; and inadequate, inefficient systems in place. Yet, these can be over-
come by appropriate and adequate inputs, during the process of pursuit towards the
goals by the health planners.
The health programs in the developing world do experience this act of pursuit to
achieve goals, and already the results have been seen in reducing the incidence of
HPV infections and cervical cancer, especially in the low and limited resource
settings of many countries.
16. Raj’s cancer control clock
A complimentary model
The Keys for the Cancer Control Clock’s 12 hours [20]:
1.Area—define a geographic area for your study/services
2.Enumerate—the resident population, document the sociodemographic data
3.Inference—prevalence of HPV-related diseases—establish registries
4.Education—about prevention at individual, family, and community levels
5.Invitation—to attend awareness programs, screening, and vaccination
6.Counseling—the participants about possible outcomes and solutions
7.Screening—acceptable, available, accessible, affordable, answerable,
achievable—the A-6 model for screening and vaccination programs
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8.Patterns—of diseases detected in screening—disclosure of results—
individualized, ensure confidentiality and offer solution for health problems
9.Confirmation—diagnosis—at screening and follow-up stages
10.Treatment—of the HPV infections and related diseases, precancer lesions,
and ensure the availability of posttreatment services
11.Follow-up—by confirmation of disease free status, counseling, and referrals
to the government/private health systems
12.Monitoring, evaluation, replan—effectiveness of interventions, health
economics,and advocating prevention policies
17. Conclusion
The problem of high incidence of HPV infections and cervical cancer, all over
the world, especially in developing countries is of great concern and warrants
immediate control measures. Many programs have been planned and implemented
and they all show promising outcomes. The HPV vaccine uptake has increased due
to various inputs in developing countries. The increased vaccine coverage has
shown reduced incidence of cervical precancers in longitudinal studies. The screen-
ing programs for cervical cancer have resulted in reduction in the incidence rate of
cervical cancer and mortality due to cervical cancer.
18. The STAR model P-6 principles of raj©
This is a time-tested concept of the author, which was found to be very success-
ful in the proof of concept project quoted earlier. Hence, for effective implementa-
tion of HPV and cervical cancer screening programs, especially in the phase of
translating knowledge into practice, the above model is recommended, for the
benefit of health programs in developing countries.
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